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Abstract
Background: Patients with malignant pleural disease (MPD) have advanced cancer and
high symptom burden. Goals of patient care are to optimise health-related quality-of-life
(HR-QoL) and participation in daily physical activities. Supportive care interventions such
as nutrition and exercise could offer benefit to patients. However, there is a lack of
information on the prevalence of low muscle mass (i.e., pre-sarcopenia), malnutrition,
inactivity and poor physical functioning in patients with MPD. Additionally, little is known
about the factors associated with development of pre-sarcopenia and malnutrition or their
associations with patient outcomes.
Purpose: The objectives were to: 1) characterise physical activity levels and their
relationship with patient outcomes; 2) compare methodology used to classify presarcopenia; 3) determine the prevalence of pre-sarcopenia and malnutrition and investigate
their relationship with activity behaviours and HR-QoL; 3) determine the prevalence of
poor physical functioning and nutritional outcomes throughout the two years postdiagnosis; 5) describe body composition changes and investigate their relationship with
physical activity and dietary intake; and 6) examine the effects of nutritional status and
dietary intake on outcomes of an exercise intervention.
Methods: Three studies in patients with MPD were conducted: a cross-sectional study, a
prospective observational study, and an exercise intervention study. Participants in the
cross-sectional study (n=46) underwent assessment of physical activity levels
(accelerometer). Participants in the observational (n=36) and exercise intervention (n=33)
studies underwent assessment of nutritional status (Patient-Generated Subjective Global
Assessment), body composition (computed tomography [CT], dual-energy x-ray
absorptiometry [DXA]), physical activity levels (accelerometer), physical functioning
(Timed Up-and-Go), HR-QoL (Short-Form 36; Functional Assessment of Cancer Therapy
[FACT]-General), appetite (FACT-Anorexia Cachexia Scale) and fatigue (FACTFatigue). Participants in the intervention study underwent additional tests of physical
functioning (Six-Minute Walk Test, chair rise) and muscular strength (1-repetition
maximum leg press).
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Results: In the cross-sectional study, 89% of participants did not meet physical activity
guidelines. There was moderate agreement between CT and DXA for the classification of
pre-sarcopenia (ĸ=0.424; p=0.006). Fifty-four percent of participants were pre-sarcopenic,
and 38% were malnourished. Compared to participants with normal muscle mass, presarcopenic participants were more sedentary (p=0.001) and participated in less light
activity (p=0.008). Compared to participants who were well-nourished, malnourished
participants had poorer HR-QoL (p<0.001). Throughout the two years post-diagnosis, the
prevalence of poor physical functioning and low appetite was ≥50%. Participants with
muscle loss (56%) became more sedentary (p=0.008), however energy and protein intake
did not change (p>0.05). In the exercise intervention, participants with adequate dietary
intake (40%) had a significant increase in muscle mass (p=0.004), while participants with
inadequate dietary intake (60%) maintained muscle mass (p=0.737). There were no
differences between well-nourished and malnourished participants with respect to
completion, adherence or tolerance of the intervention (p>0.05).
Conclusion: Overall, there were high rates of pre-sarcopenia, malnutrition, inactivity,
and poor physical functioning among participants with MPD. Pre-sarcopenia and
malnutrition were associated with negative patient outcomes. Muscle loss was associated
with decline in physical activity. The results indicate dietary intake could influence the
effects of exercise. Interventions that target both physical activity and dietary intake could
be most impactful.
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Glossary of Terms
Aerobic exercise

Exercise in which the body’s large muscles move in a rhythmic
manner for sustained periods.1

Cancer cachexia

A multifactorial syndrome that is defined by an ongoing loss of
skeletal muscle mass with or without loss of fat mass.2

Chronic diseaserelated malnutrition
with inflammation

A condition that results from the activation of systemic
inflammation by an underlying disease such as cancer.3

Computed
tomography

A method of measuring body composition based on the density
of pixels in an image of a person’s body tissues.4

Dual energy x-ray
absorptiometry

A method of measuring body composition based on the amount
of energy absorbed when photons pass through a person’s body
tissues.4

Exercise

Bodily movement that is planned, structured and repetitive and
undertaken with the purpose of maintaining or improving
physical fitness.5

Malignant pleural
disease

The collective term given to cancers that involve the pleurae.6

Malignant pleural
effusion

Excessive accumulation of fluid in the pleural cavity attributed
to malignancy.6

Malignant pleural
mesothelioma

A primary pleural cancer primarily attributed to asbestos
exposure.7

Malnutrition

A state resulting from lack of intake or uptake of nutrition that
leads to altered body composition and body cell mass leading to
diminished physical and mental function and impaired clinical
outcome from disease.3

Muscle strength

The amount of force a muscle can produce with a single
maximal effort.8

Physical activity

Any bodily movement produced by skeletal muscles that results
in energy expenditure above resting levels.5

Physical function

The capacity of an individual to carry out the physical activities
of daily living.1

Physical performance

An objectively measured whole body function related with
mobility.8
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Glossary of Terms

Pre-sarcopenia

A term given to the presence of low skeletal muscle mass in the
absence of low muscle strength and function.9

Resistance exercise

Exercise that causes muscles to work or hold against an applied
force or weight.1

Sarcopenia

A progressive and generalised skeletal muscle disorder that is
associated with an increased likelihood of adverse outcomes
including falls, fractures, physical disability and mortality. 10
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Chapter One. Introduction

1.1

Background
Malignant pleural disease (MPD) is the collective term given to cancers that involve

the pleurae.1 MPD currently affects more than 8000 people within Australia and 1 million
people across the world each year.2 MPD includes primary pleural cancers such as
malignant pleural mesothelioma (MPM) and secondary pleural cancers or metastatic
disease.1 Globally, 90% of cases of MPD are comprised of patients with metastatic disease,
with cancers of the lung and breast most likely to metastasise to the pleurae.3 In Western
Australia approximately 40% of cases of MPD are comprised of patients with MPM.4
MPM is a unique cancer in that its aetiology is primarily attributed to asbestos
exposure.5 Asbestos is a group of naturally occurring hydrated mineral silicate fibres6 that
were extensively used in Australia in the manufacturing and construction industries.7
Historically, people working in mining, manufacturing and construction occupations were
more likely to be exposed to asbestos.8 As these occupations were made up of a
predominantly male workforce, there is a higher incidence of MPM among men.9 Notably,
there is a long latency period (mean 44 years)10 between exposure to asbestos and the
development of MPM, therefore the mean age of patients at the time of diagnosis is
approximately 70 years.10
MPD represents incurable cancer and the 1-year survival rate is less than 25%.11
However, the median survival of patients with MPD varies considerably depending on the
tumour type. Patients with primary lung cancer have the shortest median survival of less
than 3 months while patients with MPM have the longest median survival of 12 months.4
Other factors associated with poorer survival include poor performance status and high
inflammatory markers.4, 11 While patients with MPM have the longest median survival,
additional factors associated with poorer survival include the non-epithelioid subtype of
disease12-15, elevated platelet count12-14 and weight loss.14, 16
Patients with MPD typically have a high symptom burden.17 The majority of patients
present with a pleural effusion, which is the excessive accumulation of fluid in the pleural
cavity.1 Fluid in the pleural cavity, which is in excess of 1 litre for most patients with MPM,18
can cause breathlessness and chest pain.1 Research in patients with lung cancer indicates that
breathlessness is negatively associated with activity levels and quality of life.19 Therefore,
the management of patients with MPD is mainly focused on controlling symptoms in order
to optimise physical activity levels and quality of life. While there is substantial data
regarding quality of life,20, 21 there is a notable lack of data measuring physical activity in
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this population. Information on the physical activity of patients with MPD is currently
limited to self-report of physical functioning as part of quality of life assessment.22
Standard management of malignant pleural effusions has changed substantially over
time with an increasing focus toward least invasive interventions that will alleviate
symptoms, ideally without need for a hospital admission.23 Current practice for
symptomatic patients typically involves insertion of an indwelling pleural catheter to allow
for ambulatory drainage of pleural fluid.23 For patients with MPM, first-line treatment of
the disease with cisplatin and pemetrexed chemotherapy can improve symptoms22 and
offers a modest survival benefit.24
Malnutrition is defined by a low body weight, weight loss or low muscle mass in
combination with reduced dietary intake or inflammation.25 The potential relationship
between malnutrition and patient survival in MPM has been raised in previous research
studies.14, 26 However, an accurate description of the nutritional status of patients with MPM
is not available as the amount and timing of weight loss has been poorly described,13, 27 and
there has been no measurement of muscle mass, appetite or dietary intake using validated
tools. An existing challenge in the measurement of muscle mass is that there is no consensus
on the optimal technique or cut-points for the classification of low muscle mass. There is
also evidence that the techniques are not comparable.28 Therefore, further investigation into
the comparability of methods used for the measurement of muscle mass is relevant.
In advanced cancer populations, low muscle mass and weight loss are associated with
poorer quality of life29-36 but no study in this population has examined the association with
activity levels. Further, no study in MPM has investigated the relationship between body
composition, nutritional status, and quality of life and activity levels. While anecdotally
clinicians and patients are concerned about malnutrition and low muscle mass,37 there is a
lack of evidence available to empirically inform development of interventions to address
these concerns.
There are multiple factors which contribute to the development of malnutrition and
low muscle mass in the cancer context.38 As MPD indicates advanced cancer, it is plausible
that the cancer may indirectly contribute to reduced dietary intake, physical activity and
altered metabolism which could lead to the development of malnutrition and low muscle
mass.39 This condition is commonly known as cancer cachexia and it is thought to be at
least partly reversible in its early stages.39 An understanding of the factors associated with
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the development of malnutrition and low muscle mass in MPD could lead to more targeted
interventions to address these conditions.
Exercise is regarded as a potential strategy to reverse the effects of cancer cachexia.39
Resistance exercise training is defined as exercise in which muscles work against a force
60% or higher of maximum.40,

41

Resistance exercise training is well established as

promoting gains in muscle mass,42 and is effective for improving muscle mass in patients
with early stage prostate cancer43 and breast cancer.44, 45 However, patients with advanced
cancer are a distinctly different population. The high symptom burden46 and high rates of
malnutrition47 among patients with advanced cancer could negatively impact on adherence
and tolerance to the intervention. Furthermore, reduced dietary intake could limit muscle
gains as amino acids mobilised from muscle are used as an energy source. 48 There is
limited body composition data available from resistance exercise intervention studies in
advanced cancer populations. Furthermore, no studies have reported on the impact of
nutritional factors on exercise outcomes.49

1.2

Significance of the research
Patients with MPD face debilitating symptoms and a disease that has no cure. Research

aimed at improving daily physical activity and quality of life is imperative for improving
clinical care. Results from this study will provide information about the nutritional status
and body composition of patients with MPD and their relationship with patient-centred
outcomes, which will serve as a rationale for future supportive care interventions.
Effective supportive care interventions are both feasible and target the underlying causes
of the problem. Reduced dietary intake, physical activity and altered metabolism have all
been implicated in the overall body weight and muscle loss associated with cancer.39
Therefore, Fearon et al39 in their review of mechanisms and treatment options for cancer
cachexia have recommended the use of multi-modal interventions inclusive of dietary
counselling and nutrition support, resistance exercise training and pharmacological agents.39
A potential problem is that few studies have reported on the feasibility of resistance exercise
training in patients with malnutrition. This is a particularly important factor to consider as
malnutrition is associated with high symptom burden which could negatively affect
adherence to exercise.50 Additionally, there is no data available on the dietary intake of
patients with MPD or the relationship between dietary intake, biochemical markers and
nutritional status and body composition. There is paucity of data available to inform the
design of supportive care interventions in patients with MPD. Results from this work will
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provide information on the feasibility of resistance exercise training in patients with
malnutrition and the relationship between changes in body composition and dietary intake
and physical activity to guide the development of future supportive care interventions.

1.3

Research purpose
The overall purpose of this research was to describe the physical activity, physical

functioning, nutritional status and body composition of patients with MPD. Further, this
research sought to evaluate the physical activity and body composition methodology that
underpins the research. The objectives were to determine if there was a relationship
between physical activity, nutritional status and body composition, and important patient
outcomes; describe body composition changes over time and investigate the relationship
with physical activity and dietary intake; and examine the effects of nutritional status and
dietary intake on outcomes of an exercise intervention.

1.4

Overview of thesis content
Chapter One is an introduction to the thesis. This chapter provides background to the

research along with an overview of thesis content. The significance and purpose of the
research are also stated.
Chapter Two is a critical review of existing literature related to the measurement of
body composition, physical activity and functional status; the prevalence of malnutrition,
pre-sarcopenia, physical inactivity and functional impairment in advanced cancer
populations; the aetiology and consequences of malnutrition and pre-sarcopenia in
advanced cancer populations; the effects of exercise in advanced cancer populations; and
the impact of dietary intake on the effects of exercise.
In Chapter Three the results of a cross-sectional study (Study 1) conducted with 46
patients with MPD are presented (Figure 1.1). This chapter provides information on
adherence to an accelerometer wear protocol, describes objectively measured physical
activity and sedentary behaviour and compares these results to physical performance
measures used in clinical practice (Manuscript published).51
In Chapters Four and Five, data from the baseline assessment of a longitudinal
observational study (Study 2) and exercise intervention study (Study 3) conducted in
patients with MPM are presented (Figure 1.1). In Chapter Four, the measurement of
skeletal muscle mass and rates of pre-sarcopenia measured with Dual-Energy X-Ray
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Absorptiometry and Computed Tomography is compared. In Chapter Five the rates of
malnutrition and pre-sarcopenia are reported and the relationship between nutritional
status, body composition and dietary intake, biochemical markers, quality of life and
activity levels are reported (Manuscript published).52
In Chapters Six and Seven, results from a longitudinal observational study (Study 2)
conducted in 36 patients with MPM are presented (Figure 1.1). In Chapter Six, the rates
of nutritional impairment (high need for nutrition support and poor appetite) and
functional impairment (self-reported physical functioning and Timed Up and Go) at
different points in the disease course are reported. In Chapter Seven, changes in body
composition over time are described and the relationships between energy and protein
intake, and physical activity and sedentary behaviour are assessed.
In Chapter Eight, results from an exercise intervention study (Study 3) conducted in
33 patients with MPD are reported (Figure 1.1). Adherence to and tolerance of the
intervention were compared between malnourished participants and well-nourished
participants. Additionally, the relationships between energy and protein intake and
outcomes from resistance exercise training, namely body composition and objectively
measured physical functioning were assessed.
Chapter Nine is an overall discussion of major findings and conclusions of the
collective work with recommendations for future research.
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2.1

Malignant pleural disease
Malignant pleural disease (MPD) is the collective term for cancers that involve the

pleurae, which are two serous membranes that attach to the chest wall and lungs.1 The
small amount of fluid secreted by the pleurae acts as a lubricant to enable the membranes
to slide against each other during breathing.1 MPD comprises both primary pleural cancers
and secondary pleural cancers.2 Primary pleural cancers include malignant pleural
mesothelioma (MPM), localised fibrous tumour and pleural liposarcoma.2 Secondary
pleural cancers include metastatic disease, thymoma and lymphoma 2

2.1.1

Clinical presentation and symptom burden

Most patients with MPD present with a pleural effusion,2 which is the excessive
accumulation of fluid in the pleural cavity.2 A malignant pleural effusion is a unique fluid
that is rich in protein (4 g/100 mL) and tumour secretions such as cytokines.3 The
accumulation of pleural fluid occurs when the volume of fluid that enters the pleural space
exceeds the capacity of the lymphatic system to remove the fluid. 2 Approximately 60% of
patients with MPD have at least 1 litre of fluid in the pleural space at the time of
presentation.4 A high proportion of patients with a malignant pleural effusion present with
symptoms;5 half of patients report breathlessness, while one-quarter of patients report
chest pain at presentation.2

2.1.2

Aetiology of malignant pleural effusions

The imbalance between the volume of fluid that enters and is removed from the
pleural space occurs when a tumour increases the permeability of the pleural surface;
involves the lymphatic system; causes an obstruction which decreases pleural pressure; or
involves the pericardium.2

2.1.3

Prevalence

Approximately half of all patients with cancer will develop a pleural effusion over the
disease course.6 Currently, 8000 people in Australia and 1 million people worldwide are
affected by a malignant pleural effusion each year.7 The majority of patients with a
malignant pleural effusion (90%) have metastatic cancer.8 Patients with lung and breast
cancer represent approximately 55% of all cases of a malignant pleural effusion.5
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2.1.4

Prognosis

MPD represents advanced cancer, however the median survival of patients with MPD
varies according to tumour, biochemical and functional factors.9 Patients with lung and
gastrointestinal cancers have the shortest median survival of less than 3 months while
patients with MPM have the longest median survival of approximately 12 months.10 High
pleural lactate dehydrogenase levels, which is indicative of localised inflammation within
the pleural cavity,9 and a high neutrophil to lymphocyte ratio, which is indicative of
systemic inflammation, are associated with poorer survival.9, 11 Poorer performance status
is also associated with poorer survival.9

2.1.5

Treatment

The management of malignant pleural effusions has changed substantially over time.
Early clinical trials for the management of malignant pleural effusions were focused on
preventing the reaccumulation of pleural fluid using surgical techniques and sclerosing
agents.12 However, the key goals of patient management have evolved over time to a more
patient-centred approach to alleviate symptoms, with the least invasive means and without
need for a hospitaladmission.12 Consequently, recent clinical trials have focused on
improving patient-reported outcome measures including breathlessness,13, 14 chest pain,14
and quality of life,13, 14 and reducing the amount of time spent in hospital.15 Due to the high
failure rate of talc pleurodesis (~30%) and the subsequent need for reintervention, many
centres now use an indwelling pleural catheter12 for the management of malignant pleural
effusions, which enables ambulatory drainage of pleural fluid and reduces the need for
reintervention and time spent in hospital.15 Existing guidelines on pleural fluid
management state that symptoms may also be managed with medication.16 Where patients
are asymptomatic, observation is the recommended approach.5

2.2

Malignant pleural mesothelioma
MPM represents 90% of primary pleural cancers8 and develops from the mesothelial

surfaces of the pleurae.17 There are four histological subtypes of MPM: epithelioid,
sarcomatoid, desmoplastic and biphasic, which contains both epithelioid and sarcomatoid
components.17 The most common of the histological subtypes is epithelioid, which is
present in 60% of cases.18
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2.2.1

Aetiology

Most cases of malignant pleural mesothelioma (MPM) can be attributed to asbestos
exposure.19 The association between MPM and asbestos was first described in 1960.20
Asbestos is defined as a group of naturally occurring hydrated mineral silicate fibres.17 The
proposed mechanisms for development of MPM from asbestos exposure include pleural
irritation, interference with mitosis, generation of toxic oxygen radicals and persistent
kinase-mediated signalling.19 People exposed to brown and blue asbestos are more likely
than those exposed to white asbestos to develop MPM although the reason is unknown.21

2.2.2

Patient characteristics

In Australia, asbestos was mined, manufactured into building products and used in
construction from the 1950s. A total ban on the use of any type of asbestos was not
introduced in Australia until 2003.22 Historically, people working in mining,
manufacturing and construction occupations were more likely to be exposed to asbestos.23
As these occupations were made up of a predominantly male workforce there is a higher
incidence of MPM among men.24 While concerns around MPM originally centred on those
workers who were responsible for mining asbestos and manufacturing asbestos products,
the ‘new wave’ of MPM could be attributable to those who have had short term or lowlevel exposure to asbestos through home maintenance or renovation.22
Data from New South Wales indicates there is typically a long latency period between
exposure to asbestos and development of MPM19 with a mean latency period of 44 years,25
and a mean age at diagnosis of 70 years.25

2.2.3

Clinical presentation and symptom burden

Patients with MPM often have a high symptom burden. Between 60-80% of patients
with MPM have breathlessness and chest pain at presentation.19, 26 Breathlessness in MPM
is related to the presence of a malignant pleural effusion or the restriction of lung
movement by the tumour.27 Chest pain is usually a consequence of the invasion of tumour
to the chest wall or rib involvement and is therefore more prevalent amongst those with
advanced stage disease.27 Other commonly reported symptoms at diagnosis are the
constitutional symptoms of fatigue and weight loss.19 Between 20-50% of patients with
MPM report weight loss at the time of diagnosis, although the amount, composition
(muscle vs. fat loss), and timing of weight loss has been poorly described.28, 29
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2.2.4

Prevalence

Australia has the highest incidence of MPM per capita in the world with 30 cases per
million people and rates of disease are expected to peak between 2014 and 2021.17, 30 These
high rates of MPM are reflected in studies of patients with MPD. Patients with MPM are
usually less than 10% of an MPD cohort, however in Western Australia patients with
MPM comprise almost 40% of an MPD cohort.9

2.2.5

Prognosis

MPM is a universally incurable cancer.19 Unlike other advanced cancers, MPM is
predominantly a localised disease and the reason for death remains largely unknown.31 In
the largest post-mortem study published, including 318 patients from Western Australia,
a precise cause of death could be determined in only 20% of cases. Notably, patients with
an unknown cause of death had significantly lower body mass index (BMI) than those
with an identified cause of death (18.8 ± 4.3 vs. 21.0 ± 4.7; p=0.034), and the authors
proposed that nutritional status or body composition could be associated with the cause of
death in patients with MPM.31
Patients diagnosed with MPM have a median survival of 12 months 32 with the oneyear survival rate reported as 41% and the three year survival as 12%.33 In the largest
prospective study investigating prognostic factors in MPM (n=8740) the presence of nonepithelioid histological sub-type of the disease and poor performance status were
associated with poorer survival.33
The most recent prognostic model for MPM was published in 2016. 32 The study,
which included patients with newly diagnosed MPM (n=482) identified individual
clinical characteristics associated with survival and defined four risk groups based on a
combination of clinical characteristics. 32 The individual clinical characteristics associated
with poorer survival were non-epithelioid histological subtype, weight loss, performance
status ≥2 and altered blood parameters (haemoglobin ≤121 g/L and albumin ≤43 g/L). 32
Regarding the risk groups, those with a combination of no weight loss and haemoglobin
≥153 g/L and albumin ≥43 g/L had the longest median survival (34.0 [IQR 22.9 – 47.0]
months),32 while those with a combination of weight loss, performance status 0-1 and the
sarcomatoid histological sub-type of MPM had the shortest median survival (7.5 [IQR
3.3 – 10.9] months).32
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2.2.6

Treatment options

Treatments are usually provided to MPM patients with palliative intent.
Chemotherapy, with pemetrexed and cisplatin is the only first-line treatment available.34 In
a phase III randomised study of patients with MPM (n=456), patients who received
pemetrexed and cisplatin in combination had a greater median survival time compared with
those who received cisplatin alone (12.1 vs. 9.3 months; p=0.020);35 and greater response
rates to treatment compared with the single agent (41.3% vs. 16.7%; p<0.001).35
Radical surgical resection, which involves en bloc resection of the parietal pleura,
pericardium, diaphragm, lung and visceral pleura has been shown to be detrimental to
patients with MPM.36 In a randomised controlled trial (n=50) the reported hazard ratio for
overall survival was 2.75 (1.21 – 6.26; p=0.016) between those who underwent surgery
and those who did not.36 Median survival for the surgery group was 14.4 (5.3 – 18.7)
months vs 19.4 (13.4 to time not yet reached) months in the non-surgery group.
Research trials are currently investigating the effects of immunotherapy in patients
with MPM. While there are some promising results from phase I and phase II trials, results
of phase III trials are needed to determine if and how immunotherapy should be integrated
into standard care for patients with MPM.37
There are several treatment options available for symptom management.
Radiotherapy for localised pain can improve pain temporarily in approximately half of
patients.16 Pleural fluid management should be considered to manage breathlessness in
patients with a pleural effusion.

2.3

Measurement of physical function, physical performance and
physical activity

2.3.1

Physical function

Physical function is defined as a person’s ability to complete the physical activities
of daily living and is a reflection of a person’s physical fitness and their usual physical
activity level.38 In clinical practice, performance status measures are commonly used to
describe a person’s level of physical function.
The most commonly used performance status measures in cancer are the Eastern
Cooperative Oncology Group (ECOG) performance status39 and the Karnofsky
Performance Status (KPS).40 The ECOG performance status scale consist of six levels
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from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5
(dead) (Table 2.1).39 The Karnofsky performance status scale consists of eleven levels,
which decrease by ten points at each level, from 100 (normal no complaints; no evidence
of disease) to 0 (dead).40
Table 2.1

Eastern Cooperative Oncology Group Performance Status Scale39

Grade

Performance Status

0

Fully active, able to carry on all pre-disease performance without restriction

1

Restricted in physically strenuous activity but ambulatory and able to carry out
work of a light or sedentary nature

2

Ambulatory and capable of all self-care but unable to carry out any work
activities; up to and about more than 50% of waking hours

3

Capable of only limited self-care; confined to bed or chair more than 50% of
waking hours

4

Completely disabled; cannot carry on any self-care; total confined to bed or chair

5

Dead

Assessment of performance status is an important part of clinical care in cancer
patients, including those with MPD. There is a strong relationship between performance
status and prognosis in patients with advanced cancer41 and MPD,34 therefore performance
status ratings are used to determine a person’s suitability for treatment and predict
treatment tolerability.34
Although performance status scales are simple to administer,42 assessment is
subjective and could inaccurately assess a person’s actual functioning.42 This is
highlighted in research that has compared patient and physician ratings of performance
status;41 patients rated their performance status worse than physicians, which suggests that
patient and physician ratings of performance status differ. Additionally, performance
status categories are broad, and where a response to an intervention is expected to be small,
performance status scales may not detect this small, but meaningful change in a person’s
activity. Therefore alternative measures are required provide a more accurate and objective
assessment of physical function.

2.3.2

Physical performance tests

Physical performance tests objectively measure a person’s functional capacity.
Suboptimal physical performance may be present before a person’s usual daily activities
are affected,43 and could predict a decline in activities of daily living. 44 As these tests
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assess the integrative capacity of skeletal muscle in a functional setting they have greater
clinical utility than muscle function tests, such as handgrip strength, that measure only
strength and power of individual muscles.43
Several studies have reported on the relationship between physical performance and
patient outcomes. In a recent systematic review, the authors concluded that poorer physical
performance was associated with reduced survival in patients with cancer.45 Physical
performance tests can predict patient outcomes better than performance status.46 In a study
of 62 patients with non-small cell lung cancer, better physical performance test results
were associated with an increased likelihood of completing more cycles of chemotherapy
and decreased adverse effects of treatment.46 Notably, no relationship was observed
between ECOG performance status and treatment outcomes.46 These result indicate that
physical performance tests are associated with important patient outcomes.
Commonly used physical performance tests are described in Table 2.2. Physical
performance tests are typically low-cost and easy to administer. Currently, there is no
information on the physical performance of patients with MPD.
Table 2.2

Commonly used physical performance tests43
Time to
complete

Test

Purpose

Description

Short-distance walk
test (i.e., 4 m walk)

Measures gait speed

The time taken to walk the required
distance is recorded with a
stopwatch.

2 min

Long-distance walk
tests (i.e., 400 m
walk)

Measures gait speed

The time taken to walk the required
distance is recorded with a stop
watch

15 min

Chair rise test

Measures lower body The time taken to stand from a chair
power, balance and and sit down five times.
endurance

1-2 min

Timed Up and Go test Measures gait and
dynamic balance

Short Performance
Physical Battery

The time taken to rise from an
armed chair, walk 8-feet, turn and
walk back to the same chair and sit
back down again

2-3 min

Measures standing
Includes three physical performance
balance, gait speed
tests: standing balance, a shortand lower body
distance walk test and chair rise
strength
test.

10 min
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2.3.3

Physical activity questionnaires

Caspersen et al47 defined physical activity as movement of the body that is generated
by skeletal muscles and leads to an increase in energy expenditure. Physical activity is
most commonly assessed with a self-report physical activity questionnaire. Questionnaires
are inexpensive and relatively low burden, which is often advantageous, particularly for
large population based studies. The Godin Shepherd Leisure-Time Physical Activity
Questionnaire (GSLTPAQ) is frequently used in cancer research to assess physical
activity.48 Participants completing the GSLTPAQ are asked to recall how many times in a
week they participate in mild, moderate and strenuous physical activity for 15 minutes or
more.49 The International Physical Activity (IPAQ) and Global Physical Activity (GPAQ)
questionnaires have also been used in cancer research.50
Self-report physical activity questionnaires can appropriately classify patients as
sufficiently active or inactive relative to physical activity guidelines. 50,

51

However,

participants tend to overestimate the time spent in moderate and vigorous physical activity
(MVPA), for example brisk walking, vacuuming, running, swimming, and underestimate
their time spent as sedentary such as sitting or lying down.50, 52, 53 Factors that affect the
level of accuracy include education level, sex, and age52 as well as activity level.54
Therefore, physical activity monitors may offer more accurate information about a
person’s individual activity levels.

2.3.4

Physical activity monitors

Physical activity monitors objectively measure a person’s activity levels. Physical
activity monitors are small and portable to facilitate continuous monitoring of activity
behaviours. The current available physical activity monitors are pedometers,
accelerometers and multi-sensor systems.55 Pedometers only measure step counts.
Accelerometers assess and quantify a range of movements associated with activity
including sedentary time, light activity, such as shopping or walking around the home, and
MVPA.56 Multi-sensor systems measure the amount and intensity of physical activity
alongside a physiological measure such as heart rate or body temperature. Therefore,
accelerometers and multi-sensor systems provide more comprehensive information about
activity behaviours compared with pedometers.
Accelerometers are reliable and valid when compared with the doubly-labelled water
method of determining energy expenditure.55, 57 Despite their validity, there are several
factors that need to be considered in research using accelerometers. Accelerometers collect
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continuous data and convert physical activity behaviours into a digital signal. Data are
compressed, filtered and analysed using algorithms to generate physical activity outputs.
These activity end points include measures of the amount of activity, for example time
spent in light activity, and total number of steps, and patterns of activity such as bouts of
light activity, and breaks in sedentary time).
Decisions made regarding accelerometry measurement and processing can affect
accelerometry outcomes. Accelerometers can differ in their placement on the body and
how they collect data.56 Additionally researchers can choose how to process data by
making choices around physical activity cut-points and non-wear time.56 These factors can
impact on reproducibility and comparability of the physical activity outputs produced.56

2.4

Physical activity levels in cancer populations
In recent years there has been a growth in research examining physical activity in

cancer populations.56 Existing research indicates patients with lung cancer are less
physically active than healthy adults.58, 59 Several studies have evaluated activity levels in
lung cancer patients with early stage disease. In a study of patients following curative
intent treatment for early stage non-small cell lung cancer, participants with non-small cell
lung cancer (n=20), compared with healthy controls, spent a greater proportion of their
waking hours in prolonged bouts (≥30 min) of sedentary behaviour (42 [30-58]% vs. 49
[42-65]%; p=0.048) and lesser proportion of waking hours light intensity physical activity
(26 ± 8% vs. 21 ± 9%; p=0.04).58 In another study of patients with stage I-IIIB non-small
cell lung cancer (n=50), the participants with lung cancer, compared with age and gender
matched controls, took significantly fewer steps per day (8483 ± 558 vs. 6120 ± 579;
p<0.01);59 and fewer participants with lung cancer met recommendations of 150 minutes
of MVPA per week (71% vs. 40%; p=0.01).59 Therefore, even in lung cancer patients with
early stage disease, the majority were inactive.
Few studies have reported on the activity levels of patients with advanced cancer, and
no study has included patients with MPD. In one study of patients with advanced lung cancer
(n=84), participants took, on average, 4246 ± 2983 steps per day and spent 19.7 ± 2.1 of all
hours per day as sitting or lying down.60 Similarly in another study that included patients
with early and advanced stage lung cancer (n=124),61 participants completed on average,
4596 ± 2106 steps per day and spent 9.8 ± 1.6 of their waking hours per day as sedentary;
only 23% of participants met recommendations of 150 minutes MVPA per week.61 In a
study of patients with brain metastases (n=31), the average step count was lower, at 2784 ±
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2278 steps per day.62 By comparison in Australia, an average healthy adult accumulates
7400 steps per day.63 These data indicate that patients with advanced cancer have
particularly low activity levels. However, research is needed to understand the physical
activity levels of patients with MPD, and how this relates to important clinical outcomes.

2.5

Physical performance and muscle strength in cancer populations
Research indicates that patients with lung cancer have poorer physical performance

and muscle strength compared with healthy adults.59, 64 In a study of patients with early
stage lung cancer (n=50) the average Six-Minute Walk Distance was 84% of the predicted
value for healthy adults,59 and handgrip strength and quadriceps strength were lower
among participants with lung cancer.59 In another study of patients with lung cancer
(n=39), including a high proportion with advanced stage disease, the average Six-Minute
Walk Distance was 76% of the predicted value for healthy adults;64 and the majority of
participants had upper and lower extremity strength that was 20% below the healthy
reference population.64
A number of studies have also reported on the physical performance and strength of
older adults with cancer.44, 65-67 In a study of breast cancer survivors aged >65 years (n=40),
the average chair stand time, handgrip strength and Short Performance Physical Battery
score were lower than for healthy controls,65 while in another study of patients with early
stage breast cancer aged >65 years (n=123), 20% of participants had a slow 4-m walk
speed, 31% had a suboptimal Short Performance Physical Battery score and 57% had a
low handgrip strength. In two larger studies of older adults with cancer (n=389 and
n=354),66, 67 with approximately half who had advanced stage disease, a suboptimal Short
Performance Physical Battery score was recorded for 71% and 78% of participants,
respectively. Overall, these findings suggest that physical performance and strength are
commonly impaired in people with cancer. Two of these studies65, 67 also reported a higher
symptom burden was associated with poorer physical performance. While the high
symptom burden associated with MPD indicates patients could be vulnerable to physical
performance limitations, research is needed to understand the extent of the issue of
functional impairment in MPD.

2.6

Measurement of body composition
Body composition refers to the relative amounts of muscle, fat and bone within the

body.68 The evaluation of muscle and fat, in particular, is integral for the diagnosis of a
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range of conditions relevant to cancer populations. There are multiple methods available
for assessing body composition and knowledge of how these techniques measure body
composition is essential for understanding their potential research application.

2.6.1

Levels of body composition

The science that underpins current body composition assessment methodology has
been explained in a five-level model of human body composition published in 1992.69
The model depicts human body composition as atomic, molecular, cellular tissue and
whole body levels (Figure 2.1).69
The atomic level, describes the elements which are the building blocks of human body
composition.69 Ninety-eight percent of the human body is made up of six atomic
elements.69 Oxygen is the most abundant element in the human body, followed by carbon,
hydrogen, nitrogen, calcium and phosphorous.69
The molecular level divides body composition into six compartments; water, lipids,
protein, carbohydrates, bone minerals and soft tissue minerals.69 Water is the most
predominant molecule, comprising 60% of the human body.69 Fats, the term given to the
body’s triglyceride stores, are the largest source of lipid in the body.69 Non-fat lipids, for
example phospholipids, which play an important structural role in the body are present in
much smaller proportion.69 Protein includes the nitrogen containing compounds found in
the body.69 Carbohydrates, mainly stored as glycogen, minimally contribute to body
composition.69 The predominant minerals found in the body are calcium and phosphorous,
which make up bone.69
The cellular level, divides body composition into cell mass, extracellular fluids and
extracellular solids.69 Cell mass refers to the components found within a cell, including
water, protein and minerals.69 Extracellular fluid is predominantly water referred to as
plasma (intravascular space) or interstitial fluid (extravascular space).69 Bone minerals,
collagen and elastic fibres make up the majority of extracellular solids.69
The tissue level is comprised of skeletal muscle, adipose tissue, bone, visceral organs,
the heart and brain.69 At this level, the measurement of tissues, for example, adipose tissue,
includes both the fat (triacylglycerol) as well as the protein, minerals and water that make
up the tissue.69 Analysis of adipose tissue at this level can be further categorised as
subcutaneous, visceral or interstitial.69
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Figure 2.1 The five levels of human body composition. Source: Wang et al. 1992

2.6.2

Methods for body composition assessment

Methods for body composition assessment can be combined into five categories.
These categories are anthropometry, total body water, major body elements, impedance
and imaging.70 Imaging is considered to be the most valid method for body composition
assessment.71 Imaging methods are comprised of computed tomography (CT), magnetic
resonance imaging (MRI), dual-energy x-ray absorptiometry (DXA) and ultrasound.70 CT
and DXA are the most commonly used methods for body composition assessment and
therefore, are described in more detail in the following sections.
Computed Tomography
CT evaluates body composition at the tissue level and identifies bone, skeletal muscle,
visceral organs and adipose tissue (Figure 2.2).70 Participants undergoing CT are exposed
to x-rays. The x-ray attenuation through tissues is detected by a computer software
program and cross-sectional images are reconstructed.72 The pixels that make up the image
have a known attenuation relative to air and water and this is signalled by the Hounsfield
Units allocated to it.72 The body tissues have their own specific Hounsfield Unit ranges
and these are used for body composition analysis.72 The total number of pixels in the given
surface area are summed to give the cross-sectional tissue area (cm2).70
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CT is a valid and reliable method for whole-body and regional measurement of body
composition.72 An advantage of CT is its capability to measure body composition at the
tissue level, meaning it can examine individual muscle groups and intramuscular adipose
tissue.70 However, the precision of the CT method may be affected by the phase of the CT
scan and the use of contrast during the scan.73, 74 Whole-body CT imaging is associated
with a high radiation dose and cost.70
CT scans that are typically used for patient care can be re-purposed to examine body
composition.75 This has the potential to reduce radiation exposure, research costs and
participant burden. When re-purposed CT scans are used in research, skeletal muscle and
adipose tissue are measured from a single cross-sectional image at the third lumbar
vertebrae.76 Abdominal skeletal muscle is strongly correlated with whole body skeletal
muscle in healthy adults77 and in patients with lung and gastrointestinal cancer.76
Although, prediction equations used to provide an estimate of whole-body skeletal muscle
mass may be inaccurate.78
Dual Energy X-Ray Absorptiometry
DXA evaluates body composition at the molecular level and therefore measures bone
mineral mass, lean soft tissue and fat mass (Figure 2.2).70 Participants that undergo a DXA
scan are exposed to low-dose x-rays. All DXA machines have an x-ray source and a
detector. The x-ray beams have two different photon-energy levels (low and high).79 When
the photons pass through an absorber (i.e., a person’s body tissues; person), the amount of
energy absorbed (i.e., how much the photons are scattered; attenuated) can be measured
by a detector.79 The overall attenuation is expressed as a ratio (R) of the absorption
(attenuation) for the lower energy photon to absorption of the higher energy photon.79
Each atomic element in the body has a characteristic R value/ratio, and the R values of
molecules (calculated from elemental composition) and various body composition
components (i.e., bone mineral, protein) have been calculated.79
DXA assumes that humans consist of three components that are distinguishable by
their x-ray attenuation properties: fat, bone mineral and lean soft tissue. 79 Bone is
separated out from fat and lean soft tissue because bone has a much higher R value.79
Tissues are quantified from the assumed component R values, image processing methods
and soft tissue distribution models.79
DXA is considered to be a valid and reliable method for body composition
assessment.72 Additionally, DXA involves a relatively low radiation dose and is quick to
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complete.70 Although, the precision of the DXA method may be affected by differences in
machine software or the machine itself, patient positioning and hydration.80 An additional
limitation of DXA is that measured lean soft tissue includes skeletal muscle, organs, fibrous
and connective tissue and there is no way to assess whole-body skeletal muscle separately.81
DXA has the capacity for regional body composition analysis. This means the arms
and legs can be segmented from the trunk, enabling measurement of appendicular lean
soft tissue, which is predominantly skeletal muscle.70 Existing research indicates that
appendicular lean soft tissue is highly correlated with whole-body skeletal muscle.82, 83
Therefore, DXA can be used for research where skeletal muscle is an outcome of interest.
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Figure 2.2 Components of body composition measured by dual energy x-ray
absorptiometry and magnetic resonance imaging or computed
tomography. Source: Prado et al. 2014.

2.7

Malnutrition
Malnutrition is a term used to describe weight loss and the associated reduction in

muscle and fat mass.84 Malnutrition can result from inadequate nutrient intake, impaired
nutrient absorption, impaired nutrient utilisation, or a combination of these factors. 84 The
development of malnutrition and subsequent loss of skeletal muscle is of concern due to
its important role within the body. Skeletal muscle is primarily known for its role in
physical movement therefore, the loss of skeletal muscle mass could negatively impact on
locomotion and activities of daily living.85 Skeletal muscle also has an important role in
body metabolism and is the reservoir from which amino acids can be supplied to other
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organs for the synthesis of new body proteins.86 Consequently, reduced skeletal muscle
mass could impact on the body’s ability to prevent and respond to illness.

2.7.1

Diagnosis of malnutrition

Multiple diagnostic criteria have been developed for malnutrition.87-89 In 2012, an
expert group from the European Society for Parenteral and Enteral Nutrition (ESPEN)
convened to produce a consensus statement on diagnostic criteria for malnutrition. 87 The
recommendations from the ESPEN expert group were that malnutrition could be defined
by either 1) BMI of <18.5 kg/m2 or 2) unintentional weight loss of >10% over any time
period; or unintentional weight loss of >5% over a 3 month time period in combination
with several factors including: a BMI <20 kg/m2 if aged <70 years; or a BMI <22 kg/m2
if aged ≥70 years; or muscle mass of <17 kg for men and <15 kg for women.87 Therefore,
earlier diagnostic criteria for malnutrition focused on the physical characteristics
associated with the condition.
The clinical nutrition community has recommended that the aetiology of malnutrition
is identified within the diagnosis.90 In 2017, an ESPEN working group published a list of
clinical nutrition terminology that recognised aetiology-based diagnosis of malnutrition. The
ESPEN working group recommended the use of ‘disease-related malnutrition’ to describe
situations where underlying disease has caused a reduction in nutrient intake, absorption or
utilisation84 and the use of ‘disease-related malnutrition with inflammation’ is used where
malnutrition exists in the context of a disease that results in underlying inflammation.84
Updated diagnostic criteria for malnutrition were required to reflect the aetiologybased diagnosis. In 2016, members of the Global Leadership Initiative on Malnutrition
(GLIM) convened to produce an updated consensus on the diagnostic criteria for
malnutrition.88 The recommendations were that malnutrition should be defined by both the
physical characteristics, known as phenotypic factors, and aetiologic factors associated
with the condition.88 According to the GLIM criteria, a diagnosis of malnutrition requires
the presence of either low BMI, weight loss or reduced muscle mass plus evidence of
reduced nutrient intake, absorption or utilisation or the presence of inflammation.88
Of several nutrition assessment tools which include the phenotypic and aetiologic
factors of malnutrition,88 the Patient-Generated Subjective Global Assessment (PG-SGA)
has been validated for use in patients with cancer.91 The PG-SGA includes a patientgenerated component where weight history, food intake, symptoms and function are
assessed, and involves a professional component where muscle and fat stores are visually

28

Chapter Two. Literature Review

inspected and disease and metabolic factors are assessed. 92 Completion of the PG-SGA
results in a score as well as a global rating of nutritional status.92
While existing research indicates that weight loss is common in patients with MPD
at diagnosis,28, 29 the amount and timing of weight loss is seldom described and there has
been no assessment of associated changes in muscle mass, dietary intake or inflammation
using validated tools. Therefore, a more comprehensive evaluation of nutritional status and
body composition is needed to determine the extent of malnutrition over the disease course
in patients with MPD.

2.8

Cancer cachexia
Cancer cachexia is an example of ‘disease-related malnutrition with inflammation’

and is characterised by the preferential loss of muscle mass but can be accompanied by fat
loss.93 Three stages of cancer cachexia have been defined.94 Pre-cachexia is the term given
to the first stage of the syndrome, while cachexia is the second stage and refractory
cachexia is the final stage.94 Pre-cachexia is characterised by weight loss of ≤5% in
combination with a poor appetite and metabolic changes.94 Cachexia is defined as weight
loss of >5% in 6 months; or weight loss >2% in 6 months in combination with a BMI of
<20 kg/m2 or clinically low levels of muscle mass.94 These physical characteristics of
cancer cachexia are often accompanied by reduced dietary intake and systemic
inflammation.94 Refractory cachexia is characterised by weight loss in the context of a
poor performance status and expected survival of less than 3 months.94

2.8.1

Mechanisms of cancer cachexia

In healthy adults, there is a balance between muscle protein synthesis and degradation
which helps to preserve muscle mass.86 For muscle loss to occur, there must be a decrease
in muscle protein synthesis, an increase in muscle protein degradation or a combination of
both.95 Muscle protein synthesis is affected by dietary protein intake, especially the
essential amino acid leucine, as well as exercise and anabolic hormones.96 Muscle protein
degradation can be affected by inflammation.86 Although the mechanisms are unclear,
cancer cachexia is influenced by a combination of both reduced dietary intake and altered
metabolism.93
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Reduced dietary intake
Studies in patients with advanced cancer have reported that individual dietary intake
varies substantially97 and a proportion of patients do not meet energy and protein
requirements.97, 98 In a study of patients with advanced lung or gastrointestinal cancer
(n=51), energy intake ranged from 14 – 55 kcal/kg/day and protein intake from 0.6 – 2.2
g/kg/day,97 and 27% of participants did not achieve an energy intake of ≥25 kcal/kg/day,
while 43% did not achieve a protein intake of ≥1.0 g/kg/day.97 In another study of patients
with advanced lung or gastrointestinal cancer (n=84), 27% of participants did not achieve
an energy intake of ≥30 kcal/kg/day, 1% did not achieve a protein intake of ≥1.0 g/kg/day
and 33% did not achieve an energy intake of ≥30 kcal/kg/day or protein intake of ≥1.0
g/kg/day.98 These results indicate that inadequate energy intake, in particular, is common
in patients with advanced cancer.
A number of factors are thought to be responsible for the reduced dietary intake
frequently observed in patients with advanced cancer. In particular, pro-inflammatory
cytokines and hormonal changes are thought to result in a lack of appetite. A recent review
article on the pathophysiology of cancer cachexia suggests inflammatory cytokines can
mimic the hormone leptin, which is responsible for reducing appetite.95 At the same time,
hormones that stimulate appetite such as ghrelin and neuropeptide Y are suppressed.95 The
resultant lack of appetite can lead to a reduction in dietary intake.
There are no data to confirm a causal relationship between lack of appetite and
reduced dietary intake, however, there is a reported association between appetite and
energy intake. In a study of patients with breast cancer who underwent chemotherapy
(n=114), each point decrease in appetite was associated with a 26.5 kcal (95% CI 14.4 –
38.5) decrease in energy intake.99 Research in patients with advanced cancer (n=143)
found that those self-reporting a lack of appetite had significantly lower energy intake
compared to those reporting a normal appetite (1515 ± 544 vs. 1149 ± 580 kcal/day;
p<0.001).100 These results indicate that a poor appetite is associated with lower energy
intake, which if unresolved could lead to the development of cancer cachexia.
Beyond lack of appetite, cancer and its treatment can cause additional symptoms that
negatively impact on dietary intake. For example, in the study of patients with breast
cancer who underwent chemotherapy, compared to healthy controls participants with
breast cancer reported poorer taste when measured with the Appetite, Hunger feelings and
Sensory Perception questionnaire (30.9 ± 0.71 vs. 22 ± 0.57; p<0.05). Additionally, each
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point decrease in taste was associated with a 16.4 kcal (95% CI 7.0 – 25.8) decrease in
energy intake.99 In a study of patients with advanced pancreatic cancer (n=39) who were
followed prospectively every 4 weeks until the end of life,101 moderate to severe pain at
rest (≥4 on Edmonton Symptom Assessment Scale) was associated with significantly
lower energy intake compared with low pain at rest at study inclusion and at three, monthly
follow up assessments. Other symptoms including oral dryness, nausea and fatigue were
also associated with a lower energy intake.101
The difference in energy intake between weight losing and weight stable patients with
cancer has been investigated in several studies. In a large study of patients with mixed
cancer diagnoses (n=297), where weight loss was defined as >5% body weight, there were
no significant differences in energy intake between weight stable and weight losing
participants.102 Weight losing participants consumed 28 ± 12 kcal/kg/day compared with
weight stable patients who consumed 24 ± 8 kcal/kg/day (p=0.052). A similar result was
observed in a study of patients with advanced pancreatic cancer (n=20) where cachexia was
defined as >5% weight loss within 6 months or >2% weight loss in those with a BMI <20
kg/m2.103 Participants with cachexia consumed 22.1 [14.3 – 33.9] kcal/kg/day compared
with participants who were non-cachectic who consumed 28.9 [8.6 – 79.7] kcal/kg/day
(p=0.09).103 These results indicate that energy intake is not significantly different between
those with and without weight loss. These findings may be attributable to variable energy
requirements between individuals related to differences in age, sex and lean mass.104
However, these result could also indicate that factors beyond reduced food intake are likely
to be involved in the development of cancer cachexia.
Altered metabolism
Pro-inflammatory cytokines and hormones could play a key role in the altered
metabolism of cancer cachexia. There are multiple components to the altered metabolism
seen in cancer cachexia including hypercatabolism, hypermetabolism and hypoanabolism.
Regarding hypercatabolism, tumour necrosis factor α (TNFα) and interleukin-6 (IL-6)
promote insulin resistance that decreases protein synthesis and stimulate the ubiquitinproteasome pathway that leads to protein catabolism.105 Adipose tissue is lost as a result of
increased lipolysis which occurs due to the tumour-induced lipid mobilising factor. 105
Several studies have evaluated differences in cytokines or biomarkers between weight
losing and weight stable patients with cancer. Although findings are inconsisent106-108 IL6 is the most commonly studied of the cytokines, with the most consistent results. 109-111
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Several studies have reported that serum IL-6 concentrations are higher in weight losing
compared with weight stable patients.109-111 Additionally, albumin concentrations are
lower and C-reactive protein (CRP) concentrations are higher in cancer patients with
weight loss and low muscle mass.112-116
Low concentrations of anabolic hormones such as testosterone could contribute to the
loss of skeletal muscle in patients with cancer. Testosterone concentrations can be lowered
by increasing age, cancer treatment,117 inflammation,117 and opioid medications used to
treat pain.117 Consequently, low testosterone concentrations are common among patients
with cancer, affecting between 40 and 90% of patients.117 Two studies in patients with
advanced cancer have previously examined the relationship between testosterone levels
and weight loss,118, 119 and both studies reported that there was an inverse correlation
between testosterone concentrations and weight loss.118, 119
Hypermetabolism, which is an increase in resting energy expenditure, could also play
a role in the onset and progression of cancer cachexia. When energy expenditure is
increased, amino acids are released from skeletal muscle for energy production resulting in
an overall loss of skeletal muscle.85 The tumour, hepatomegaly and liver metastases, and
activation of brown adipose tissue may contribute to an increase in resting energy
expenditure.120 Conversely, some patients with cancer may have a lower total energy
expenditure due to low physical activity levels and reduced food intake.120 Hypermetabolism
affects approximately 40% of patients with advanced lung cancer.121,

122

Despite the

theoretical relationship between hypermetabolism and weight loss, research indicates that
weight loss does not differ between hyper- and normo-metabolic patients.102 Overall, these
results highlight that more research is needed to fully understand the relationship between
metabolism and weight loss in patients with cancer, including those with MPD.

2.8.2

Treatment of cancer cachexia

Cancer cachexia could also be partly reversed by addressing inadequate dietary intake
before the refractory stage of cachexia is reached.93 Where weight loss is present, the
American Society of Clinical Oncology (ASCO) guidelines for the management of cancer
cachexia recommend referral to a dietitian for dietary counselling on a high-energy, highprotein diet.123 Energy and protein intakes of 25 – 30 kcal/kg/day and 1.0 – 1.5 g/kg/day
are considered appropriate targets.124
Exercise has been proposed as another potential treatment for cancer cachexia. As
resistance exercise training is associated with muscle hypertrophy, 125 this type of
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intervention could help to negate muscle loss associated with cancer cachexia. There are
currently a lack of exercise interventions in patients with cancer cachexia, 123 therefore
there is insufficient evidence to make a recommendation of the role of exercise in the
management of cancer cachexia.123
Cancer cachexia cannot be fully reversed without also addressing the underlying
metabolic alterations.94 Early clinical trials suggest that ghrelin analogues, selective
androgen receptor modulators, anti-inflammatory agents and cannabinoids are promising
pharmacological treatments for cancer cachexia.126 However, there is insufficient evidence
to recommend any of the studied pharmacological treatments for cancer cachexia, and no
treatments are clinically available.123
Multi-modal interventions that include a combination of nutrition support, exercise
training and pharmacologic agents could have an important role in the management of
cancer cachexia. Fearon et al93 has proposed that multi-modal interventions may be more
effective than single interventions as they address the multiple factors that contribute to
cancer cachexia. However, information on the relationship between nutritional status,
body composition and dietary intake, physical activity and inflammation are needed to
establish the potential for multi-modal interventions in patients with MPD.

2.9

Prevalence of malnutrition in cancer populations
Approximately one-quarter of patients with cancer have malnutrition.127 However,

the prevalence varies according to the cancer population, stage of disease and type of
cancer treatment received.127 Research from Australia indicates that upper gastrointestinal,
head and neck and lung cancer populations have the highest prevalence of malnutrition.127
Additionally, those who have metastatic disease or are receiving chemotherapy or
combined chemo-radiation are more likely to have malnutrition.127
There is a lack of information on the prevalence of malnutrition in patients with MPM,
as patients with MPM have historically been included in studies of patients with lung
cancer.128 Several studies have evaluated the prevalence of malnutrition in advanced lung
cancer populations.107, 129-137 The studies range in size from 25 – 1219 participants and the
majority of studies assessed nutritional status using the PG-SGA130, 132-134 or SGA,129, 131,
138

although other studies used the Mini-Nutritional Assessment (MNA),107 Malnutrition

Universal Screening Tool,135 or GLIM criteria.137 Notably, there was a large range in the
prevalence of malnutrition of between 24 – 100% of participants (Table 2.3). This large
range in the prevalence of malnutrition is likely related to the different criteria used to
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assess nutritional status. The lowest prevalence of malnutrition was observed where the
MNA or GLIM criteria were used, while the highest prevalence of malnutrition were
observed where a PG-SGA score of 2-8 was considered indicative of moderate
malnutrition. A PG-SGA score of two can be reached if a person is older than 65 years
and has a diagnosis of cancer, therefore this cut-point can result in a false positive
diagnosis of malnutrition. Regardless of these differences in assessment methods, these
results highlight that malnutrition is common in patients with advanced lung cancer.
However, as advanced lung cancer is distinctly different from MPM, research is needed
on the prevalence of malnutrition specifically in patients with MPM.
Several studies have also evaluated weight changes over time in patients with advanced
cancer. In a study of patients with unresectable pancreatic cancer (n=20), participants were
assessed for a median duration of 27 weeks.139 The median BMI at diagnosis was 20.7 kg/m2
and BMI just before death was lower at 17.7 kg/m2, which represented a median weight loss
of 5 kg over the course of the disease.139 This result indicated that weight loss could be
progressive over the disease course in patients with advanced cancer.
Further studies have indicated that weight loss occurs only in a proportion of patients
during any given time period. In a large prospective observational study of patients with
incurable cancer (n=544) patient-reported weight loss was graded from 0 to 4 based on
percentage weight loss and BMI.140 While the majority of participants did not change weight
loss grade in 3 months, between 19 and 39% of patients progressed to a more advanced
grade within 3 months140 and between 4 and 13% improved weight loss grade.140 A similar
result was reported from a multi-institutional prospective, observational study in patients
with non-small cell lung cancer (n=406) where the incidence rate of ≥5% weight loss was
reported at four time points over the disease course.141 At 3, 6, 9 and 12 months the incidence
rate of ≥5% weight loss ranged between 0.248 and 0.288. Therefore, within any 3-month
period approximately 30% of participants experienced greater than 5% weight loss.141 These
results indicate that in some advanced cancer populations there is a risk of weight loss
across the disease course. However, research is needed to understand the extent of the
issue of malnutrition across the disease course specifically in patients with MPM.
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Table 2.3

Prevalence of malnutrition in advanced cancer populations

Study

Cancer population

Study design,
sample size

Study
population
(age, % men)

Timing of
observation

Assessment criteria

Prevalence of
malnutrition

Antoun, 2019142

Metastatic colorectal cancer Prospective, n=76 Mean age 61
years, 50%
men

Prior to
chemotherapy

>5% weight loss or
>10% weight loss

49% with >5% weight
loss
26% with >10% weight
loss

Araujo dos Santos,
2015143

All cancer groups (27%
Cross-sectional,
prostate, 22% breast, 9%
n=96
lung). 49% with metastatic
disease

No specified
time point

PG-SGA global rating
of B or C

44% malnourished

Arrieta, 2010129

Advanced non-small cell
lung cancer

Prospective, cross- Median age 59
sectional, n=100 years, 53%
men

Prior to
chemotherapy

SGA global rating of B 51% malnourished (34%
moderately
or C
malnourished, 17%
severely malnourished)

Barata, 2017130

Advanced lung cancer

Cross-sectional,
n=37

While awaiting PG-SGA global rating
medical
of B or C
consultation or
treatment

Bozzetti, 2009144

All cancer types (42%
colorectal, 18% head and
neck, 16% stomach, 12%
lung); 42% stage IV
disease

Prospective, cross- Median age 64 No specified
sectional study,
years, men-totime point
women ratio
n=1000
1.8

NRS score ≥3 and
weight loss >10%

Cehreli, 2019131

Advanced lung cancer

Prospective, n=25 Mean age 63
years, 16%
men

SGA global rating of B 80% malnourished (48%
or C
moderately
malnourished, 32%
severely malnourished)

Mean age 71
years, 50%
men

Mean age 67,
84% men

35

Newly
diagnosed,
prior to
chemotherapy

81% malnourished (73%
moderately
malnourished, 8%
severely malnourished)
40% malnourished
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Study

Cancer population

Study design,
sample size

Study
population
(age, % men)

Timing of
observation

Assessment criteria

Prevalence of
malnutrition

No specified
time point

MNA score ≤11

Prospective, n=59 36% aged ≥65
years, 70%
men

No specified
time point

PG-SGA score 2-8 is
100% malnourished (25%
moderate
moderately
malnutrition; and ≥9
malnourished, 75%
is severe malnutrition severely malnourished)

Advanced lung cancer

Prospective,
n=495

61% aged >60
years, 71%
men

Newly
diagnosed

PG-SGA score ≥9
indicates need for
symptom
management and/or
nutrition support

25% with need for
symptom management
and/or nutrition support

Gioulbasanis, 2011107

Metastatic lung cancer

Cross-sectional,
n=115

Median age 66
years, 88%
men

Newlydiagnosed,
prior to
chemotherapy
treatment

MNA score ≤11

25% malnourished

Kiss, 2014146

Lung cancer; 25% with
advanced disease

Retrospective,
n=96

Median age 67
years, 64%
men

First or second
week of
radiotherapy

PG-SGA global rating
of B or C

15% malnourished (15%
mildly to moderately
malnourished, 0%
severely malnourished)

Koom, 2012147

Head and neck, lung and
gastrointestinal cancer
(lung 27%); included
palliative treatment intent

Prospective,
n=1,000

Mean age 59
years, men to
women ratio
7:3

Assessed 3
SGA global rating of B 40% malnourished (35%
weeks after the or C
moderately
initiation of
malnourished, 5%
radiation
severely malnourished)
therapy.

Chabowski, 2018145

Lung cancer; 40% with
metastatic disease

Cross-sectional,
n=257

Dong, 2020132

Advanced lung cancer

Ge, 2019133

Mean age 63
years, 55%
men
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23% malnourished
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Study

Cancer population

Study design,
sample size

Study
population
(age, % men)

Timing of
observation

Assessment criteria

Prevalence of
malnutrition

Li, 2018148

All cancer sites (lung 20%); Cross-sectional,
45% metastatic cancer
n=1138

Mean age 61
years, 58%
men

No specified
time

>5% weight loss in 6
months or BMI <20
and >2% weight loss

41% malnourished

Lin, 2019134

Advanced lung cancer

Prospective,
n=465

Mean age 60
years, 52%
men

Prior to
chemotherapy

PG-SGA global rating
of B or C

77% malnourished (66%
moderately
malnourished, 11%
severely malnourished)

Mohan, 2017135

Advanced non-small cell
lung cancer

Prospective,
n=148

Mean age 57
years, 87%
men

Not specified

MUST score ≥2
indicates a need for
treatment of
malnutrition

64.9% with a score ≥2

Montoya, 2010149

All cancer groups receiving Cross-sectional,
chemotherapy (lung cancer n=88
23%); 55% stage IV
disease

Mean age 56
years, 36%
men

During
chemotherapy

SGA global rating of B 48% malnourished (43%
moderately
or C
malnourished, 5%
severely malnourished)

Muscaritoli, 2017150

All cancer groups lung
cancer 16%); 48%
metastatic

Prospective,
observational
study, n=1,952

Mean age 63
years, 48%
men

First medical
oncology visit

MNA score ≤11

Percival, 2013151

Thoracic cancer (0.4%
mesothelioma); 74%
palliative treatment intent

Prospective,
n=243

Mean age 70
years, 57%
men

No time
specified

BMI <18.5 kg/m2,
35% malnourished (20%
>10% weight loss, or
of patients with
BMI <20 kg/m2 and
mesothelioma
>5% weight loss
malnourished)

37

9% malnourished
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Study

Cancer population

Study design,
sample size

Study
population
(age, % men)

Timing of
observation

Assessment criteria

Prevalence of
malnutrition

Platek, 2011152

All cancer groups (lung
cancer 39%); 40%
metastatic disease

Retrospective
study, n=227

Mean age, 56%
men

During hospital
admission

ICD-9 codes
documented by
physician
Dietitian assessment
that patient
“compromised”
BMI of <18.5 kg/m2

Sanchez-Lara, 2012136

Advanced non-small cell
lung cancer

Cross-sectional,
n=119

Mean age 62
years, 46%
men

Newly
diagnosed
prior to
chemotherapy

SGA global rating of B 60% malnourished (33%
moderately
or C
malnourished, 27%
severely malnourished)

Segura, 2005153

All cancer groups (lung
cancer 23%); 56% locally
advanced or metastatic
cancer

Retrospective,
cross-sectional
study, n=781

Median age 62
years, 64%
men

All treatment
phases
included

PG-SGA global rating
of B or C

Wie, 2010154

All cancer groups (lung
cancer 20%); 60.5% stage
III or IV cancer

Prospective, cross- Mean age 55
sectional study,
years, 56%
n=8895
men

During hospital
admission

BMI <18.5 kg/m2,
61% malnourished (36.5%
albumin <2.8 g/dL,
high risk of malnutrition,
total lymphocyte
24.8% at moderate risk
count <1200
of malnutrition).
cells/mm3 and nothing
per oral intake

Yin, 2020137

Lung cancer, 40% with
stage IV disease

Prospective,
n=1219

During hospital
admission

GLIM criteria with calf 24% malnourished
circumference and
body weight
standardised handgrip
strength to assess
reduced muscle mass

Mean age 59
years, 67%
men

38

9% malnourished using
ICD-9 codes
26% malnourished using
dietitian assessment
9% malnourished using
BMI

52% malnourished (40.4%
moderately
malnourished, 11.8%
severely malnourished)
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2.10 Relationship between malnutrition and patient-related
health outcomes
2.10.1 Quality of life
The relationship between malnutrition, defined by percent weight loss, and quality of
life in cancer populations has been reported in multiple studies.155 No data are available
on the relationship between malnutrition and quality of life in patients with MPM, however
some data is available from patients with lung cancer.136, 156 One large study in patients
with non-small cell lung cancer (n=531) with predominantly advanced stage disease,
compared the relationship between the different stages of cachexia, and quality of life
using the European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ-C30).157 The study reported that the functional, role and
social domains of quality of life decreased with advancing cachexia stage.157 Additionally,
in a cross-sectional study of patients with newly diagnosed advanced lung cancer (n=119),
participants with malnutrition had significantly lower physical functioning and role
functioning scores on the EORTC QLQ-C30 compared with well-nourished
participants.136 In another cross-sectional study which included patients with all stages of
lung cancer (n=180), global quality of life on the EORTC QLQ-C30 as well as all of the
questionnaire domains, including physical, role, emotional, cognitive and social, were
significantly lower in patients with malnutrition compared to well-nourished
participants.156 These results highlight a relationship between malnutrition and poorer
quality of life, particularly for domains related to physical and functional aspects of life,
however it is not known if this relationship exists in patients with MPM.

2.10.2 Physical activity, physical functioning and muscle strength
There is little information available in cancer populations on the relationship between
malnutrition and physical activity. However, one study in patients with non-small cell lung
cancer (n=531) with predominantly advanced stage disease, compared the relationship
between the different stages of cachexia, and self-reported physical activity.157 The study
reported that physical activity decreased with advancing cachexia stage, such that
participants who were well nourished participated in a median of 2712 metabolic
equivalent minutes of activity per week and participants who were cachexic participated
in only 495 metabolic equivalent minutes of activity per week.157
Several studies have reported on the relationship between malnutrition and physical
functioning and muscle strength. One study of patients with unresectable lung cancer
(n=37) assessed nutritional status with the PG-SGA prior to treatment and reported that

39

Chapter Two. Literature Review

those who were malnourished were more likely to have a handgrip strength in a lower
percentile compared with those who were not malnourished (p=0.026). Additionally, in a
study of patients with colorectal cancer (n=67)158 where nutritional status was assessed
prior to surgery, those who were malnourished, defined as weight loss >10%, had
significantly lower handgrip strength compared to those who were well-nourished, defined
as weight loss <10% (19.4 vs. 27.3 kg; p=0.013). Regarding measures of physical
functioning, a cross-sectional study conducted amongst older adults with cancer (n=185)
reported that compared to participants without weight loss, participants with unintentional
weight loss (weight loss >3 kg) had significantly lower handgrip strength (p=0.040) but
there was no difference in walking speed (p=0.172).159 The available data indicates that
malnutrition could be associated with poorer physical activity and muscle strength. In
patients with MPM one of the goals of care is to improve daily physical activities so an
understanding of the factors that could impact on daily physical activities will help to
inform future research and could impact on clinical practice.

2.11 Sarcopenia
The term sarcopenia was first defined in 1988,160 and is used to describe the presence
of low skeletal muscle mass and the resulting impairment of physical function.161 More
recently, sarcopenia has been defined as a skeletal muscle disorder that is progressive and
generalised in nature and is associated with a range of negative outcomes.162 Sarcopenia
was originally used to describe the age-related loss of skeletal muscle mass, however it is
now accepted that loss of skeletal muscle mass can be a consequence of inactivity,
inadequate dietary intake, disease or a combination of these factors.161

2.11.1 Diagnosis of sarcopenia
The first consensus statement on the diagnosis of sarcopenia was published by the
European Working Group on Sarcopenia in Older People (EWGSOP) in 2010. 161 The
working group identified three stages of sarcopenia: pre-sarcopenia, sarcopenia and severe
sarcopenia.161 Pre-sarcopenia was defined as the presence of low skeletal muscle mass,
while sarcopenia was defined as the presence of low skeletal muscle mass with either low
muscle strength or function and severe sarcopenia was defined as low skeletal muscle mass
with both low strength and function.161
An updated consensus statement on the diagnosis of sarcopenia was published by
EWGSOP in 2019.162 The updated statement does not refer to pre-sarcopenia and rather
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provides an alternative algorithm to facilitate the diagnosis of sarcopenia in clinical
practice.162 The working group recommended that assessment of sarcopenia begins with
an evaluation of muscle strength, and only if this measurement is low, is evaluation of
muscle mass or muscle quality performed.162 Although the EWGSOP criteria are
commonly used to define sarcopenia, it is acknowledged that multiple definitions of
sarcopenia exist, and there remains no international consensus on diagnostic criteria for
sarcopenia in older adults.
There is currently no consensus on the optimal body composition assessment method
for the measurement of muscle in patients with cancer. CT and DXA are both considered
appropriate for the measurement of muscle,162 although each has limitations as outlined in
section 2.6.2. To determine if muscle mass is indicative of low or normal muscle mass a
cut-point is applied. Multiple cut-points are available for both CT and DXA (Table 2.4).
CT cut-points have been established from values that were associated with mortality,163,
164

however it is not known if these values correspond with other clinical outcomes such

as physical function. DXA cut-points have been established from values that were more
than 2 standard deviations below a reference population of healthy young adults 165, 166 or
the lowest 20% of values of a population of older adults,167, 168 and are associated with
functional impairment in older adults.169 There is limited information on the comparability
of CT and DXA cut-points, however results from one study in advanced lung and
gastrointestinal cancer indicate only moderate agreement between methods for the
classification of low muscle mass.78 Further comparison of CT and DXA and their cutpoints are needed to investigate the impact of methodological decisions on research
findings.
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Table 2.4

Published cut-points for the classification of low muscle mass

Study

n/sex/age

Reference
population

Cut-point method Cut-point value

Computed tomography
Prado et al.
2008163

250; 54% men; Cancers of the
35-88 years
respiratory or
gastrointestinal
tract

Optimal
<52.4 cm2/m2 for
stratification, cut- men
off values
<38.5 cm2/m2 for
associated with
women
mortality

Martin et al.
2013164

1473; 56%
Cancers of the
men; 64.7 ±
respiratory or
11.2 years for gastrointestinal
men, and 64.8 tract
± 11.5 years
for women

Optimal
<43 cm2/m2 for
stratification; cut
men with BMI
off values
≤24.9 kg/m2;
associated with
<53 cm2/m2 for
mortality
men with
BMI>24.9
kg/m2
<41 cm2/m2 for
women

Dual energy x-ray absorptiometry
Baumgartner et
al. 1998165

808; 53% men; Healthy young
73.6 ± 5.8
adults
years for men
and 73.7 ±
6.1 years for
women

2 SD below mean <7.26 kg/m2 for
of healthy young
men
adults
<5.45 kg/m2 for
women

Newman et al.
2003167

2984; 48%
men; 70-79
years

Older adults

Sex-specific lowest <7.23 kg/m2 for
20% of the
men
distribution index <5.67 kg/m2 for
women

Delmonico et al. 2976; 48%
men; 70-79
2007168
years

Older adults

Sex-specific lowest <7.25 kg/m2 for
20% of the
men
distribution index <5.67 kg/m2 for
women

Gould et al.
2014166

Healthy young
adults

2 SD below mean <6.94 kg/m2 for
of healthy young
men
adults
<5.30 kg/m2 for
women

2371; 60%
men; 20-93
years
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2.11.2 Aetiology of low muscle mass
Age
As people age, and particularly from the fifth decade of life, muscle mass declines. 170
In a review which included five longitudinal studies ranging in duration from 5 – 12
years, the authors reported that median yearly muscle loss in participants with a mean age
of 75 years ranged from -0.024% to 1.3%,171 the decline in strength was disproportionate
to muscle mass; and that strength deteriorated at a greater rate than muscle mass. Notably,
changes in muscle mass and strength differed according to the sex of participants.
Compared to women, men experienced a greater decline in muscle mass (0.64 – 0.70%
vs. 0.8 – 0.98%) and strength (2.5-3.0% vs. 3.0 – 4.0%).171 These findings indicate that
while muscle loss and functional decline occur in both men and women, men are more
severely impacted.
As a result of this gradual decline in muscle mass, the prevalence of low muscle mass
increases with older age. In the New Mexico Elder Health Survey study of older adults
(n=426), the authors reported the prevalence of sarcopenia in Caucasian adults of different
age brackets, where sarcopenia was defined as muscle mass >2 standard deviations below
healthy adults.165 Sarcopenia was present in 13.5% of Caucasian men aged <70 years and
23.1% of women aged <70 years; and in 52.6% of men aged ≥80 years and 43.2% of
women aged ≥80 years.165 In another study, the authors reported the prevalence of
sarcopenia in healthy older adults (n=4504), where class II sarcopenia was defined as
muscle mass >2 standard deviations below healthy adults. The prevalence of sarcopenia
was low and remained consistent across age brackets.169 Class II sarcopenia was present
in only 6% of men aged and 9% of women aged 60-69 years; and in 7% of men and 11%
of women aged 70-79 years and ≥80 years.169 These results indicate that the prevalence of
low muscle mass increases with advancing age, although rates of low muscle mass vary
by gender and between populations.
The mechanisms responsible for the decline in muscle mass and function are
unknown, although several physiological changes that occur with older age could be
involved. These include an increase in the proportion of muscle fibres to a single motor
unit, fatty infiltration of the muscle, neural changes and hormonal changes such as
anabolic resistance, and inflammatory changes.172
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Physical activity
Individuals with higher physical activity levels are reported to have a lower risk of
developing low muscle mass. Steffl et al173 conducted a systematic review and metaanalysis173 of observational studies to evaluate the risk of low skeletal muscle mass among
adults aged older than 40 years (n=4605) according to their physical activity level and
reported that the odds ratio was 0.45 (95% CI 0.37 – 0.55) for those with the highest
physical activity level. This finding indicates that adequate physical activity could be
protective against the development of low skeletal muscle mass in older adults. However,
there is little information on the relationship between physical activity and changes in
skeletal muscle in patients with cancer. This information could be used to guide the
development of supportive care interventions aimed at preserving skeletal muscle mass.
Dietary intake
Higher protein intakes are associated with greater skeletal muscle mass and less loss
of skeletal muscle mass over time. In a cohort study of older adults (n=740),174 participants
who did not meet the recommended daily intake (RDI) for protein, of 64 – 81 g/day for
men and 46 – 57 g/day for women depending on the age group, had lower levels of
appendicular lean mass at baseline after adjusting for confounding factors (mean
difference -0.81, [95% CI -1.54 - -0.08] kg; p=0.03). In the Health, Aging and Body
Composition study175 where older adults aged between 70 and 79 years (n=2732) were
followed for three years, total protein intake was inversely associated with change in total
lean mass and appendicular skeletal muscle mass after adjusting for confounding factors.
Specifically, higher protein intake was associated with less muscle loss. Additionally,
participants with the highest protein intake of 1.2 g/kg/day lost 43% less total lean mass
and 39% less appendicular lean mass than those with the lowest protein intake of 0.8
g/kg/day (p<0.01). This indicates that adequate protein intake is protective against muscle
loss and that the level of adequate protein intake is higher in older adults compared to
young adults. As with physical activity, there is a lack of information on the relationship
between dietary intake and changes in skeletal muscle in patients with cancer, which is
critical for the development of supportive care interventions.
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2.11.3 Prevalence and factors contributing to low muscle mass in cancer
populations
The overall prevalence of low muscle mass in patients with cancer is reported to be
40%.176 In a review paper, Ryan et al177 summarised the prevalence of low muscle mass
according to cancer diagnosis, and reported the median prevalence of low muscle mass
ranged between 38 – 70%, although there was a large prevalence range within each
diagnosis. There is little information on the prevalence of low muscle mass in patients
with MPD, however a systematic review and meta-analysis has reported the overall
prevalence of low muscle mass in patients with lung cancer was 45%.178 Five of the studies
included in this publication were specifically in advanced lung cancer (Table 2.5).179-183
Other studies have also reported on the prevalence of low muscle mass in advanced lung
cancer.184, 185 The studies ranged in size from 33 – 441 participants and the majority of
studies used CT180-185 to measure muscle mass with only one study using DXA. 179 There
was a large range in the prevalence of low muscle mass of between 38 – 71% of
participants. This large range in prevalence of low muscle mass could be related to the
different cut-points used to assess muscle mass between studies. Regardless, these results
indicate high rates of low muscle mass among patients with advanced lung cancer. This
suggests that low muscle mass may also be common among patients with MPD, however
currently there is a lack of body composition data specific to patients with MPD to
investigate this hypothesis.
There is limited data available on characteristics associated with low muscle mass in
patients with cancer, however the prevalence of low muscle mass in men, at 25%, is almost
double that of women, at 13%.176 While chemotherapy is thought to contribute to muscle
loss in patients with cancer, due to its proteolytic effect on muscle,186 existing research
indicates that muscle loss can occur regardless of cancer treatment.183, 187 In a study of
patients with advanced lung cancer (n=222) who received a placebo in phase III trials, and
were therefore not receiving active treatment, 53% of participants lost skeletal muscle over
the trial period.187 In another study of patients with lung cancer (n=35) who were receiving
cancer treatment,183 54% of participants lost skeletal muscle over the treatment period, and
46% of participants maintained skeletal muscle.183 These findings indicate that muscle loss
may be related to factors beyond cancer treatment.
Progressive or advanced disease is a factor associated with muscle loss over time.
Conceptually, this make sense as the tumour is assumed to be responsible for the
catabolism associated with cancer cachexia.93 In a large study of patients with advanced
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cancer (n=368),188 skeletal muscle loss was greater and occurred more rapidly within 1
month of death compared with skeletal muscle loss that occurred more than 9 months from
death (cross-sectional muscle area -20.4 ± 13.4 cm2 vs. -13.6 ± 5.5 cm2; p<0.003),188 and
the chance of skeletal muscle loss within 90 days of death was increased (OR 2.67 [95%
CI 1.45 – 4.94]; p=0.002).188 These results could indicate that an increased rate and amount
muscle loss are indicative of the end of life. Prospective evaluation of body composition
in patients with MPM is needed to provide knowledge of the body composition changes
that occur over time and the factors associated with these changes. This could lead to the
development of targeted interventions to prevent or manage losses.
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Table 2.5

Prevalence of low muscle mass in advanced cancer populations
Study design/
sample size

Study population
(age, % men)

Prospective, n=76

Mean age 61 years, Prior to
50% men
chemotherapy

CT SMI at L3 <43
53%
cm2/m2 for men if BMI
<25 kg/m2 and <53
cm2/m2 if BMI >25
kg/m2, and <41 cm2/m2
for women

Advanced non-small cell Prospective, n=441
lung cancer

Mean age 67 years
for men and 65
years for women;
52% men

CT SMI at L3 <55.4
cm2/m2 for men and
<38.9 cm2/m2 for
women

Chambard, 2018179

Non-small cell lung
cancer with bone
metastasis

Mean age 52 years, Time of first bone DXA ASM <7.26 kg/m2
75% men
metastasis
for men and >5.45
kg/m2 for women

Daly, 2018189

Foregut cancer (61%
Prospective, n=225
gastro-oesophageal,
39% hepato pancreatobiliary); 51% with
stage IV disease

Mean age 66 years, Prior to
67% men
chemotherapy

Kakinuma, 2018185

Advanced non-small cell Retrospective, n=65
lung cancer

Mean age 66 years, Prior to
CT SMI at L3 <49
chemotherapy or cm2/m2 for men and
62% men
molecular
31cm2/m2 for women
targeted therapy

Study

Cancer group

Antoun, 2019142

Metastatic colorectal
cancer

Baracos, 2010184

Prospective, n=64

47

Timing of
observation

New patient
assessments
referred for
treatment

Assessment criteria

Prevalence low
muscle mass

47%

47%

CT SMI at L3 <43
40%
cm2/m2 for men if BMI
<25 kg/m2 and <53
cm2/m2 if BMI ≥25
kg/m2, and <41
cm2/m2 in women
40%
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Study

Cancer group

Study design/
sample size

Study population
(age, % men)

Kim, 2015190

Small cell lung cancer;
68% extensive disease

Retrospective, n=149 Mean age 69 years, Newly diagnosed
85% men

CT SMI at L3 <49
cm2/m2 for men and
31cm2/m2 for women

Kim, 2018191

Lung cancer; 72% with
advanced disease

Retrospective, n=778 Mean age 68 years, Newly diagnosed
73% men

CT SMI at L3 of <55
48%
cm2/m2 for men and
<39 cm2/m2 for women

Kimura, 2015180

Advanced non-small cell Retrospective, n=134 Median age 66
lung cancer
years, 60% men

Kiss, 2018192

Non-small cell lung
Retrospective
cancer; 44% with stage (secondary
IIIB disease
analysis), n=41

Mean age 66 years, Prior to
71% men
radiotherapy

Nipp, 2018193

Incurable lung or noncolorectal
gastrointestinal cancer
(57% lung cancer)

Prospective, n=237

Mean age 64 years, Within 8 weeks of CT SMI at L3 of <55
55%
diagnosis; no
cm2/m2 for men and
54% men
prior therapy for <39 cm2/m2 for women
metastatic
disease

Onishi, 2019194

Unresectable advanced
oesophageal cancer

Prospective, n=176

Mean age 65 years; Prior to treatment
85% men

CT SMI at L3 of <52.4
cm2/m2 for men and
<38.5 cm2/m2 for
women

57%

Prado, 2008163

Respiratory and
Prospective, n=250
colorectal cancer (43%
lung cancer); 34%
stage IV disease

Mean age 64 years, New patient
54% men
assessments

CT SMI at L3 of <52.4
cm2/m2 for men and
<38.5 cm2/m2 for
women

15%

48

Timing of
observation

Newly diagnosed

Assessment criteria

Prevalence low
muscle mass
53%

CT SMI at L3 of <41
38%
cm2/m2 for men and
<38 cm2/m2 for women
<43cm2 for men if BMI 61%
<24.9 kg/m2 and <53
cm2 in men if BMI >25
kg/m2, and <41cm2 for
women,
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Study design/
sample size

Study population
(age, % men)

Timing of
observation

Cancer group

Prado, 2013195

Advanced non-small cell Retrospective
lung or colorectal
(secondary
cancer
analysis); n=28

Mean age 65 years, No particular time DXA ASMI <7.26 kg/m2 36%
68% men
point described.
for men and <5.45
kg/m2 for women

Rier, 2018196

All cancer groups
(haematological and
solid cancers); 45%
stage IV disease

Median age 72
years, 56% men

Rossi, 2018181

Advanced non-small cell Retrospective, n=33
lung cancer

Mean age 66 years, Prior to treatment
18% men
with Gefinitib

CT SMI at L3 <55
61%
cm2/m2 for men and
<39 cm2/m2 for women

Sheean, 2019197

Metastatic breast cancer
(oestrogen receptor
positive)

Median age 62
years, 0% men

Currently
undergoing
treatment

CT SMI at L3 <41
cm2/m2

Srdic, 2016182

Advanced non-small cell Prospective, n=55
lung cancer

Median age 64
years, 67% men

Prior to
chemotherapy

CT SMI at L3 <55
47%
cm2/m2 for men and
<39 cm2/m2 for women

Stene, 2015183

Advanced non-small cell Prospective, n=35
lung cancer

Mean age 67 years, Prior to
52% men
chemotherapy

Prospective cohort,
n=131

Prospective, n=41

49

Prior to, during
and after
chemotherapy

Assessment criteria

Prevalence low
muscle mass

Study

CT SMI at L3 <43
48%
cm2/m2 for men if BMI
<25 kg/m2 and <53
cm2/m2 if BMI ≥25
kg/m2, and <41 cm2/m2
for women

CT SMI at L3 of <52.4
cm2/m2 for men and
<38.5 cm2/m2 for
women

34%

71%
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2.12 Relationship between low muscle mass and patient-related
health outcomes
2.12.1 Quality of life
A small number of studies have reported on the relationship between low muscle mass
and quality of life in cancer populations.193, 198 In a large study in chemotherapy naïve
patients with advanced lung cancer (n=734)198 the authors reported an association between
skeletal muscle mass and global quality of life among men, where men with lower skeletal
muscle mass had significantly poorer scores on the EORTC QLQ-C30. Notably, the
researchers identified a cut-point for both men and women below which quality of life
scores began to deteriorate, while above the cut-point quality of life scores were stable.198
In a retrospective, study of patients with newly diagnosed advanced cancer (n=237), low
skeletal muscle mass, was associated with lower scores on the Functional Assessment of
Cancer Therapy – General (FACT-G) quality of life assessment after adjusting for age, sex,
marital status, education and cancer type (p=0.048).193 These data indicates that low
skeletal muscle mass could be associated with poorer quality of life in patients with
advanced cancer, however it is not known if this relationship exists in MPM.

2.12.2 Physical activity, physical functioning and muscle strength
There is a lack of information on the relationship between low muscle mass and
physical activity in patients with cancer, however a small number of studies have reported
on the relationship between low muscle mass, physical functioning and strength. In a study
of older adults with cancer (n=131), including 45% with stage IV disease, participants
underwent evaluation of muscle mass via CT and completed five functional tests; the five
times sit to stand test (FTSTS); handgrip strength; steep ramp test; walking speed and Timed
Up and Go.199 There was a significant association between muscle mass and FTSTS,
handgrip strength and the steep ramp test, but not walking speed or Timed Up and Go;199
and participants with low muscle mass in combination with slow walking speed or low
handgrip strength (n=10) had greater limitations in their activities of daily living following
chemotherapy.199 In a study of overweight patients with advanced cancer (n=28),195
participants completed handgrip strength testing and a two-minute walk test. Compared to
those with normal muscle mass, mean handgrip strength was lower among participants with
low skeletal muscle mass;195 no differences were observed in two-minute walk test results
between groups. Similar findings were reported in a prospective study of older adults with
advanced lung cancer (n=30) undergoing chemotherapy.200 Participants in this study
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underwent handgrip strength measurements and completed an incremental shuttle walking
test at study enrolment, 6 and 12 weeks;200 a significant linear association was found between
changes in skeletal muscle index and changes in handgrip strength, however no differences
were observed with regard to the walk test.200 These preliminary data indicate a relationship
between muscle mass and handgrip strength, however handgrip strength may not reflect
overall strength or function.201 Physical activity data and physical performance tests,
especially muscle strength-dependent tests such as the chair rise and Timed Up and Go,43
are therefore needed to evaluate the relationship between low muscle mass and physical
functioning in patients with MPM.

2.13 Effects of exercise on physical function and body composition
Exercise is distinct from physical activity in that it is planned, structured and
repetitive; and undertaken with the purpose of maintaining or improving physical fitness.47
The two principal modes of exercise are resistance and aerobic exercise training. The
American College of Sports Medicine has defined resistance exercise training as exercise
in which muscles work against a force 60% or higher of maximum, 38, 202 while aerobic
exercise training has been defined as exercise in which the large muscles of the body move
in a rhythmic manner over a period of time.38
Considerable research has examined the impact of exercise interventions on patients
with cancer203 and more recently the impact of exercise has been examined in patients with
advanced cancer. When the first systematic review article of exercise interventions in
patients with advanced cancer was published in 2009204 only three were randomised
controlled trials were identified. Several review articles of exercise interventions in
patients with advanced cancer have since been published205-208 and 15 randomised
controlled trials have now been identified.206

2.13.1 Physical functioning
Physical functioning is commonly reported as an outcome measure in exercise
intervention studies in patients with advanced cancer.208 Outcome measures include a
combination of self-report questionnaires, physical performance tests and muscle strength
tests.208 The physical performance tests included were the Six Minute Walk Test, 400 m
walk, 6 m walk, chair stand, timed up and go and Self Physical Performance Battery. 208
Results showed that 87% of the studies that assessed physical function reported a
significant improvement in at least one physical functioning measure following the
exercise intervention.208
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A Cochrane review has recently investigated the effects of exercise training
specifically in patients with advanced lung cancer.209 Regarding the outcome measures,
three randomised trials included six-minute walk test (n=59) and three randomised trials
included self-reported physical functioning (n=73).209 The findings were that exercise
participants had a significantly greater improvement in six-minute walk distance when
compared with the control participants.209 However, there was no difference between
groups for self-reported physical functioning.209
In another randomised trial in advanced lung cancer (n=218),210 patients participated
in a 12 week supervised aerobic and resistance exercise intervention or received usual care
and completed measurements of muscle strength and a six-minute walk test. Participants in
the intervention group had significantly greater strength at the end of the intervention, when
compared with the control group.210 However, there was no difference between groups for
six-minute walk distance.210
In a randomised trial of women with metastatic breast cancer (n=14), women
participated in a supervised resistance exercise and unsupervised walking intervention or
received usual care.211 Participants completed a measurement of leg strength and a sixminute walk test. While adherence to the supervised resistance exercise was high, there
were no differences between the intervention and control group for leg strength or sixminute walk distance.211 Overall, exercise interventions appear to have a positive effect on
physical functioning outcomes in advanced cancer populations.

2.13.2 Body composition
There has been substantial research on the effects of exercise interventions on body
composition outcomes in patients with prostate and breast cancer. A meta-analysis which
included seven prostate cancer studies,212 concluded that whole body lean mass increased
significantly following resistance exercise interventions. The estimated improvement in
whole body lean mass was 1 kg (95% CI [0.15 – 1.84]; p=0.028). Two randomised
controlled trials in prostate cancer have been published since this meta-analysis. The first
was a study of the effect of aerobic and resistance exercise training in men treated with
androgen deprivation therapy.213 The findings were that, compared with the control group
the intervention group gained significantly more lean mass (mean difference 0.8 kg;
p=0.015).213 The second study, was an investigation of the effects of aerobic, resistance
and flexibility training in men with advanced prostate cancer and bone metastases.214 In
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contrast, there were no differences between the control and intervention group with regard
to the change in lean mass (mean difference 0.3 kg; p=0.584).
Randomised controlled trials conducted in patients with breast cancer also indicate
that resistance exercise interventions have a positive impact on lean mass.215, 216, 217, 218 In
a study of patients with breast cancer undergoing chemotherapy, resistance exercise
training was compared with aerobic exercise and usual care.215 Compared with the usual
care group the resistance exercise group gained significantly more lean mass (mean
difference 0.32 kg/m2; p=0.017), however there were no differences between the aerobic
and resistance exercise intervention groups (mean difference 0.18 kg/m2; p=0.35).215 This
indicates that there is evidence that exercise training improves lean mass in patients with
prostate and breast cancer.
There is currently limited data on the effects of exercise training on body composition
outcomes in advanced cancer populations. Of the review articles on exercise interventions
in patients with advanced cancer, only one reported on body composition outcomes.208 In
this review, nine randomised controlled trials were identified that assessed body
composition.208 Of these, only four used non-anthropometric measures for body
composition assessment; three used DXA and one used plethysmography. The four studies
were conducted in patients with prostate cancer, lymphoma and myeloma. All exercise
interventions were of 3-months duration, but differed in the level of supervision and type
of exercise. The findings were that exercise training significantly improved lean mass in
all four studies. Notably, none of these studies included patients with MPD or other
thoracic cancers. As patients with thoracic cancers have a particularly high disease burden,
it may be more difficult to achieve improvements in lean mass with exercise training in
these cancer populations.

2.14 Effects of dietary intake on exercise efficacy
One concern around exercise training in advanced cancer populations is the potential
impact of inadequate dietary intake on exercise outcomes. Approximately one-quarter of
patients with advanced cancer have inadequate energy intake.97,

98

During periods of

inadequate energy intake amino acids from the diet or skeletal muscle may be used as an
energy source rather than for muscle protein synthesis,219 which may result in a reduced
physical functioning and body composition response to exercise. However, there is a lack
of published research on the relationship between dietary intake and response to exercise
interventions in cancer populations.
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Although there is a lack of information on the relationship between dietary intake and
exercise outcomes in cancer populations, there are a small number of studies in healthy
older adult populations. A recent systematic review and meta-analysis reported on
randomised controlled trials that compared the effects of dietary protein on body
composition outcomes in healthy older adults.220 Only three of the studies had compared
dietary protein intakes and body composition outcomes following resistance exercise
training.221-223 Overall, findings indicated that participants with protein intakes greater than
the Recommended Daily Allowance (RDA) of 0.8 g/kg/day had significant improvements
in lean mass while participants who had protein intakes consistent with the RDA had no
change in lean mass.220 These findings indicate that higher than usual protein intakes may
be required to produce improvements in lean mass in older adults participating in
resistance exercise training.
Contrasting results were reported in a randomised controlled trial of postmenopausal
women (n=23) who participated in a 10-week resistance exercise intervention.224 All
participants in the study were given individualised dietary plans with the same calories as
their usual diet, however the intervention group consumed 1.2 g/kg/day of protein and the
control group consumed 0.8 g/kg/day of protein.224 Both the intervention and control
groups had a significant improvement in lean mass.224 Therefore, higher protein intake in
excess of the RDA did not result in greater improvements in lean mass.
One study has explored the effects of protein intake on body composition and physical
functioning outcomes in older women living in retirement villages.225 The women, aged 60
– 90 years, participated in a 4-month progressive resistance exercise intervention.225 The
intervention group had two 80 g servings of cooked lean red meat per day, while the control
group had cooked rice or pasta as the alternative.225 There were no significant differences
between the intervention and control groups with regard to energy intake but protein intake
was significantly higher in the intervention group.225 Compared with the control group, the
intervention group had a greater improvement in lean mass and muscle strength. However,
both groups had similar improvements in the physical performance tests.225 This indicates
that while adequate protein intake may be important for optimising muscle mass,
improvements in physical performance could be independent of dietary intake.
There is limited information on the relationship between energy intake and outcomes
of exercise training. However, one study in adults aged 56 – 80 years (n=12) has reported
on the relationship between energy intake and body composition outcomes following a
12-week resistance exercise intervention.223 Energy expenditure increased as a result of
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increased resting metabolic rate and exercise, and the mean energy intake required for
weight maintenance increased by approximately 15%.223 These results indicate that during
exercise training participants may need greater amounts of energy to achieve muscle gains
and maintain a stable weight. This finding is particularly relevant for development of
exercise interventions for patients with advanced cancer, as participants may have
difficulty increasing their energy intake to meet the metabolic demands of exercise. As
weight maintenance is an important clinical goal it is imperative that this outcome is not
disrupted with exercise training. Research is needed to clarify the relationship between
dietary intake and exercise outcomes in advanced cancer populations, which will help to
inform the design of future exercise interventions.
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Abstract
Purpose: Malignant pleural effusion (MPE) affects 1 million people worldwide annually
and can significantly impair physical activity. Accelerometry is a validated method of
objectively assessing physical activity. The purpose of this study was to determine the
compliance in patients with MPE to accelerometry and describe their activity.
Methods: Patients with MPE wore an Actigraph GT3X accelerometer over a 7-day
continuous wear protocol. Compliance was measured as the percent of patients who had
≥4 valid days (i.e., 8-hour/day of waking wear-time). Eastern Cooperative Oncology
Group performance status was documented the day of actigraphy initialization.
Results: Forty-six patients with MPE received accelerometers; 44 (95.7%) returned their
device. No complications were reported on their use. Forty subjects (90.9%) had ≥4 valid
days of wear-time. Patients spent most of their waking hours sedentary [mean 11.0 (SD 1.95)
hours], with limited participation in moderate and vigorous physical activity [mean 9.5 (SD
14.16) minutes]. Compared to patients with better performance status (n=32), patients with
poorer performance status (n=11) spent significantly more hours/day sedentary [mean
difference 2.1 (CI 0.86-3.32); p=0.001], as did those who survived <3 months (n=5)
compared to >12 months (n=27) [mean difference 2.6 (CI 0.49-4.77); p=0.013).
Conclusion: Accelerometry was applied successfully in patients with MPE with high
compliance and no adverse events. This is the first reported objectively measured physical
activity in patients with MPE and revealed high sedentary behavior and low physical
activity. The data reflected patient performance status and discriminated between survival
groups. Accelerometry can provide a useful measure for future interventional studies in
patients with MPE.
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3.1

Introduction
Malignant pleural effusions (MPE) are estimated to develop in 200,000 people in the

United States each year.1 The development of an MPE can be a consequence of metastatic
spread of any cancer, but more commonly lung, breast and gynecological cancers or from
primary pleural neoplasms (e.g., mesothelioma).2 The presence of MPE represents
incurable disease and median survival ranges from 3 to 12 months from first presentation.2
Breathlessness is a common and debilitating symptom reported by this patient group and
interventions are aimed at managing symptoms for optimal quality of life. 3
Breathlessness and other symptoms that result from MPE are likely to limit a person’s
ability to be physically active. In patients with lung cancer, breathlessness and fatigue
appear to be associated with lower physical activity levels. 4,

5

Preliminary research

suggests that patients with advanced cancer spend the majority of their time sedentary,
with Lowe et al6 reporting that patients with brain metastases spend an average of 20.2
hours per day supine or sitting, and none met physical activity guidelines of 150 minutes
per week of moderate to vigorous physical activity (MVPA). In patients with breast,
colorectal, lung and ovarian cancer, those that are more physically active report better
quality of life.7-12 However, activity levels in patients with MPE remain unknown.
Considering this clinical population has a poor prognosis, high symptom burden, and often
undergoes invasive medical treatments (e.g., indwelling pleural catheter, chemotherapy). 3
data regarding physical activity and sedentary behavior in patients with MPE is needed.
Performance status rating is routinely used in cancer populations to assess patient
suitability for interventions13 and is a reliable predictor of survival in patients with MPE.2
The Eastern Cooperative Oncology Group (ECOG) and Karnofsky performance status
scales are the most commonly used measures of performance status in this population. 14,
15

These ratings are largely based on the ability of patients to engage in their usual activities

of daily living, including physical activity.14, 15 However, as performance status ratings are
subjective and broad, they may fail to detect small but meaningful changes in physical
activity levels. Accelerometers, which objectively measure physical activity and sedentary
behavior, may be more sensitive to these modest changes and could be more reliable.
However, it remains to be seen if accelerometry derived objective measures of physical
activity and sedentary time can differentiate between patients by performance status
category or categorized survival groups.
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The primary aim of this study was to determine if patients with malignant pleural
effusion (MPE) were compliant with accelerometry designed to measure physical activity
and sedentary behavior. Second, we aimed to describe the physical activity and sedentary
behavior of patients with MPE. We also aimed investigate the relationship between
physician ratings of physical performance status, survival and accelerometer measured
physical activity and sedentary behavior.

3.2

Methods

3.2.1

Participants

This study was approved by the Sir Charles Gairdner Group Human Research Ethics
Committee (Quality Improvement No: 11149). From December 2014, patients with MPE
at this center were asked by their physician to wear an accelerometer as part of clinical
care. Patients were included in this study if they had a confirmed diagnosis of MPE and
had worn an accelerometer between December 2014 and April 2016.

3.2.2

Measures

Demographic and medical variables
Patient’s medical records were reviewed for baseline demographic data, cancer
diagnosis, performance status, pleural effusion characteristics and comorbidities. iSOFT
Clinical Manager was used to access date of death. Survival was calculated as the time
between accelerometer initialization and date of death. Patients were then categorized into
groups <3 months, 3-12 months or >12 months based on their survival. Chest radiographs
completed within one week of accelerometer wear were characterized and graded on a
scale of 0 to 5 according to established criteria.16 Specifically, a grade 1 effusion
represented blunting of the costophrenic angle, grade 2 is more than blunting of the
costophrenic angle but less than 25% of the hemithorax occupied by pleural fluid, grade 3
occupying 25-50% of the hemithorax, grade 4 occupying 50-75% of the hemithorax and
grade 5 occupying >75% of the hemithorax.16
Accelerometer compliance
Compliance with actigraphy protocol was assessed by the number and percentage of
patients who wore the actigraph for 4 or more valid wear days.17
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Physical activity and sedentary behavior
Patients were instructed to wear the accelerometer (Actigraph GT3X+; Actigraph,
Pensacola, FL, USA) on their hip continuously (24hr/day) for 7 days and record any nonwear time in a diary provided for the 7-day period.
Accelerometers were programmed to record raw data at a frequency of 30Hz. Data
were later reduced to vertical axis movement counts per 60-second epoch. Accelerometer
data were downloaded and processed in SAS (version 9.3, SAS Institute, Cary, NC, USA).
Waking wear time was determined by visual inspection of the ActiGraph file by a trained
rater and an automated algorithm.18 A valid day was defined as 8-hours (hr) of waking
wear time.19 Accelerometers with at least one valid day of data were analyzed.
Common cut off points were used to classify sedentary time as <100 counts/minute
(cpm), light activity as 100-1952 cpm and MVPA as >1952 cpm.20, 21 Bouts of sedentary
time and physical activity were classified as <5 min, 5 to <10 min, 10 to <20 min, 20 to
<30 min, 30 to <60 min and ≥ 60 min. Prolonged sedentary time was defined as time spent
in sedentary bouts of ≥20 and ≥30 minutes. Step counts were processed as uncensored
(Low Frequency Extension turned on) and censored (36% adjustment for
overestimation).22 We used commonly reported targets of ≥150 minutes moderate
intensity activity/week and ≥7,000 accelerometer measured steps/day to assess adherence
to physical activity recommendations.23 All variables were calculated per day and then
averaged across all valid days for each patient. Data from returned Actigraph GT3X
devices were analyzed and the results filed in the patient’s medical record. For the current
study, the information on physical activity and sedentary behavior was accessed from
medical records retrospectively.
Performance status
Physicians’ recorded physical performance status was assigned according to the
ECOG rating classification.14 An ECOG rating of 0 is assigned to a person who is fully
active and able to carry on all pre-disease performance without restriction, a rating of 1 is
given when a person is restricted in physically strenuous activity but ambulatory and able
to carry out work of a light or sedentary nature, a rating of 2 is assigned to a person who
is ambulatory and capable of all self-care but unable to carry out any work activities and
are up and about more than 50% of waking hours, a rating of 3 is assigned to a person
capable of only limited self-care and confined to bed or chair more than 50% of waking
hours, a rating of 4 is given when a person is completely disabled and cannot carry out any
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self-care and is totally confined to bed or chair.14 Physician rated performance status was
recorded on the same day that accelerometers were initialized and accessed from medical
records retrospectively. Patients were grouped as either good performance status (I.e.,
ECOG 0-1) or poor performance status (I.e., ECOG ≥2), as these are common cut-points
used in decision making for treatment and clinical trials.

3.2.3

Statistical analyses

Patients with at least one valid day of data were included in the analysis. Statistical
analyses were conducted using SPSS (version 23, IBM Corporation, Somers, NY, USA).
Data were expressed as mean (SD) unless otherwise stated. Demographic and medical data
were analyzed using descriptive statistics. Patients were grouped according to ECOG
status (i.e., 0-1 and ≥2) and physical activity and sedentary behavior were analyzed using
descriptive statistics. Two-tailed independent t tests were used to test for differences
between the mean physical activity and sedentary time for ECOG groups 0-1 and ≥2. Oneway ANOVA was used to test for differences between the mean physical activity and
sedentary time for survival groups <3 months, 3-12 months and >12 months. Where the
data were not normally distributed, the Mann-Whitney and Kruskal Wallis tests were
applied and the median and inter-quartile range (IQR) is reported. An alpha of 0.05 was
used to determine statistical significance. Figures were created using GraphPad Prism
(version 7, GraphPad Software, La Jolla, California, USA).

3.3

Results

3.3.1

Participant characteristics

Actigraph GT3X accelerometers were given to 46 patients with MPE [72% male; mean
age 69 (SD 8.2)]. Thirty-three patients (71.7%) had an ECOG performance status rating of
0 to 1, seven patients (15.2%) had an ECOG rating of 2 and six patients (13.0%) were given
an ECOG rating of 3. Twenty-nine patients (63.0%) survived more than 12 months from the
date of accelerometer initialization, eleven patients (23.9%) survived 3-12 months, six
(13.0%) survived less than three months. Demographic and medical characteristics of
patients are reported in Table 3.1. Approximately two-thirds (65.2%) of patients had a
diagnosis of mesothelioma. Most (70%) of the patients had a mild to moderate sized effusion
occupying up to 50% of the hemithorax (i.e., grade 2 or 3 on chest radiograph).
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3.3.2

Accelerometer compliance

Forty-four accelerometers (95.7%) were returned and one accelerometer did not meet
the minimum requirements for analysis. Of the two accelerometers that were not returned,
one patient died shortly after the 7-day wear time was completed and the patient’s family
did not return the accelerometer, the second patient reported they lost the device. Of the
forty-three accelerometers analysed, forty (93.0%) were returned with four or more valid
days. The number of valid days and average wear time obtained from returned
accelerometers is presented in Table 3.2.

3.3.3

Physical Activity and sedentary behavior

Patients in this study averaged 15.3 (SD 1.69) hours of waking wear time per day.
On average patients spent 11.0 (SD 1.95) hours sedentary and participated in 4.2 (SD
1.65) hours of light activity and 9.5 (SD 14.16) minutes of MVPA per day, which was
equivalent to 71.6%, 27.4% and 1.0% of their waking hours, respectively. Five (10.9%)
patients completed ≥150 minutes of MVPA over the seven-day period. More than a third
(37.1%) of all sedentary time was spent in bouts of 30 minutes or more, equivalent to 4.1
(SD 2.10) hours per day. On average patients took 8817 (SD 4838) uncensored or 5643
(SD 3096) censored steps per day. Fifteen (34.9%) patients achieved the target of ≥7000
censored steps per day.

3.3.4

Physical activity and sedentary behavior according to performance
status and survival groups

Patient physical activity level according to performance status is reported in Table
3.3. The two performance status groups had equivalent wear time however, patients with
good performance status spent significantly less time as sedentary compared to those with
poor performance status [10.4 (SD 1.67) hr/day vs. 12.5 (SD 1.94) hr/day; p=0.001]. Light
activity in patients with good performance status was on average 1.5 hours higher than for
the poor performance status group [4.6 (SD 1.65) hr/day vs. 3.1 (SD 1.04) hr/day; p=0.06].
Patients with good performance status took more than double the median number of steps
compared with patients of poor performance status [6721 (IQR 4150 - 9193) vs. 3126
(IQR 1035 - 3845); p<0.001; Figure 3.1].
Wear time and patient physical activity according to survival groups is reported in
Table 3.4. Patients with a survival of >12 months and 3-12 months spent significantly less
time sedentary compared to those who survived <3 months [10.8 (SD 2.09) hr/day and
10.6 (SD 1.51) hr/day vs. 13.3 (SD 2.62) hr/day; p=0.013 and p=0.044 respectively;
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Figure 3.2]. Those patients who survived >12 months participated in almost 2 hours more
light activity per day than those who survived <3 months [4.5 (SD 1.48) vs. 2.6 (SD 1.45)
hr/day; p=0.044; Figure 3.2]. The median number of steps taken by patients with a survival
of >12 months was 1.5 times the steps recorded by those with 3-12 months survival and more
than double the steps taken by those with <3 months survival. However, this result was not
statistically significant [6340 (IQR 3728-9224) vs. 4114 (IQR 1753-6632) vs. 3216 (IQR
1831-5830); p=0.106; Figure 3.1].
Patients with good performance status had two fewer bouts of prolonged sedentary time
of ≥20 minutes compared with patients of poor performance status [7.5 (SD 2.26) vs. 9.4
(SD 2.14); p=0.019]. Performance status groups did not differ significantly in the number of
prolonged bouts of sedentary time ≥30 minutes [4.2 (SD 1.81) vs. 5.0 (SD 1.78; p=0.177].
Patients with good and poor performance status participated in a similar number of
bouts of light activity for short periods of <5 minutes [71.7 (SD 14.06) vs. 72.4; (SD
10.81); p=0.871]. These short bouts of light activity were the most common form of light
activity in both performance status groups. Patients with good performance status spent
50.9% (SD 14.23) of total light activity in short bouts compared to 69.0% (SD 16.48) for
those with poor performance status (p=0.001). Patients with good performance status
completed almost five additional bouts of light activity of between 5 and 10 minutes [11.7
(SD 4.41) vs. 6.9 (SD 4.52); p=0.004]. Light activity according to performance status
accumulated in bouts of 5 minutes or more is presented in Figure 3.3.
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Table 3.1

Demographic and medical characteristics of patients
Eastern Cooperative Oncology Group
performance status
Total (n=46)
n (%)

Age (years)

Good (n=33)
n (%)

Poor (n=13)
n (%)

68.5 (SD=7.85)

69.2 (SD=7.16)

66.7 (SD=9.46)

Male

33 (71.7)

22 (66.7)

11 (84.6)

Female

13 (28.3)

11 (33.3)

2 (15.4)

26.7 (SD=4.82)

27.2 (SD=3.73)

Mesothelioma

30 (65.2)

24 (72.7)

6 (46.1)

Lung Cancer

11 (23.9)

6 (18.2)

5 (38.5)

5 (10.9)

3 (9.1)

2 (15.5)

0

0 (0)

0 (0)

0 (0)

1

8 (21.6)

4 (15.4)

4 (36.4)

2

14 (37.8)

12 (46.2)

2 (18.2)

3

12 (32.4)

7 (26.9)

5 (45.4)

4

3 (8.1)

3 (11.5)

0

5

0 (0)

0 (0)

0

3 (8.1)

2 (6.1)

1 (9.1)

Loculation

13 (35.1)

11 (33.3)

2 (18.2)

Catheter

19 (51.4)

12 (36.4)

7 (63.6)

COPD

5 (10.9)

3 (9.1)

2 (15.4)

Asthma

4 (8.7)

4 (12.1)

0 (0)

IHD

5 (10.9)

4 (12.1)

1 (7.7)

Diabetes

2 (4.3)

2 (6.1)

0 (0)

OA

6 (13.0)

5 (15.2)

1 (7.7)

Depression

2 (4.3)

1 (3.0)

1 (7.7)

Gender (%)

Body mass index
(kg/m2) (n=43)

25.3 (SD=7.19)

Cancer diagnosis (%)

Other
Pleural effusion (%) (n=37)
Effusion grade (0-5)

Bilateral effusions

Comorbidities (%)

COPD: Chronic Obstructive Pulmonary Disease; IHD: Ischemic Heart Disease, OA: Osteoarthritis
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Table 3.2

Number and mean valid days of accelerometry data.
Eastern Cooperative Oncology Group
performance status
Total (n=46)
n (%)

Good (n=33)
n (%)

Poor (n=13)
n (%)

7

16 (36.4)

13 (40.63)

3 (27.27)

6

17 (38.6)

13 (40.63)

4 (36.36)

5

4 (9.1)

3 (9.38)

1 (9.09)

4

3 (6.8)

3 (9.38)

0 (0)

3

3 (6.8)

0 (0)

3 (27.27)

2

0 (0)

0 (0)

0 (0)

1

0 (0)

0 (0)

0 (0)

0

1 (2.3)

0 (0)

0 (0)

5.9 (SD=1.18)

6.12 (SD=0.94)

5.36 (SD=1.63)

Number of valid days (%)

Mean valid days
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Table 3.3

Comparison of physical activity levels and sedentary time according to Eastern Cooperative Oncology Group performance status group
Eastern Cooperative Oncology Group
performance status group
Mean difference (95% CI)

Test
statistic

Good (n=32)

Poor (n=11)

P value

Waking wear time (hr/day)

15.3 (SD 1.13)

15.6 (SD 1.99)

-0.40 (-1.38, -0.59)

t = -0.81

0.421

Sedentary time (% waking wear time)

68.6 (SD 10.20)

80.1 (SD 6.32)

-11.46 (18.09; -4.82)

t = -3.49

0.010

Light activity (% waking wear time)

30.1 (SD 10.08)

19.7 (SD 6.24)

10.34 (3.78; 16.90)

t = 3.18

0.003

MVPA (% waking wear time), median

0.9 (IQR 0.32 – 1.43)

0.1 (IQR 0.05 – 0.25)

z = -3.67

<0.001

Prolonged sedentary time
≥30 min bouts (hr/day), median

3.4 (IQR 2.09 – 4.78)

4.5 (IQR 2.97 – 6.97)

z = -1.56

0.119

5 (15.63)

0 (0.00)

Meeting MVPA guidelines
≥150 mins/wk, n (%)
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Table 3.4

Comparison of physical activity levels and sedentary time according to survival group.
Survival group
<3 months (n=5)

3-12 months (n=11)

>12 months (n=27)

Test
statistic

P value

Waking wear time (hr/day)

15.9 (SD 1.26)

15.0 (SD 1.90)

15.4 (SD 1.16)

F = 0.77

0.470

Sedentary time (% waking wear time)

82.6 (SD 11.27)

72.4 (SD 11.61)

69.2 (SD 8.93)

F = 3.92

0.028

Light activity (% waking wear time)

17.1 (SD 10.76)

27.2 (SD 11.32)

29.4 (SD 8.84)

F = 3.39

0.044

MVPA (% waking wear time), median

0.04 (IQR 0.01-0.72)

0.26 (IQR 0.18-0.57)

Chi square
= 8.25

0.016

Prolonged sedentary time
≥30 min bouts (hr/day), median

7.0 (IQR 4.65-9.70)

3.6 (IQR 2.97-4.51)

0 (0.00)

0 (0.00)

Meeting MVPA guidelines
≥150 mins/wk, n (%)

90

0.93 (IQR 0.32-1.69)

3.4 (IQR 2.08-4.84)
5 (18.52)

Chi square
= 7.04

0.030
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Figure 3.1 Median censored steps taken per day by patients of A) ECOG performance
status 0-1 and ≥2 and B) survival group >12 months, 3-12 months and <3
months. (*) p<0.001
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Figure 3.2 Time spent as sedentary and in light activity according to survival group
of <3 months, 3-12 months and >12 months. a) sedentary b) light activity.
(*) p<0.05
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Figure 3.3 Time spent in light activity according to duration of activity and
performance status (ECOG) group. Data are presented as median and IQR.
a) 5 to <10 min; p=0.004, b) 10 to <20 min; p=0.004, c) 20 to <30 min;
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3.4

Discussion
Our study is the first to report the use of accelerometry in patients with MPE and

provides objective measurements of their physical activity and sedentary behavior using a
24-hr wear protocol. Overall, patients with MPE were compliant with accelerometer wear.
These patients with MPE were predominantly sedentary and only a small portion met
current physical activity recommendations. This research indicates that physical activity
in patients with MPE was associated with performance status. Compared to those with a
good performance status, patients with poorer performance status were more sedentary
and participated in fewer and shorter bouts of physical activity. Patients who survived less
than three months were also more sedentary and participated in less physical activity than
patients who survived more than twelve months.
Over 90% of patients with MPE provided ≥4 valid days of data from the 7-day
recording period. The mean valid accelerometer wear was 5.9 days. These results are
consistent with those from a study of 500 women with breast cancer where compliance
with a hip-worn accelerometer was 90%17 and also with those from the National Health
and Nutritional Examination Survey study of healthy older adults,24 where mean valid hipworn accelerometer wear was 5.8 days. Two studies of cancer survivor populations
reported slightly higher mean valid accelerometer wear of 6.6 – 6.8 days.7, 25 However,
these studies used different accelerometer devices, the first used a hip-worn accelerometer7
and the second used an accelerometer positioned on the anterior mid thigh.25 Other
accelerometry studies in people with cancer have not reported on patient compliance with
the accelerometer protocol.7,

26-28

The high compliance rate in the current study

demonstrates that accelerometry is a feasible tool for measuring physical activity and
sedentary behavior in patients with MPE.
During the 7-day recording period only one in ten patients in our study met physical
activity recommendations and mean MVPA was only 9.5 min/day. Within a cohort with
colorectal cancer, patients participated in an average of 28.5 min/day of MVPA as
measured by accelerometry, which is almost three times our result.7 In contrast, in a study
of patients with brain metastases, none of the participants registered any activity on their
accelerometer that could be considered of moderate or vigorous intensity. 6 The very low
activity level of these patients with brain metastases8 was also reflected in the average step
count of 2784 steps/day, which is half of the average steps taken by patients in our study.
Two studies of patients with lung cancer reported higher average step counts of 604727
and 8863.26 These large differences in physical activity are likely related to differences in
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symptom burden, disease stage and prognosis between cancer groups. Variance in
accelerometer wear protocols in relation to the wear time (24 hr vs. waking hours),
placement of accelerometer (hip vs. thigh vs. wrist) and the device used amongst studies
and processing of step counts as uncensored or censored may also contribute to differences
in physical activity results.
Sedentary behavior comprised the bulk of the waking wear time in our study, with
patients on average spending 72% percent or 11 hours of their day sedentary. These results
were comparable with a sample of twenty patients with lung cancer26 were sedentary 68%
of the time but higher than a cohort of patients with colorectal cancer who spent 61% of
their day sedentary.7 In a prospective study of patients with colorectal cancer who
completed a self-reported recreational physical activity questionnaire, the risk of cancerspecific mortality was higher for those who spent ≥6 hr/day sedentary compared to patients
who were sedentary for <3 hr/day.29 However, in healthy adults who were predominantly
sedentary, the risk of mortality was reduced through replacing 1hr/day of sedentary time
with physical activity of any intensity.30 Therefore it is reasonable to consider that
replacing modest amounts of sedentary behavior with light activity may also be an
important consideration in optimizing the health of cancer patients, particularly those with
very low levels of physical activity like our current study population.
Our results were that the physical activity of patients with MPE was associated with
their performance status and survival group. In this setting, performance status is a strong
predictor of survival, and is often used to differentiate between patients well enough to
receive treatment and those not.13 The ability of accelerometry to function in a similar way
to performance status suggests the information provided by objective measurement of
physical activity may benefit physicians or researchers who need to determine patient
suitability for and response to treatment.
In the current study, those patients with good performance status engaged in longer
periods of light activity compared to patients with poor performance status. Only one other
study to-date has reported on the duration of bouts of light activity. Previous research into
patients with lung cancer revealed median percentage of waking wear time in bouts of 10
or more minutes of light activity was 13% compared to 19% in healthy controls
(p=0.025).26 As MVPA is very low in these clinical populations, the ability to engage in
light activity for longer periods is likely the most suitable indicator of better or improving
health. Accelerometry can accurately and reliably determine the duration of bouts of light

94

Chapter Three. Feasibility of Objectively Measured Physical Activity and Sedentary Behaviour

activity and this information may be of benefit in interventional studies where increasing
physical activity level is the goal.
There are limitations in the current study that should be considered when interpreting
the results. A retrospective audit design was used in this study because accelerometers
were part of clinical care. However, as a result we have no data on patient factors that
may have influenced physical activity and sedentary behavior such as quality of life or
symptom burden. Regarding the measurement protocol, as only one 7-day monitoring
period was completed for each patient, intra-person reliability of the protocol has not been
established in this clinical sample. Further, the sample may have selection bias as patients
with MPE were not consecutively asked to wear an accelerometer, rather it was at the
discretion of the physician to ask patients to wear an accelerometer and physicians may
have avoided asking a patient if they were unwell or in need of another procedure at the
time. As not all patients with MPE wore the accelerometers it is plausible that the
compliance, physical activity and sedentary behavior of patients in our study could differ
to those who did not wear an accelerometer. Additionally, there was a large proportion of
patients with mesothelioma in our sample, which is not representative of the worldwide
population with MPE. A diagnosis of mesothelioma has a favourable prognosis compared
to other primary cancers with MPE2 and it is probable that this may also impact on physical
activity and sedentary behavior.
Despite these limitations, the current study is the first time accelerometer use has been
investigated in a population with MPE and it provides a good starting point for further
research in this area. A strength of our study is that a 24-hr, 7-day protocol was used to
objectively assess physical activity and sedentary behavior in this population. A 24-hr
accelerometer protocol has not been used in any previous research in cancer patients
rather, all studies have asked participants to wear the accelerometer during waking hours
only.7,

26

However, a 24-hr protocol is thought to maximize waking wear time.31

Furthermore, the 7-day protocol used in this study is the current best practice for objective
measurement of physical activity as it accurately reflects habitual sedentary behaviour.32
To better understand the mechanisms contributing to low physical activity levels in
the MPE population, future studies should be prospective in nature and include
measurements of breathlessness and fatigue amongst others, as these appear to correlate
to physical activity levels in other populations.4, 5 Considering the very low levels of
participation in MVPA paired with the high levels of sedentary behavior, the target of
interventions to increase physical activity in this population should consider focusing on
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increasing light activity and reducing sedentary bouts rather than on the traditional goal of
increasing MVPA which may be unachievable for patients with poor performance status.
In addition, targeted exercise in particular involving strength training should be considered
to slow or reverse deconditioning and functional decline likely to be underlying factors in
the low physical activity levels in this population.33, 34 As this study has demonstrated
patients with MPE are compliant with accelerometer wear, future studies can now examine
the usefulness of accelerometry in determining suitability for treatment and assessing
response to treatment as a patient-centred outcome measure in clinical interventions.
Accelerometry, on a 7-day continuous wear protocol, can be applied successfully in
patients with MPE with high compliance and no adverse events. The data obtained
reflected patient performance status as assessed with ECOG ratings. The accelerometry
results provided, for the first time, quantitative data of the physical activity of patients with
MPE and revealed low physical activity and high sedentary behavior in this population.
Accelerometry can provide a useful measure for future interventional studies to improve
physical activity levels in patients with MPE.
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Abstract
Body composition analysis techniques commonly used to classify low muscle mass
in cancer populations are used interchangeably, yet there has been little comparison of
these methods reported. This study in patients with malignant pleural mesothelioma
(MPM) aimed to assess the relationship between muscle measured with computed
tomography (CT) and dual-energy x-ray absorptiometry (DXA) and the agreement
between cut-points for the classification of low muscle mass. This was a retrospective
study of patients with available CT and DXA data collected ≤28 days apart. Skeletal
muscle index (SMI; cm2/m2) was measured with CT at the third lumbar vertebrae using
sliceOmatic software v.5.0. Appendicular skeletal muscle index (ASMI; kg/m2) was
segmented from whole-body DXA. Commonly cited CT and DXA cut-points for low
muscle mass were used to assess the agreement between methods.

Thirty-seven

participants with MPM were included (81% male; median age 67.0 [IQR 62.0-73.0]
years). There was a positive correlation between SMI and ASMI (r=0.679; p<0.001).
Percent agreement between CT and DXA cut-points ranged between 54-73%. There was
moderate agreement between the CT cut-points from Prado et al and the DXA cut-points
from Baumgartner et al (ĸ=0.424; p=0.006). There was no significant agreement between
the other cut-points evaluated (p>0.05).
Novelty
 For the first time in patients with MPM, we reported that SMI and ASMI were
positively correlated.
 Classification of low muscle mass differs according to the method and cut-point used,
and are not universally interchangeable.
 Choice of method needs to be made carefully with consideration of the patient
outcome of interest.
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4.1

Introduction
In many cancer populations, low muscle mass is associated with poorer outcomes,

including decreased survival and greater treatment toxicity. 1 Patients with malignant
pleural mesothelioma (MPM) commonly experience weight loss, 2 which is an adverse
prognostic indicator.3 However, few studies have investigated body composition in
patients with MPM. As MPM is an incurable cancer, an understanding of the relationship
between muscle mass and patient outcomes has the potential to improve clinical practice.
We previously reported difficulty completing dual-energy x-ray absorptiometry
(DXA) scans in unwell patients with MPM,2 which was likely due to the additional burden
this placed on them. In contrast, thoracic computed tomography (CT) scans obtained from
medical records are performed routinely as part of standard patient care, are more easily
accessible to researchers, and do not add to participant burden. Therefore, when available,
CT may be a more practical alternative to DXA in patients with MPM. Existing guidelines
state that either CT or DXA can be used to identify low muscle mass in patients with
cancer,4 however inherent differences between these methods suggest that they would not
produce comparable results, which would hinder our ability to draw conclusions when
comparing studies.
CT and DXA are both imaging techniques, one measures skeletal muscle mass, the
other lean soft tissue, (i.e., lean mass), which is fundamentally different. Skeletal muscle
quantification by CT is possible due to the different radiodensity thresholds (Hounsfield
units) of different tissues. The third lumbar vertebrae (L3) is the best correlate of whole
body muscle mass, hence used as a single abdominal cross-sectional CT image to provide
body composition information.5 DXA does not measure skeletal muscle. It uses dualphotons to determine lean mass, which is comprised of skeletal muscle, organs and other
soft tissue.6 As skeletal muscle cannot be distinguished from whole body lean mass,
appendicular lean mass, which is known to be predominantly skeletal muscle, is
segmented from whole body lean mass, and termed appendicular skeletal muscle mass;
we will hereby refer to this compartment as “muscle” or appendicular skeletal muscle for
consistency in terminology but acknowledge it is actually lean mass, therefore including
muscle, water, fibrotic and connective tissue.6
To determine whether an individual has low muscle mass, muscle measured with CT
and DXA is compared to cut-points, derived from each of these methods. Most commonly
used CT cut-points were developed in cancer populations using values associated with
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shorter survival,7, 8 while others were derived from DXA and converted to CT units using
a regression equation.9, 10 Commonly used DXA cut-points were determined in older adults
using values that were 2 standard deviations below the mean of a young adult reference
population.11 These cut-points were associated with functional impairment.12 Therefore,
cut-points associated with these body composition assessment methods were derived from
different populations, with differing outcomes of interest.
Our previous research suggests that low muscle mass determined with DXA has the
potential to predict important clinical outcomes in patients with MPM, 2 however DXA
may not be feasible for a sub-group of the population. Information on the comparability
of CT and DXA will allow us to understand if these methods categorise patients in the
same way, which is important for interpretation and comparability of our research within
the literature. Therefore, the aim of this study was to assess the relationship between
muscle measured with CT and DXA and compare the agreement between CT and DXA
cut-points for the classification of low muscle mass in patients with MPM.

4.2

Materials and methods

4.2.1

Study design and setting

The study was a retrospective, cross-sectional analysis which included a subset of
MPM participants from a longitudinal observational study and an exercise intervention
study.9 The studies were approved by the Sir Charles Gairdner Group and Edith Cowan
University Human Research Ethics Committees (ID: 2014-124 and 13255).

4.2.2

Participants

Patients were recruited from a tertiary specialist pleural disease and medical oncology
clinic in Western Australia between August 2015 and May 2017. Patient and physician
consent was obtained prior to study participation. Participants in the observational and
intervention studies with a diagnosis of MPM were screened for eligibility for the current
study. Inclusion criteria were completion of a CT and DXA scan within 28 days of each
other. Participants were only included in the analysis once, using the first valid set of scans
for participants in the observational study or the baseline scans for participants in the
intervention study. Those with no CT image available at L3 or of inadequate image quality
were excluded.
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4.2.3

Measures

Demographic and medical characteristics
Participant’s medical records were reviewed for baseline demographic and medical
data. Eastern Cooperative Oncology Group performance status was assigned by the
physician on the date of assessment.10
Anthropometric measures
Weight and height, measured with participants dressed in light clothing with shoes
removed, were used to calculate the body mass index (BMI). Participants were classified
as underweight, normal weight, overweight or obese based on World Health Organization
BMI criteria.11
Computed tomography
CT scans performed as part of routine medical care were retrieved from the tertiary
specialist imaging system and downloaded in Digital Imaging and Communications in
Medicine (DICOM) format. A trained person (EJ) identified a single cross-sectional image
at L3 and measured skeletal muscle cross-sectional area (cm2) using sliceOmatic software
v.5.0 (Tomovision, Montreal, QC, Canada). To ensure the reliability of our data, a second
independent person (CS) measured skeletal muscle cross-sectional area on all included CT
scans. The radiodensity of skeletal muscle was defined as -29 to +150 Hounsfield units12 and
pixels were manually corrected at tissue boundaries. The skeletal muscle index was
calculated by dividing the cross-sectional muscle area (cm2) by the participant’s height in m2.
The following cut-points were used to define low muscle mass from CT: 1) Prado et al7:
<52.4 cm2/m2 for men and <38.5 cm2/m2 for women, and 2) Martin et al8: <43 cm2/m2 for
men with a BMI ≤24.9 kg/m2, <53 cm2/m2 for men with BMI >24.9 cm2/m2 and <41
cm2/m2 for all women.
Dual energy x-ray absorptiometry
Whole-body lean mass was measured using whole-body DXA scans (Hologic Discovery
A, Hologic Inc., Marlborough, MA, USA). A trained person (EJ) segmented appendicular
skeletal muscle from whole-body lean mass at the acromio-humeral and pelvic-femoral
joints.5 Appendicular skeletal muscle mass was then adjusted for height (kg/m2). To define
low muscle mass based on this variable, we used appendicular skeletal muscle index cutpoints from 1) Baumgartner et al17: ≤7.26 kg/m2 for men and ≤5.45 kg/m2 for women, and
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2) Cruz-Jentoft et al11: ≤7.00 kg/m2 for men and ≤5.50 kg/m2 for women, which for ease
of use, were rounded from cut-points reported by Gould et al18 of ≤6.94 kg/m2 for men
and ≤5.30 kg/m2 for women.

4.2.4

Statistical analysis

Statistical analyses were conducted using Statistical Package for the Social Sciences
(v. 25, IBM Corporation, Somers, NY, USA). Data were expressed as mean ± SD or
median [IQR] where the data were not normally distributed. An Intraclass Correlation
Coefficient (ICC) was obtained to assess the inter-rater reliability for skeletal muscle index
measured at L3. Pearson’s correlations were performed to assess the relationship between
skeletal muscle index measured at L3 and appendicular skeletal muscle index measured
by DXA. Kappa (ĸ) coefficients were used to assess the agreement between commonly
used low muscle mass cut-points on CT and DXA. Receiver Operating Characteristics
analysis were used to evaluate the ability of skeletal muscle index to predict low muscle
mass on DXA by comparing the sensitivity versus the specificity.

4.3

Results

4.3.1

Participants

Participant characteristics are described in Table 4.1. The participants were
predominantly male (81%), with the epithelioid subtype of MPM (73%) and all had an
ECOG performance status rating of 0 – 1. Participants had a median age of 67.0 [IQR 62.0
– 73.0] years and a mean BMI of 25.9 ± 2.9 kg/m2.

4.3.2

CT and DXA scans

Of the 40 eligible CT scans, 37 (93%) scans were included in the analysis (Figure
4.1). Two scans (5%) were excluded as there was no image available at L3, while one scan
(2%) was excluded as the scan was of inadequate quality to apply the analysis technique.
Mean time elapsed between CT and DXA scan was 10.8 ± 8.5 days. Twenty-five scans
(68%) were completed within 0 – 14 days of DXA, while 12 scans (32%) were completed
within 15 – 28 days from DXA.
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4.3.3

Relationship between body composition techniques for
measurement of skeletal muscle

A high degree of reliability was found between raters for skeletal muscle index when
assessed using the ICC (r=0.992 [95% CI 0.984 – 0.996]; p<0.001). The median skeletal
muscle index and appendicular skeletal muscle index of included scans are presented in
Table 4.2. There was a moderate positive correlation between skeletal muscle index and
appendicular skeletal muscle index (r=0.679, p<0.001; Figure 4.2).

4.3.4

Agreement between CT and DXA for the classification of low muscle
mass using existing cut-points

For each cut-point comparison, the proportion of scans with agreement and
disagreement is presented in Figure 4.3. Moderate agreement was observed between CT
cut-points from Prado et al7 and DXA cut-points from Baumgartner et al17 (ĸ=0.424;
p=0.006). There was no significant agreement between the CT cut-points from Martin et al8
and DXA cut-points from Baumgartner et al17 (ĸ=0.132; p=0.419). There was no significant
agreement between the CT cut-points from Martin et al8 and DXA cut-points from
Baumgartner et al17(ĸ=0.173; p=0.173). There was no significant agreement between the
CT cut-points from Prado et al7 and Martin et al8 and DXA cut-points supported by CruzJentoft et al11 (ĸ=0.173; p=0.173; and ĸ=0.087; p=0.582, respectively).

4.3.5

Skeletal muscle index for predicting low muscle mass using DualEnergy X-Ray Absorptiometry as the reference standard

Skeletal muscle index was a fair predictor of low muscle mass in males (n=30) when
the DXA cut-point from Baumgartner et al17 was used as the reference standard
(AUC=0.787, 95% CI 0.613 – 0.961; p=0.009). A skeletal muscle index cut-point of 52.9
cm2/m2 had a sensitivity of 0.947 and specificity of 0.462 for predicting low muscle mass.
Skeletal muscle index was not a significant predictor of low muscle mass in males when
the DXA cut-point supported by Cruz-Jentoft et al11 was used as the reference standard
(AUC=0.715, 95% CI 0.529 – 0.901; p=0.059). Skeletal muscle index was not a significant
predictor of low muscle mass in females (n=7) when the DXA cut-points from
Baumgartner et al17 and supported by Cruz-Jentoft et al11 were used as the reference
standards (AUC=0.667, 95% CI 0.229 – 1.000; p=0.480 and AUC=0.417, 95% CI 0.000 –
0.886; p=0.724, respectively).
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Table 4.1

Participant characteristics, n=37
n

%

Age, years^

67

62.0 – 73.0

Sex, male

30

81.0

BMI, kg/m2#

25.9

ECOG performance status
0-1

37

100.0

0

0.0

27

73.0

Sarcomatoid

2

5.4

Biphasic

3

8.1

Unspecified

4

10.8

Unknown

1

2.7

0

0.0

3 – 12 months

12

32.4

>12 months

25

67.6

14

37.8

8

21.6

Radiotherapy

2

5.4

Chemotherapy and radiotherapy

2

5.4

Chemotherapy, radiotherapy and surgery

2

5.4

≥2

2.9

Histological subtype
Epithelioid

Survival
<3 months

Cancer treatment prior to assessment, yes
Type of cancer treatment
Chemotherapy

^mean,

standard deviation; #median, interquartile range; ECOG – Eastern Cooperative Oncology Group

Table 4.2

Participant skeletal muscle index and appendicular skeletal muscle
index, n=37
All participants
(n=37)

Men
(n=30)

Women
(n=7)

Mean

SD

Mean

SD

Median

IQR

SMI, cm2/m2

46.9

6.5

48.6

5.5

37.9

35.9–43.2

ASMI, kg/m2

6.8

0.9

7.1

0.7

5.5

5.4–5.9

SMI – skeletal muscle index, ASM – appendicular skeletal muscle index

108

Chapter Four. Agreement between Computed Tomography and Dual Energy X-Ray Absorptiometry

I

Participants screened for eligibility

(n=56)

I

.

Excluded (n= I 6)
No CT scan available <27 days from DXA

.

Excluded (n=3)
Image of inadequate quality (n=l)
L3 not visible (n=2)

Potentially eligible participants

(n=40)

I

I

.
I

Participants included in the analysis

(n=37)

I

Figure 4.1 Participants included in the retrospective, cross-sectional study
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Figure 4.2 Correlation between appendicular skeletal muscle index (ASMI) and
skeletal muscle index (SMI) at L3, n=37
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2

Agreement normal muscle mass
[Agreement low muscle mass

■

No agreement: low muscle mass on CT only
No agreement: low muscle mass on DXA only

19

a)

Prado and Baumgartner

b)

Martin and Baumgartner

2
CT cut-points:

Prado: <52.4 cm/m- for men and <38.5 em/m for
women
Martin°: <43 em/m for men with a BMI <24.9 kg/m,

<53 em/m for men with BMI 24.9 em/m and <41
em/m for all women
DXA cut-points:
Baumgartner": <7.26 kg/m for men and <5.45 kg/m

15
11

for women

Cruz Jentoft!: <7.00 kg/m for men and <5.50 kg/m for
women

8
e)

Prado and Cruz-Jentoft

d)

Martin and Cruz-Jentoft

Figure 4.3 Agreement between CT and DXA cut-points for low muscle mass, n=37
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4.4

Discussion
Methods commonly used to assess body composition in cancer populations are

inherently different, yet current guidelines do not indicate whether these methods differ in
their classification of low muscle mass.4 There has been little comparison of techniques
reported, which make it difficult to come to informed conclusions when comparing studies.
In our study we compared muscle measured with CT and DXA and the agreement between
cut-points for the classification of low muscle mass in a cohort of patients with MPM. We
reported that skeletal muscle index and appendicular skeletal muscle index were positively
correlated, but as expected, there was no significant agreement between CT and DXA for
the classification of low muscle mass for the majority of cut-points compared.
We found a moderate correlation between skeletal muscle index and appendicular
skeletal muscle mass index (r=0.679). In studies of patients with advanced lung and
gastrointestinal cancer, the correlation between skeletal muscle index and appendicular
skeletal muscle is reported as moderate to strong (ρ=0.704 and r=0.89, respectively).10, 19
One possible reason for this variability could be the inherent differences between methods.
Appendicular skeletal muscle is lean soft tissue and includes muscle, water, fibrotic and
connective tissue, therefore individual variability in the proportion of fibrotic and
connective tissue in the arms and legs could affect the strength of the relationship between
CT and DXA. The proportion of fibrotic and connective tissue present in the lean soft
tissue of the arms and legs is greater in older age20 and with increasing adiposity.21 Our
participants with MPM were heterogeneous with regard to their age (range 42 – 81 years)
and BMI category (54% overweight or obese), which may explain the lack of a strong
correlation between CT and DXA in our study. Although DXA does not directly measure
skeletal muscle, it is an important body composition assessment technique. If research
intends to investigate the relationship between body composition and functional outcomes
then DXA may preferred over CT as it can estimate the muscle in the arms and legs which
are typically responsible for movement. We previously reported that DXA cut-points from
Baumgartner et al17 were associated with poorer physical activity levels and self-reported
physical functioning in patients with MPM.2 It is not known if this relationship exists with
skeletal muscle index.
An alternate hypothesis for our finding of a moderate correlation between methods is
possible differences in trunk and appendicular loss of skeletal muscle in MPM. Multiple
factors could affect the distribution of muscle in patients with MPM. Age is known to
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affect skeletal muscle distribution.22 In a study of healthy older adults, lower body skeletal
muscle was lost more rapidly than upper body skeletal muscle.22 Therefore, it is possible
that participants in our study, with a median age of 67 years, could be affected by a similar
wasting pattern. One third (n=12) of our participants had received chemotherapy
treatment. To our knowledge, no study has reported on regional changes in muscle
following chemotherapy, however in a study of patients with prostate cancer receiving
androgen deprivation therapy, participants lost a greater percentage of lean mass in the
upper limbs compared with the lower limbs.23 Additionally, MPM is a very localised
disease where the bulk of the tumour burden resides in the pleural space and rarely
metastasises.24 This difference, compared to other advanced cancers where tumour burden
tends to be more widespread could also impact on wasting patterns. Thus, skeletal muscle
distribution could vary between different populations. Further research is needed to
determine if there are differences in skeletal muscle distribution between cancer
populations, and to understand the implications for body composition research.
There was moderate agreement between CT and DXA cut-points for low muscle mass
(ĸ=0.438) using the CT cut-points from Prado et al7 and DXA cut-points from
Baumgartner et al17, however there was no significant agreement between CT and DXA
for the other cut-points compared. When we used receiver operating characteristics using
the Baumgartner cut-point to determine the skeletal muscle index value that had the
optimal sensitivity and specificity for detecting low muscle mass in men, it was
comparable to the Prado cut-point (52.9 cm2/m2 vs. 52.4 cm2/m2). These results indicate
that in patients with MPM, greater agreement between methods may not be achieved by
creating new cut-points. This outcome is not surprising given our finding of a moderate
correlation between methods. Researchers should be cognisant that criteria for the
classification of low muscle mass are not interchangeable. As there is currently no
consensus on diagnostic criteria for the classification of low muscle mass, researchers
could consider using continuous variables to evaluate the relationship between muscle and
patient outcomes, which would enable comparison between studies.25
This study has several limitations. The sample size is small and consists only of patients
with MPM and therefore, may not be representative of other cancer populations. There is
heterogeneity in our sample with regard to disease status and cancer treatments.
Additionally, MPM is substantially more common in men than in women, hence women
were underrepresented in this study. This was a retrospective study of CT scans performed
as part of routine clinical care and therefore the make and model of CT scanner, slice
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thickness and use of contrast enhancement, were not standardised.26, 27 Changes in muscle
could have occurred between the time of CT and DXA scan, although the mean time elapsed
between scans was 10.8 days and two thirds of scans were performed on participants >12
months prior to death, a time where reported changes in muscle over time are small.28
Furthermore, the strong correlation between raters for CT-measured cross-sectional skeletal
muscle area indicates that the data is reliable. As this was a retrospective study that utilised
CT scans completed as part of routine clinical care, the high inclusion rate of participants
(71%) from our longitudinal observational study and exercise intervention study indicates
that CT evaluation of body composition is feasible in patients with MPM.
The present study supports the hypothesis that there is a lack of agreement between
CT and DXA for the classification of low muscle mass in patients with MPM. Although
CT and DXA cannot be used interchangeably, both are relevant body composition
assessment methods in cancer research. The decision to use CT or DXA may be dependent
on the patient outcome of interest, such as survival or physical functioning, as well as
practical considerations. Thoracic CT scans are performed routinely in patients with
MPM, and researchers can access scans for retrospective analysis, which can be valuable
as prospective research could take many years to complete given the low prevalence of
disease and challenges of performing DXA scans in unwell patients with MPM. 2
Considering cut-points for the classification of low muscle mass are subjective, future
research in MPM should use continuous data to evaluate the relationship between muscle
and patient outcomes.
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Abstract
Background/Objectives: Malignant pleural mesothelioma (MPM) is an incurable cancer
and optimizing daily physical activity and quality-of-life are key goals of patient
management. Little is known about the prevalence of pre-sarcopenia and malnutrition in
MPM or their associations with patient outcomes. This study aimed to determine the
prevalence of pre-sarcopenia and malnutrition in MPM and investigate if activity levels
and quality-of-life differed according to body composition and nutritional status.
Subjects/Methods: Patients with a diagnosis of MPM were recruited. Pre-sarcopenia was
defined as low appendicular skeletal muscle mass (≤7.26 kg/m2 for men and ≤5.45 kg/m2
for women), measured by Dual Energy X-Ray Absorptiometry. Malnutrition was defined
as a rating of B or C on the Patient-Generated Subjective Global Assessment. Outcome
measures included objective activity levels (Actigraph GT3X) and health-related qualityof-life (HRQoL; Functional Assessment of Cancer Therapy General).
Results: Sixty-one people participated (79% male, median age 69 [IQR 62-74] years and
median BMI 25.8 [IQR 24.3-28.4] kg/m2). Fifty-four percent were pre-sarcopenic and
38% were malnourished. Percent of time spent in light activity/day was lower in
participants with pre-sarcopenia compared with non-sarcopenic participants (median 25.4
[IQR 19.8–32.1]% vs. 32.3 [27.1–35.6]%; p=0.008). Participants with malnutrition had
poorer HRQoL than well-nourished participants (mean 69.0(16.3) vs. 84.4(13.3);
p<0.001).
Conclusion: Participants with MPM had high rates of pre-sarcopenia and malnutrition.
Pre-sarcopenia was associated with poorer activity levels, whilst malnutrition was
associated with poorer quality-of-life. Interventions that aim to address reduced muscle
mass and weight loss, should be tested in MPM to assess their impact on patient outcomes.
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5.1

Introduction
Malignant pleural mesothelioma (MPM) is an incurable cancer that develops

primarily as a result of exposure to asbestos.1 MPM is distinctly different from advanced
lung cancer given the longer median survival of 9 – 12 months,2 localized nature of the
disease 3 and lack of clarity surrounding cause of death.3 Standard treatment for MPM is
chemotherapy, which offers a modest survival benefit.4, 5 Given the palliative nature of
management of MPM, optimizing and maintaining daily physical activity and quality-oflife are primary goals of treatment. As weight loss has been identified as an independent
predictor of poor survival in people with MPM,2 body composition and nutritional status
could be integral to optimal supportive care for those with MPM.
While weight loss is commonly noted in MPM, the prevalence of malnutrition has
not been reported and no body composition analyses are available. Low muscle mass and
malnutrition can exist in people who are not underweight,6-8 making it challenging for
clinicians to identify. If undetected, patients with low muscle mass and malnutrition are
unlikely to receive timely treatment to address these conditions.
The implications of low muscle mass and malnutrition on patient-centred outcomes
have not been studied in MPM. In patients with advanced cancers, low muscle mass 9, 10
and weight loss, or malnutrition,11-16 have been associated with poorer quality-of-life.
However, none have examined the associations between body composition and nutritional
status and daily physical activity. Given that management of MPM is of palliative intent,
understanding how modifiable factors, such as muscle mass and nutritional status,
influence health-related quality-of-life and patients’ ability to take part in daily activities
is critical for planning interventions to improve supportive care in MPM.
In cancer populations, reduced muscle mass and malnutrition are conditions with a
complicated etiology that could be impacted by dietary intake as well as systemic
inflammation.17 Weight loss can occur in those with adequate energy intakes, suggesting
that factors beyond dietary intake influence weight loss.18 Inflammatory cytokines and
many other molecules have been associated with the pathobiology of low muscle mass
and malnutrition in cancer patients.19-24 Knowledge regarding dietary intake and
inflammatory profile is therefore essential for guiding the development of interventions to
address low muscle mass and malnutrition in MPM.
The primary aim of this study was to determine the prevalence of low muscle mass
and malnutrition in patients with MPM. Secondly, we aimed to investigate if there were
differences in activity levels, health-related quality-of-life, dietary intake and serum
biomarkers according to body composition and nutritional status.
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5.2

Materials and methods

5.2.1

Participants

Recruitment took place between August 2015 and May 2017 from a tertiary specialist
pleural disease and medical oncology clinic in Western Australia (WA), which has one of
the highest incidences of MPM per capita in the world.25 Patients were eligible if they had
cytological or histological confirmation of MPM. Patients were excluded if they were aged
<18 years, pregnant or lactating, unable to read and understand English, unable to obtain
physician consent, or unable to give informed consent or comply with the protocol.

5.2.2

Study design and setting

The study was a cross-sectional analysis of the baseline data collected from two
prospective studies. The studies were 1) a longitudinal observational study of nutritional
status and body composition and participants were followed until death or for up to 18
months and 2) a 6-week progressive resistance exercise intervention. Both were pilot
studies, designed to provide data for proof of concept and no sample size calculation was
performed. The studies were approved by the Sir Charles Gairdner Group and Edith
Cowan University Human Research Ethics Committees (ID: 2014-124 and 13255).

5.2.3

Measures

Demographic and medical variables
Participants’ medical records were reviewed for baseline demographic and medical
data. Physician-rated Eastern Cooperative Oncology Group (ECOG) performance status26
was recorded on the date of assessment.
Anthropometric measures
Weight and height, measured with participants dressed in light clothing with shoes
removed, were used to calculate the body mass index (BMI). Participants were classified
as underweight, normal weight, overweight or obese based on World Health Organization
(WHO) BMI criteria.27
Body composition
Body composition was assessed using whole body dual-energy x-ray absorptiometry
(DXA) scans (Hologic Discovery A, Hologic Inc., Marlborough, MA, USA). Low skeletal
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muscle mass was defined as an appendicular skeletal muscle mass/height 2 of ≤7.26 kg/m2
for males and ≤5.45 kg/m2 for females.28 The cut-points for appendicular skeletal muscle
mass were set as two standard deviations below the mean of a reference sample of young
Caucasian adults, and are associated with physical disability in older adults.28 Participants
with low skeletal muscle mass were categorized as pre-sarcopenic, consistent with the
European Working Group on Sarcopenia in Older People diagnosis criteria.29 Gait speed
was not measured in the study and as it is an essential criteria for the classification of
sarcopenia and severe sarcopenia, we could not further categorize participants as
sarcopenic or severely sarcopenic.29
Nutritional status
Nutritional status was assessed using the Patient-Generated Subjective Global
Assessment (PG-SGA).30 Participants were categorized with a global rating of A – well
nourished, B – suspected malnutrition/malnutrition or C – severe malnutrition.
Malnutrition was defined as a rating of B or C on the PG-SGA. As the PG-SGA categories
of B and C both represent participants with malnutrition, the two categories were
amalgamated for statistical analysis.
Accelerometer-measured activity levels
Physical activity and sedentary behavior were objectively assessed using the
ActiGraph GT3X+ accelerometer (Actigraph, Pensacola, FL, USA). Participants were
instructed to wear the accelerometer on their hip continuously (24hr/day) for 3 days, to
only remove for bathing or swimming and to record any non-wear time in a logbook.
Common cut off points were used to classify sedentary time, light activity and moderate
and vigorous physical activity (MVPA).31, 32 Variables were calculated per day and then
averaged across all valid days for each participant. Additional accelerometer data
collection and analysis methodology is presented in Supplementary Table 5.3.
Patient-rated outcomes
Participants completed validated questionnaires to assess cancer specific healthrelated quality-of-life (HRQoL, Functional Assessment of Cancer Therapy – General;
FACT-G),33 general health-related quality-of-life (Short Form – 36 (SF-36)),34 appetite
(Anorexia Cachexia Scale; ACS)35 and fatigue (Functional Assessment of Chronic Illness
Therapy – Fatigue; FACIT-Fatigue).36 A score of ≤37 on the ACS indicates poor appetite
and a score of ≤34 on the FACIT-fatigue indicates clinically meaningful fatigue.37, 38
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Dietary intake
Dietary intake was measured prospectively, using an estimated food record over three
consecutive days. Written and verbal instructions were provided to participants,
explaining how to complete the food record and accurately estimate portion sizes using
household measures (e.g. measuring cups and spoons). Returned food records were
visually inspected by the researchers and incomplete details were clarified with
participants. The food records were then analyzed using Foodworks 8 software (Xyris
Software Pty Ltd, Australia). Intake variables were calculated per day and averaged across
three days for each participant. Energy and protein intake were expressed as kJ or g per
kg of body weight per day. Participants consuming ≥105 kJ/kg/day (1 kcal = 4.186 kJ) or
≥1.0 g/kg/day were classified as meeting energy or protein requirements, respectively.39
Participant self-reported changes in dietary intake over the previous month were extracted
from the PG-SGA.
Serum biomarkers
A blood sample was taken for biomarker analysis. Enzyme linked immunosorbent
assay (ELISA) kits was used to measure serum levels of interleukin-6 (IL-6, pg/mL),
insulin-like growth factor-1 (IGF-1, ng/mL), ghrelin (ng/mL), leptin (ng/mL), myostatin
(ng/mL), adiponectin (mg/L), vascular endothelial growth factors-A (VEGF-A, pg/mL)
and C (VEGF-C, ng/mL), tumor necrosis factor-alpha (TNF-α, pg/mL) and interferongamma (IFN-γ, pg/mL). ELISA kit manufacturer information is presented in
(Supplementary Table 5.4). Serum samples of each patient were assayed in duplicates in
the same assay. Concentrations of serum CRP (mg/L) and albumin (g/L) measured as part
of standard clinical care were obtained from the hospital records.

5.2.4

Statistical analyses

Statistical analyses were conducted using Statistical Package for the Social Sciences
(v. 23, IBM Corporation, Somers, NY, USA). Data were expressed as mean (SD) or
median [IQR] where the data were not normally distributed. Two-tailed independent ttests, or the Mann-Whitney test where the data were not normally distributed, were used
to test for differences in activity levels, quality-of-life, appetite, fatigue, dietary intake and
serum biomarkers between body composition and nutritional status groups. The ChiSquared test was used to test for associations between body composition and nutritional
status and meeting dietary recommendations and self-reported changes in dietary intake.
A p-level of <0.05 was considered statistically significant.
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5.3

Results

5.3.1

Participants

Sixty-one participants enrolled in the study (Figure 5.1). Participants were
predominantly male (79%), with a median age of 69 years, and were enrolled a median 2
months from diagnosis. Forty-three (71%) participants had the epithelioid subtype of
MPM and 56 (92%) participants had an ECOG performance status of 0-1. On average
patients were overweight (median BMI was 25.8 kg/m 2): no participants were
underweight, 41% were in the normal weight range, 44% were overweight and 15% were
obese. Demographic and medical characteristics are presented in Table 5.1.

5.3.2

Prevalence of pre-sarcopenia and malnutrition

Fifty-three participants completed a DXA scan. Of those, 28 (54%) had presarcopenia. All participants completed the PGSGA, of those 23 (38%) participants were
classified as malnourished. Half (54%) of participants with pre-sarcopenia were
malnourished. The pre-sarcopenic and malnourished participants are presented according
to their BMI category and nutritional status or body composition group in Figure 5.2.
Differences in characteristics between body composition and nutritional status groups and
participants with and without DXA scans are presented in Supplementary Table 5.5 and
Supplementary Table 5.6, respectively.

5.3.3

Differences in activity levels, HRQoL, dietary intake and serum
biomarkers according to body composition

Activity levels
Participants with pre-sarcopenia spent a lower proportion of their awake time per day
in light activity (median 25.4 [IQR 19.8 – 32.1]% vs. 32.3 [27.1 – 35.6]%; p=0.008) and
a higher proportion as sedentary (mean 72.8 (9.3)% vs. 63.5 (9.0)%; p=0.001), compared
to non-sarcopenic participants. There was also a significant difference in MVPA time
between the two groups (median 0.7 [IQR 0.2 – 2.1]%; vs. 2.9 [0.8 – 4.0]%; p=0.005).
Participants with pre-sarcopenia also completed fewer bouts of light activity of 20 to <30
minutes duration (median 0.0 [IQR 0.0 – 0.3] vs. 0.3 [0.0 – 1.0]; p=0.010), 10 to <20
minutes duration (median 1.0 [IQR 0.7 – 2.8] vs. 3.7 [2.3 – 5.7]; p=0.004) and of 5 to <10
minutes duration (median 9.0 [IQR 5.9 – 11.8] vs. 12.7 [11.0 – 15.0]; p=0.002), compared
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to non-sarcopenic participants (Figure 5.3). The majority of participants (67%) recorded
no light activity in bouts ≥30 minutes therefore, statistical analysis was not performed.
HRQoL, fatigue and appetite
Between pre-sarcopenic and non-sarcopenic participants, there were no statistically
significant differences in cancer specific HRQoL (mean 78.5 (15.8) vs. 82.2 (14.0);
p=0.414), fatigue (median 35.0 [IQR 28.0 – 47.0] vs. 41.0 [IQR 33.5 – 46.5]; p=0.290),
or any of the domains for general HRQoL (p≥0.073, Figure 5.4). Appetite scores were
significantly poorer in pre-sarcopenic participants compared with non-sarcopenic
participants (median 37.0 [IQR 29.0 – 42.0] vs. 42.5 [38.8 – 44.3]; p=0.014).
Dietary intake
Pre-sarcopenic and non-sarcopenic participants did not differ significantly in their
energy or protein intake (median 125 [IQR 93.2 – 138.2] kJ/kg/day vs. 128 [87.2 – 141.0]
kJ/kg/day; p=0.975 and mean 1.4 (0.4) g/kg/day vs. 1.3 (0.5) g/kg/day; p=0.504]). There
was no difference between body composition groups with regard to the proportion of
participants meeting energy (p=0.606) or protein requirements (p=0.404). The proportion
of participants who reported a decrease from their usual intake in the past month did not
differ significantly between pre-sarcopenic and non-sarcopenic participants (57.1% vs.
33.3%; p=0.086). Of the twelve participants taking high protein supplements, seven had a
DXA scan, of whom 86% (n=6) were pre-sarcopenic.
Serum biomarkers
Differences in serum biomarkers according to body composition group are presented
in Table 5.2. Among the cytokines analyzed, only IL-6 levels were higher in presarcopenic compared with non-sarcopenic participants (p=0.006). Between pre-sarcopenic
and non-sarcopenic participants, there were no differences in levels of myostatin
(p=0.085), albumin concentration (p=0.143) or any other measured serum biomarkers.

5.3.4

Differences in activity levels, HRQoL, dietary intake and serum
biomarkers according to nutritional status

Activity levels
Malnourished and well-nourished participants did not differ in the proportion of time
per day spent in light activity (median 26.6 [IQR 21.2 – 34.8]% vs. 29.7 [24.0 – 34.6]%;
p=0.380) or as sedentary (median 72.5 [IQR 65.0 – 78.7]% vs. 68.4 [62.8 – 73.0]%;
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p=0.208). There was a significant difference in MVPA between malnourished and wellnourished participants (median 0.6 [IQR 0.2 – 1.3]% vs. 1.6 [0.6 – 3.5]%; p=0.013). There
were no significant differences between the two groups for light activity of 20 to <30
minutes, 10 to <20 minutes or 5 to <10 minutes [median 0.0 [IQR 0.0 – 0.7] vs. 0.3 [0.0 –
0.7]; p=0.267, median 1.0 [IQR 0.7 – 3.7] vs. 2.7 [1.3 – 4.3]; p=0.075, median 10.0 [IQR
5.5 – 13.0] vs. 11.3 [8.3 – 13.7]; p=0.189, respectively] (Figure 5.3). The majority of
participants (72%) recorded no light activity in bouts ≥30 minutes therefore, statistical
analysis was not performed.
HRQoL, fatigue and appetite
Compared with well-nourished participants, malnourished participants scored lower
for cancer specific HRQoL (mean 69.0 (16.3) vs. 84.4 (13.3); p<0.001) and fatigue (mean
27.4 (12.0) vs. 40.2 (8.9); p<0.001), as well as on all general HRQoL domains (p≤0.041),
with the exception of role emotional and mental health (p=0.075 and p=0.124,
respectively; Figure 5.4). Appetite scores were significantly poorer in malnourished
participants compared with well-nourished participants (median 29.0 [IQR 19.0 – 36.0]
vs. 41.0 [36.8 – 44.3]; p<0.001).
Dietary intake
There was no difference in energy or protein intake between malnourished and wellnourished participants (median 110 [IQR 86.7 – 132.0] kJ/kg/day vs. 128 [93.4 – 140.4]
kJ/kg/day; p=0.182 and mean 1.3 (0.4) g/kg/day vs. 1.4 (0.5) g/kg/day; p=0.521) or in the
proportion of participants meeting energy (p=0.388) or protein requirements (p=0.814).
The proportion of participants who reported a decrease from their usual intake in the past
month was significantly higher in malnourished compared with well-nourished
participants (91.3% vs. 26.3%; p<0.001). Ninety percent (n=11) of those consuming high
energy, high protein nutrition supplements were malnourished.
Serum biomarkers
Differences in serum biomarkers according nutritional status are presented in Table
5.2. Among the cytokines, IL-6 and was higher and myostatin was lower for
malnourished compared with well-nourished participants (p=0.002 and p=0.032,
respectively). Compared with well-nourished participants, malnourished participants had
a lower albumin concentration (p=0.004). There were no differences in any other
measured serum biomarkers.
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Table 5.1

Demographic and medical characteristics of participants, n=61
n

%

Age, years

69.0^

62.0-74.0^

Gender, male

48

BMI, kg/m2

25.8^

78.7
24.3-28.4^

BMI category
Underweight

0

0.0

Normal weight range

25

41.0

Overweight

27

44.3

9

14.8

Obese
Time since diagnosis, months

2.0^

Median survival, months

1.0-9.0^

21^

12.0-30.0^

43

70.5

Sarcomatoid

5

8.2

Desmoplastic

3

4.9

Biphasic

4

6.6

Unspecified

5

8.2

Unknown

1

1.6

0-1

56

91.8

≥2

5

8.2

21

34.4

Chemotherapy

10

47.6

Radiotherapy

3

14.3

Surgery

1

4.8

Surgery and radiotherapy

1

4.8

Chemotherapy & radiotherapy

3

14.3

Chemotherapy, radiotherapy and surgery

2

9.5

Other

1

4.8

9

14.8

Cisplatin and Pemetrexed

1

11.1

Carboplatin and Pemetrexed

4

44.4

Vinorelbine

1

11.1

Clinical trial – AZD4547

1

11.1

Clinical trial – Cisplatin, Pemetrexed and Nintedanib

1

11.1

Clinical trial – Cisplatin, Pemetrexed and Durvalumab

1

11.1

Histological subtype
Epithelioid

ECOG performance status

Received cancer treatment prior to study, yes
Type of treatment received

Undergoing cancer treatment at the time of study, yes
Type of ongoing treatment
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n

%

0

2

3.3

1

7

11.5

2

21

34.4

3

15

24.6

4

5

8.2

11

18.0

41

67.2

IPC

23

37.7

ICC

9

14.8

VATS

5

8.2

Therapeutic aspirate

5

8.2

Talc poudrage

2

3.3

Pleurectomy

1

1.6

15

24.6

1

1.6

Hypertension

22

36.1

Hypercholesterolemia

12

19.4

Ischemic heart disease

6

9.7

Atrial fibrillation

3

4.8

Type 2 diabetes

8

12.9

COPD

1

1.6

Osteoarthritis

3

4.8

Hip or knee replacement

3

4.8

Grade of pleural effusion

Unknown
Side of pleural effusion, right
Pleural effusion treatment

None
Unknown
Comorbidities

Appendicular lean mass, DXA (n=52)
kg
kg/m2

21.1^

18.0 – 23.0^

7.0^

6.2 – 7.5^

Body composition group (n=52)
Non-sarcopenic

24

46.2

Sarcopenic

28

53.8

Self-reported weight loss in 6 months, %

2.6

0.0 – 7.0

Self-reported weight loss in 6 months
<5%

43

70.5

5-10%

9

14.8

>10%

9

14.8

A – well nourished

38

62.3

B – suspected malnutrition/moderately malnourished

23

37.7

0

0

Nutritional status, PG-SGA

C – severely malnourished
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n

%

Energy intake (n=56)
kJ/day

9001

kJ/kg/day

3278

124^

91 – 140^

103.3

37.6

1.3

0.5

Protein intake (n=56)
g/day
g/kg/day
Energy and protein requirements (n=56)
Energy requirement met

35

62.5

Protein requirements met

43

76.8

Energy or protein requirements met

43

76.8

Consumed nutritional supplements (n=56)

12

21.4

Poor appetite□ (n=53)

23

43.4

Fatigued■

21

40.4

(n=52)

^Median, interquartile range; Last treatment prior to date of assessment; □Score ≤37 on Anorexia
Cachexia Scale, ■Score ≤34 on Functional Assessment of Chronic Illness Therapy – Fatigue Scale; BMI –
Body mass index; IPC – indwelling pleural catheter; ICC – intercostal catheter; VATS – video-assisted
thoracoscopic surgery; ECOG – Eastern Cooperative Oncology Group; COPD – chronic obstructive
pulmonary disease; DXA – Dual Energy X-ray Absorptiometry; PG-SGA – Patient-Generated Subjective
Global Assessment
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Table 5.2

Inflammatory markers and cytokines according to body composition and nutritional status
Body composition

Nutritional status

All participants
(n=57)

Non-sarcopenic
(n=23)

Pre-sarcopenic
(n=27)

P value

Well-nourished
(n=35)

Malnourished
(n=22)

IL-6, pg/mL

5.3 (2.0-13.5)

2.5 (2.0-7.9)

6.5 (3.1-18.3)

0.006*

2.6 (2.0-7.9)

11.0 (4.7-18.8)

0.002*

IGF-1, ng/mL

9.1 (3.4-15.0)

7.1 (1.6-10.8)

9.9 (5.3-15.0)

0.179

7.1 (2.0-14.0)

11.3 (6.4-17.4)

0.090

Ghrelin, ng/mL

0.38 (0.15-0.75)

0.28 (0.09-0.59)

0.34 (0.14-0.94)

0.255

0.38 (0.09-0.63)

0.39 (0.23-0.88)

0.294

Leptin, ng/mL

5.1 (4.0-7.4)

5.7 (3.9-7.8)

5.2 (4.0-7.2)

0.869

5.1 (4.1-7.0)

5.2 (3.9-8.4)

0.896

Myostatin, ng/mL

1.3 (0.9-1.8)

1.7 (1.0-1.9)

1.2 (0.8-1.8)

0.085

1.6 (1.1-1.9)

1.1 (0.7-1.8)

0.032*

Adiponectin, mg/L

3.5 (1.9-6.3)

3.2 (0.9-4.6)

4.0 (2.3-6.5)

0.127

3.3 (2.5-5.7)

3.8 (0.0-6.6)

0.935

VEGF-A, pg/mL

0.29 (0.13-0.57)

0.27 (0.13-0.46)

0.30 (0.13-0.64)

0.704

0.33 (0.13-0.59)

0.21 (0.13-0.53)

0.768

P value

VEGF-C, ng/mL

22.7 (16.0-26.7)

23.1 (20.4-31.6)

22.7 (15.4-23.9)

0.216

23.1 (17.0-28.0)

18.5 (13.2-23.9)

0.127

Albumin, g/L (n=55)

40.0 (37.0 – 42.0)

40.0 (38.0-43.0)

39.5 (36.0-41.0)

0.167

40.0 (38.5-42.0)

37.0 (34.8-41.0)

0.005*

CRP, mg/L (n=46)

19.5 (6.5-70.3)

13.0 (2.1-49.0)

27.0 (7.1-98.0)

0.122

19.0 (3.2-60.5)

35.0 (6.7-84.0)

0.516

Data is presented as median (interquartile range); *p<0.05; IL-6 – Interleukin-6; IGF-1 – Insulin-like Growth Factor-1; VEGF – Vascular Endothelial Growth Factor
TNF-α and IFN-γ levels were undetectable in 89.7% (n=52) and 74.1% (n=43) of samples, respectively, and statistical analyses were not performed.

129

Chapter Five. Body Composition and Nutritional Status in Malignant Pleural Mesothelioma

Patients screened
(n=ll9)

Excluded (n=58)
•

•

Not eligible (n=7)
•

Too unwell (Physician) (n=4)

•

Cognitive impairment (n=1)

•

Unable to comply with study protocol (n=2)

Declined (n=51)

•

Too unwell (n=l6)

•

Not interested (n= 13)

•

Too much time commitment (n=6)

•

Overwhelmed (n=6)

•

Lives too far away (n=4)

•

Unable to contact (n=2)

•

Other reasons (n=4)

Recruited (n=6 l)
•

PG-SGA (n=61)

•

Blood samples (n=57)
•

•

•

•

Not completed (n=4)

Questionnaire (n=54)
•

Not returned (n=4)

•

Not completed (n=3)

Accelerometer (n=54)
•

Declined (n=l)

•

Not returned (n=2)

•

Not worn or worn incorrectly (n=4)

DXA (n=52)
•

Machine error (n=2)

•

Declined, time constraints (n=2), too unwell (n=5)

Figure 5.1 Recruitment of participants to the study
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a)
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b)
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100%
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90%

80%

80%

70%

70%

80%
70%

9
9

60%
50%

60%

a Overweight

50%

Normal weight

40%
30%

Obese

40%

Pre-sarcopenic

60%

Normal muscle
mass

30%

20%

20%

10%

10%

10%

0%

0%

10

20%

Pre-sarcopenic

Malnourished

Well-nourished

40%

30%

16

Malnourished

50%
15

13

0%

Malnourished

Pre.sarcopenic

Figure 5.2 Pre-sarcopenic and malnourished participants. a) Pre-sarcopenic and malnourished participants according to BMI category (n=23 and
n=28, respectively), b) pre-sarcopenic participants according to nutritional status (n=28), and c) malnourished participants according to
body composition group (n=17)
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Figure 5.3 Differences in the number of bouts of light activity according to a) body composition (n=48) and b) nutritional status (n=54),*p<0.05
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-Non-sarcopenic

- Well-nourished

- --- Pre-sarcopenic

80

80

Mental
health

70
60

so

Role

Mental
health

Role
physical

70
60
50

Role
emotional

Bodily pain

emotional

- -- Malnourished

Physical
functioning

Physical
functioning

Bodily pain

General

Social

Social
functioning

functioning

General
health

Role
physical

health
Vitality

Vitality

Figure 5.4 Median scores for the general health-related quality of life domains according to a) body composition (n=46) and
b) nutritional status (n=54), *p<0.05
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5.4

Discussion
Our study found high rates of pre-sarcopenia (54%) and malnutrition (38%).

Compared to data from healthy older adults, we report a much higher prevalence of these
conditions in MPM.40, 41 This result is particularly striking because none of the participants
were underweight, the large majority had a good performance status and were early in
their diagnosis. Consistent with population trends, a high proportion of cancer patients are
overweight or obese.42 In our study, two thirds of participants were overweight or obese
and had similar rates of pre-sarcopenia and malnutrition compared with those in the
normal weight category. Studies in other cancer populations have reported reduced muscle
mass6 and malnutrition7, 8 across all weight categories and in those with good performance
status.43 These results highlight that pre-sarcopenia and malnutrition are common in MPM
patients where clinicians might not expect, for example, newly diagnosed, overweight and
obese patients of a good performance status.
Pre-sarcopenic participants spent significantly less time per day in light activity, and
did fewer bouts of longer periods of light activity (>5 min), compared with non-sarcopenic
patients. Self-reported fatigue and physical functioning were not lower in participants with
pre-sarcopenia which raises the possibility that habitually low levels of physical activity
may have contributed to reduced muscle mass. However, people with reduced muscle
mass need to work closer to their maximum capacity to generate the necessary strength
and power to complete activities of daily living. Therefore, reduced muscle mass could
result in increased fatigue and compensatory reductions in activity levels. Further research
is required to determine if interventions which enhance muscle mass, could improve
participation in daily physical activity for patients with MPM.
We observed a significant inverse association between malnutrition and quality-oflife, in particular poorer self-rated physical functioning, which supports work in other
cancer survivor populations.11, 14, 15 However, the relationship between malnutrition and
quality-of-life is complex, particularly as malnourished participants had higher IL-6
concentrations and fatigue levels which could be indicative of greater disease burden.44
While patients with MPM can maintain quality of life with chemotherapy,45 there are
limited effective treatments available.5 For patients who do not respond to treatment,
supportive care strategies could offer some benefit. An important next step will be to test
interventions to address malnutrition in MPM to determine their impact on quality-of-life.
Notably, nutritional interventions consisting of dietary counseling and oral nutrition
supplements alone, provided to patients with cancer receiving chemotherapy or
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radiotherapy, have had no impact on quality-of-life.46 This suggests that interventions may
need to do more than increase dietary intake or weight to impact on quality-of-life.
Interventions which also address the psychosocial aspects of eating may be an integral part
of optimizing quality-of-life in patients with MPM.47
Overall energy and protein intake did not differ between nutritional status or body
composition groups. High rates of reported nutrition supplement consumption amongst
malnourished participants suggest that participants may have already made changes to
their diet to address malnutrition. These results indicate malnourished patients with MPM
can meet their recommended energy and protein intake with nutrition support. Although,
given the higher IL-6 concentrations amongst participants with malnutrition and presarcopenia, these conditions may not be resolved without addressing the underlying
inflammation.17 Anti-inflammatory agents (e.g., eicosapentanoic acid or non-steroidal
anti-inflammatory drugs) have the potential to offer some benefit but are yet to be tested
in MPM and may be contraindicated for patients receiving active cancer treatment.17
There are several limitations to the current study. The study is cross-sectional and
therefore cannot draw causative conclusions. The study has a small sample size and was
underpowered to detect differences in quality-of-life scores, as demonstrated by the
clinically meaningful differences between body composition groups that were not
statistically significant (e.g., a 6-point median difference in the vitality domain of qualityof-life; Figure 4a). However, a larger, retrospective study of patients with advanced lung
cancer (n=734) has reported a significant association between skeletal muscle and
quality-of-life.10
There is also heterogeneity in the sample with regard to time from diagnosis and
treatments received. One of the most common reasons for non-inclusion in the study was
being too unwell. Therefore, this study possibly included patients who were in better
health, as indicated by longer the median survival of our sample, and may not be
representative of the larger MPM population. Additionally, we were unable to obtain body
composition data for 15% of participants and being too unwell was the most common
reason for not completing a DXA (Figure 5.1). Compared with participants who
completed a DXA, participants without a DXA were significantly older, and had a poorer
appetite. This data suggests that in cancer patients who are older with significant
symptoms, body composition analysis techniques that do not add to participant burden e.g.
computed tomography scan analysis, could be more feasible.
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Our study is the first to investigate body composition and nutritional status
specifically in patients with MPM and provides valuable information on the extent of presarcopenia and malnutrition in this population. Gold standard assessments were employed
to comprehensively assess body composition, nutritional status, patient-rated outcomes
and objective physical activity. We have included a relatively homogenous sample of
patients with MPM. As MPM is a unique disease with a different disease process,
prognosis and treatment options to advanced lung cancer, it is important that MPM is
studied independently.

5.5

Conclusion
Despite good performance status and a normal or high BMI, participants with MPM

had high rates of pre-sarcopenia and malnutrition. Both pre-sarcopenia and malnutrition
were associated with negative outcomes for participants. For the first time in MPM, we
report that pre-sarcopenia was associated with lower activity levels whilst malnutrition
was associated with poorer quality-of-life. Interventions that aim to address reduced
muscle mass and weight loss, should be tested in MPM to assess their impact on activity
levels and quality-of-life.
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Supplementary Tables
Supplementary Table 5.3

Accelerometer data collection and analysis methods

Paradata

Method

Raw data collection

Accelerometers were programmed to record raw data at a
frequency of 30 Hz.

Epoch length

Data were reduced to vertical axis movement counts per 60-second
epoch.

Software used

Accelerometer data were downloaded and processed in Statistical
Analysis Software (version 9.3, SAS Institute, Cary, NC, USA).

Non-wear time

Waking wear time was determined by visual inspection by a
trained rater and an automated algorithm.1

Minimum wear time

A valid day was classified as ≥10-hours of waking wear time.

Minimum valid days

Participants with at least one valid day of data were analyzed.

Reference in table
1.

McVeigh JA, Winkler EA, Healy GN, Slater J, Eastwood PR, Straker LM. Validity of an automated
algorithm to identify waking and in-bed wear time in hip-worn accelerometer data collected with a 24 h
wear protocol in young adults. Physiol Meas. 2016;37(10):1636-1652. doi:10.1088/0967-3334/37/10/1636

Supplementary Table 5.4

Manufacturer information for ELISA kits used in serum
biomarker analysis

Biomarker

ELISA kit manufacturer

Interleukin-6

Thermo Fisher Scientific, Waltham, MA, USA

Insulin-like growth factor

elisakit.com, Melbourne, Australia

Ghrelin

Thermo Fisher Scientific, Waltham, MA, USA

Leptin

eBioscience Inc., San Diego, CA, USA

Myostatin

R&D Systems Inc., Minneapolis, MN, USA

Adiponectin

R&D Systems Inc., Minneapolis, MN, USA

Vascular endothelial growth factor-A

R&D Systems Inc., Minneapolis, MN, USA

Vascular endothelial growth factor-C

R&D Systems Inc., Minneapolis, MN, USA

Tumor necrosis factor-alpha

Thermo Fisher Scientific, Waltham, MA, USA

Interferon-gamma

Thermo Fisher Scientific, Waltham, MA, USA
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Supplementary Table 5.5

Differences in demographic and medical characteristics according to body composition and nutritional status
Body composition
Non-sarcopenic (n=24)

Pre-sarcopenic (n=28)

n

%

n

Age, years

65.0

59.0–70.0^

69.0

Gender, male

19

BMI, kg/m2

26.4

79.2
25.0– 29.7^

Nutritional status

22
24.6

%

Well-nourished (n=38)
p value

62.5–74.0^ 0.042*
78.6

0.958

23.5–27.2^ 0.012*

Malnourished (n=23)

n

%

n

%

p value

67.0

61.5–74.0^

70.0

67.0–74.0^

0.171

73.9

0.479

23.7–28.7^

0.592

31
25.8

81.6
24.6–28.2^

17
25.4

BMI category
Underweight

0

0.0

0

0.0

Normal weight range

6

25.0

16

14

58.3

4

16.7

Overweight
Obese
Time since diagnosis, months

2.0

1.0–9.0^

0

0.0

0

0.0

57.1

15

39.5

10

43.5

9

32.1

18

47.4

9

39.1

3

10.7

5

13.2

4

17.4

3.0

0.064

1.0–12.0^ 0.809

2.0

1.0–9.0^

2.0

1.0–12.0

Histological subtype*
Epithelioid

20

83.3

17

60.7

31

81.6

12

52.2

Sarcomatoid

2

8.3

2

7.1

2

5.3

3

13.0

Desmoplastic

0

0.0

2

7.1

1

2.6

2

8.7

Biphasic

1

4.2

3

10.7

2

5.3

2

8.7

Unspecified

0

0.0

4

14.3

1

2.6

4

17.4

Unknown

1

4.2

0

0.0

1

2.6

0

0.0
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Body composition
Non-sarcopenic (n=24)

Nutritional status

Pre-sarcopenic (n=28)

Well-nourished (n=38)

n

%

n

%

p value

0-1

23

95.8

26

92.9

0.646

≥2

1

4.2

2

7.1

8

33.3

9

32.1

Chemotherapy

4

50.0

4

Radiotherapy

1

12.5

Surgery

1

Surgery and radiotherapy

Malnourished (n=23)

n

%

n

%

p value

38

100.0

18

78.3

0.003*

0

0.0

5

21.7

13

34.2

8

34.8

44.4

7

53.8

3

37.5

1

11.1

1

7.7

2

25.0

12.5

0

0.0

1

7.7

0

0.0

1

12.5

0

0.0

0

0.0

1

12.5

Chemotherapy &
radiotherapy

0

0.0

2

22.2

1

7.7

2

25.0

0

0.0

2

22.2

2

15.4

0

0.0

Chemotherapy, radiotherapy
and surgery

1

12.5

0

0.0

1

7.7

0

0.0

0–2

12

66.7

13

56.5

22

66.7

8

42.1

3–4

6

33.3

10

43.5

11

33.3

11

57.9

15

62.5

21

75.0

25

65.8

16

69.6

ECOG performance status

Received treatment prior
to study, yes

0.927

0.964

Type of treatment*

Other
Grade of pleural effusion (n=52)*

Side of pleural effusion, right
(n=52)
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Body composition
Non-sarcopenic (n=24)

Nutritional status

Pre-sarcopenic (n=28)

n

%

n

%

IPC

8

33.3

10

ICC

3

12.5

VATS

3

Therapeutic aspirate

Well-nourished (n=38)
p value

Malnourished (n=23)

n

%

n

%

35.7

11

28.9

12

52.2

5

17.9

5

13.2

4

17.4

12.5

2

7.1

4

10.5

1

4.3

1

4.2

4

14.3

4

10.5

1

4.3

Talc poudrage

1

4.2

1

3.6

2

5.3

0

0.0

Pleurectomy

0

0.0

1

3.6

1

2.6

0

0.0

None

7

29.2

5

17.9

10

26.3

5

21.7

Unknown

1

4.2

0

0.0

1

2.6

0

0.0

Hypertension

8

33.3

11

39.3

14

36.8

9

39.1

Hypercholesterolemia

6

25.0

3

10.7

6

15.8

6

26.1

Ischemic heart disease

2

8.3

3

10.7

2

5.3

4

17.4

Atrial fibrillation

1

4.2

2

7.1

1

2.6

2

8.7

Type 2 diabetes

2

8.3

4

14.3

4

10.5

5

21.7

COPD

0

0.0

1

3.6

0

0.0

1

4.3

Osteoarthritis

1

4.2

2

7.1

2

5.3

1

4.3

Hip or knee replacement

0

0.0

3

10.7

1

2.6

2

8.7

Back pain or spinal surgery

1

4.2

3

10.7

1

2.6

3

13.0

p value

Pleural effusion treatment*

Comorbidities*

^Median, interquartile range; Last treatment prior to date of assessment; BMI – Body mass index; IPC – indwelling pleural catheter; ICC – intercostal catheter; VATS – video-assisted
thoracoscopic surgery; ECOG – Eastern Cooperative Oncology Group; COPD – chronic obstructive pulmonary disease; *statistical comparisons not carried out
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Supplementary Table 5.6

Differences in demographic and medical characteristics
between participants with and without DXA scans, n=61
DXA available (n=52)

DXA missing (n=9)

n

%

n

%

p value

Age, years

68.0^

62.0-74.0^

73.0^

69.5-78.0^

0.026*

Gender, male

41

77.8

0.942

BMI, kg/m2

25.8^

Time since diagnosis, months

78.8

2.0^

7

24.1-28.5^

25.4^

24.8-28.9^

0.745

1.0-9.8^

2.0^

1.0-5.0^

0.483
0.814

Histological subtype (n=55)
Epithelioid

37

78.7

6

75.0

Non-epithelioid

10

21.3

2

25.0

Received treatment prior to
study, yes

17

32.7

4

44.4

0.493

Side of effusion, right (n=60)

36

70.6

5

55.6

0.371

25

61.0

5

55.6

0.764

16

39.0

4

44.4

IPC

18

35.3

5

55.6

Other

21

41.2

1

11.1

None

12

23.5

3

33.3

0-1

49

94.2

7

77.8

≥2

3

5.8

2

22.2

16

30.8

4

44.4

36

69.2

5

55.6

35

67.3

3

33.3

17

32.7

6

66.7

0

0.0

0

0.0

39

75.0

4

44.4

8

15.4

1

11.1

5

9.6

4

44.4

Poor appetite (n=53)

15

33.3

8

100.0

<0.001*

FACT-G (n=53)

80.3#

14.9#

70.9

21.3

0.132

Grade of effusion (n=50)
0-2
3-5


Effusion treatment (n=60)
0.223

ECOG performance status

Comorbidities
≤1
>1
PG-SGA global rating
A – well-nourished
B – suspected malnutrition or
malnourished

0.097

0.420

0.052

C – severely malnourished
Self-reported weight loss in 6
months
<5%
5-10%

0.024*

>10%

^Median, interquartile range; #mean ± SD, *p<0.05; Last treatment prior to date of assessment; IPC –
indwelling pleural catheter; PG-SGA – Patient-Generated Subjective Global Assessment, FACT-G –
Functional Assessment of Cancer Therapy - General
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Abstract
Context: There is little information on the functional and nutritional characteristics of
patients with malignant pleural mesothelioma (MPM).
Objectives: To report the prevalence of functional and nutritional impairment across the
2-years following diagnosis of MPM and to describe functional and nutritional status over
time.
Methods: This was a prospective observational study and participants were followed for
up to 18-months. Functional data were collected using the: Short-Form Health Survey (SF36) – physical functioning domain and Timed Up and Go (TUG). Nutritional data were
collected using the: Anorexia Cachexia Scale (ACS) and Patient-Generated Subjective
Global Assessment (PG-SGA). Two analyses were performed: the prevalence of
impairment at six time intervals within 2-years of diagnosis and status over time in
participants with ≥2 assessments.
Results: Thirty-six patients with MPM were enrolled (mean age 69.7±7.3 years, 81%
male, median survival 17.5 [IQR 10.3–29.3] months). Across all time intervals within 2years of diagnosis, 57-75% of participants had poor SF-36 physical functioning, 50-88%
had a poor TUG result, 56-71% had a poor appetite and 18-38% had a high need for
nutrition support. Of the participants studied longitudinally (n=25), 52% had poor SF-36
physical functioning, 69% had a poor TUG result, 69% had a poor appetite and 36% had
a high need for nutrition support at ≥2 assessments.
Conclusion: In patients with MPM, functional and nutritional impairment was common.
For many participants, impairments persisted or reoccurred during follow-up. Screening
for functional and nutritional impairment is recommended from diagnosis to identify those
that could benefit from supportive care interventions.
Key message statement: This article describes a prospective observational study that
provides new information about the functional and nutritional characteristics of patients
with MPM, and indicates that functional and nutritional impairments are prevalent across
the 2-years from diagnosis and commonly persist or reoccur over time.
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6.1

Introduction
Malignant pleural mesothelioma (MPM) is a universally fatal cancer attributed to

asbestos exposure.1 Given the incurable nature of the disease and short median survival of
12 months,2 the care of patients with MPM is primarily aimed at optimising quality-of-life.
The ability to perform usual daily life activities is a core component of quality-oflife.3 Additionally, malnutrition is associated with poorer quality-of-life in patients with
thoracic cancer.4-6 However, currently there is no comprehensive description of the
functional and nutritional characteristics of this patient population.
Existing research on physical functioning of patients with MPM is limited to those
who have undergone pleurectomy or decortication,7 which represents a small select
proportion of patients with MPM. Information on nutritional status in MPM is limited to
a cross-sectional analysis of patients assessed close to the time of diagnosis.8 Research in
patients with lung cancer indicates physical functioning and nutritional status decline
following diagnosis,9-11 suggesting supportive care needs are greater over time.9-11
However, a greater understanding of the functional and nutritional characteristics of
patients with MPM is needed as it is a predominantly localised disease,12 with a longer
median survival,2 which could impact on physical functioning and nutritional outcomes.
Therefore, the aim of our study was to report the prevalence of functional and nutritional
impairment across the 2 years following diagnosis of MPM and to describe functional and
nutritional status over time.

6.2

Methods

6.2.1

Participants

Recruitment took place between August 2015 and March 2017 from a tertiary
specialist pleural disease clinic in Western Australia (WA). Inclusion criteria for
participation in the study were cytological or histological confirmation of MPM. Patients
could enrol any time following MPM diagnosis. Patients were excluded from the study if
they were aged <18 years, pregnant or lactating or unable to read and understand English,
to give informed consent, or to comply with the protocol or participating in a concurrent
exercise intervention study. Patient consent and physician approval were required for
participation in the study.

149

Chapter Six. Functional and Nutritional Impairments

6.2.2

Study design and setting

In this prospective observational study, participants completed study assessments
during routine hospital visits approximately every 3 months and were followed until death
or for a maximum of 18 months. The study was approved by the Sir Charles Gairdner
Group and Edith Cowan University Human Research Ethics Committees (ID: 2014-124
and 13255).

6.2.3

Measures

Demographic and medical variables
Participants’ medical records were reviewed for demographic and medical data.
Self-reported physical functioning
Self-reported physical functioning was assessed with the physical functioning domain
of the Short-Form Health Survey (SF-36).3 Participants were classified as having a poor
self-reported physical functioning if they had a norm-based score <45.3
Objective physical functioning
Objective physical functioning was assessed with the Timed Up and Go test.13
Participants were instructed using a standard procedure to get out of a chair, walk 2.44
meters, turn around a marker and return to sitting as quickly as possible. Participants
completed three trials with a one minute rest between each test. All tests were timed using
a stopwatch, with the best time used in the analysis. We applied the age and sex specific
criterion-reference standards that are associated with maintaining physical independence in
older adults, which range from 4.8 – 8.0 seconds for men and 5.0 – 8.0 seconds for
women.14 Participants were classified as having poor objective physical functioning if they
had a result that exceeded the criterion-reference standard range, i.e. greater than 8 seconds.
Appetite
Appetite status was assessed using the validated Anorexia Cachexia Scale (ACS).15
Participants were classified as having a poor appetite if they had an ACS score ≤37.16
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Nutritional status
Nutritional status was assessed using the scored Patient-Generated Subjective Global
Assessment (PG-SGA).17 Participants were classified as having a high need for symptom
control and nutrition support if they had a PG-SGA score ≥9.17

6.2.4

Statistical analysis

Statistical analyses were conducted using the Statistical Package for the Social
Sciences (v. 26, IBM Corporation, Somers, NY, USA). Data were expressed as mean ±
SD or median [IQR] where the data were not normally distributed. To report on the
prevalence of nutritional and functional impairment, data were allocated into six time
intervals across the 2 years following diagnosis of MPM (Analysis 1). Participants with
no assessments within 2 years of diagnosis were excluded from this analysis. The number
of months between diagnosis and each participant assessment was calculated and
participant data were then categorised into the corresponding time interval. Participants
were included in multiple time intervals if they completed more than one assessment,
however no participant was included in the same time interval twice. To provide a
description of functional and nutritional status over time (Analysis 2), we examined
outcomes longitudinally at five time intervals within the 18 months of study enrolment.
Participants who did not complete ≥2 assessments were excluded from this analysis. The
number of months between study enrolment and each participant assessment was
calculated and participant data were then categorised into the corresponding time interval.
Due to small numbers in each time interval, statistical tests were not used to compare
differences in outcomes between time intervals.

6.3

Results

6.3.1

Participant characteristics

Thirty-six participants with MPM enrolled in the study with 34 (94%) included in
Analysis 1 and 25 (69%) in Analysis 2 (Figure 6.1). Participants were predominantly
male (81%) with the epithelioid subtype of MPM (69%). The mean age of participants
was 69.7 ± 7.3 years and median survival was 17.5 [IQR 10.3 – 29.3] months.
Demographic and medical characteristics are presented in Table 6.1.
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6.3.2

Analysis 1: Prevalence of functional and nutritional impairment
between diagnosis and 2-years post-diagnosis

Self-reported physical functioning
At all time intervals, there was a consistently high proportion of participants with a poor
physical functioning score on the SF-36. At diagnosis, 74% of participants had below
average self-reported physical functioning and of these participants, 14% were receiving
cancer treatment. At each of the remaining time intervals, 57 – 75% of participants reported
the poor physical functioning and of these participants, 42 – 75% were receiving cancer
treatment (Figure 6.2).
Objective physical functioning
At all time intervals, there was a consistently high proportion of participants with a
poor result from the Timed Up and Go test. At diagnosis, 91% of participants had a poor
Timed Up and Go result and of these participants, 10% were receiving cancer treatment.
At each of the remaining time intervals, 50 – 88% of participants had a poor Timed Up and
Go result and of these participants, 25 – 50% were receiving cancer treatment (Figure 6.2).
Appetite
At all time intervals, there was a consistently high proportion of participants with a
low appetite score on the ACS. At diagnosis, 68% of participants had a poor appetite and
of these participants, 31% were receiving cancer treatment. At each of the remaining time
intervals, 56 –71% of participants had a poor appetite and of these participants, 25 – 80%
were receiving cancer treatment (Figure 6.2).
Nutritional status
Diagnosis was the time interval where the greatest proportion of participants had a
high PG-SGA score indicating a high need for symptom control and nutrition support. At
diagnosis, 57% of participants had a high need for symptom control and nutrition support
and of these participants, 23% were receiving cancer treatment. At each of the remaining
time intervals, 18 – 38% of participants had a high need for symptom control and nutrition
support and of these participants, 33 – 67% were receiving cancer treatment (Figure 6.2).
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6.3.3

Analysis 2: Longitudinal description of functional and nutritional
status between enrolment and 18 months

Self-reported physical functioning
Seventeen percent of participants had normal SF-36 physical functioning scores for
the duration of follow-up. The remaining participants had poor SF-36 physical functioning
scores at one (32%), two (16%) or three or more (36%) assessments (Figure 6.3).
Objective physical functioning
Seventeen percent of participants had normal Timed Up and Go results for the
duration of follow-up. The remaining participants had poor Timed Up and Go results at
one (13%), two (26%) or three or more (43%) assessments (Figure 6.3).
Appetite
Twenty-two percent of participants had a normal appetite score for the duration of
follow-up. The remaining participants had a poor appetite at one (9%), two (30%) or three
or more (39%) assessments (Figure 6.3).
Nutritional status
Thirty-two percent of participants did not have a high need for symptom control and
nutrition support for the duration of follow-up. The remaining participants had a high need
for symptom control and nutrition support at one (32%), two (32%) or three or more (4%)
assessments (Figure 6.3).
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Table 6.1

Participant characteristics
All participants (n=36)
n (%)

Sex, % men

29 (80.6)

Histological subtype
Epithelioid
Sarcomatoid
Desmoplastic
Biphasic
Unspecified

25 (69.4)
3 (8.3)
2 (5.6)
2 (5.6)
4 (11.1)

Time since diagnosis
≤ 3 months
4-12 months
13-24 months
>24 months

24 (66.7)
8 (22.2)
2 (5.6)
2 (5.6)

Survival
≤ 3 months
4-12 months
13-24 months
>24 months

2 (5.6)
12 (3.3)
10 (27.8)
12 (33.3)

Co-morbidities
Hypertension
Hypercholesterolemia
Ischemic heart disease
Atrial fibrillation
Type 2 diabetes
COPD
Osteoarthritis
Hip or knee replacement
Chronic back pain

12 (34.3)
9 (25.7)
3 (8.6)
3 (8.6)
8 (22.9)
1 (2.9)
3 (8.6)
3 (8.6)
2 (5.7)

Cancer treatment prior to study, yes

9 (25.7)

Type of cancer treatment
Chemotherapy
Radiotherapy
Chemotherapy and radiotherapy
Chemotherapy, radiotherapy and
surgery

4 (44.4)
1 (11.1)
3 (33.3)
1 (11.1)

Cancer treatment during study, yes

22 (62.9)

Type of cancer treatment
Chemotherapy
Radiotherapy
Chemotherapy and radiotherapy

19 (86.3)
1 (4.5)
2 (9.1)
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Screened in Pleural Outpatient Clinic
(=84)
Excluded (48)
Not eligible (r=18)
Too unwell (Physician) (n=9)
Enrolled in alternate study (rel)
Cognitive impairment (ne)
Unable to comply with the study protocol (n=2)
Declined (n=30)
Not interested (ne10)
Too unwell (9)
Overwhelmed (n=6)
Too much time commitment (nee3)
Unable to contact (=I)
Other reasons (n=I)

E rolled and completed baseline
assessment (=36)
Excluded (=2)

Completed

< study assessment

within 2

years of diagnosis

ANALYSIS I(=34)
Completed 2l study assessment within l
years of diagnosis
]Lost to follow p (=D)
l· hdrawn (nee1)

Lost to follow up (=10)
Deceased (n=7)
No longer attending hospital (nee2)
Wehdrawn (seep
ANALYSIS 2 (=25)
Completed 2l study assessments at any
point in the disease course

Figure 6.1 Participants included in the prospective observational study.
Thirty-six participants were enrolled at baseline: 2 were excluded and the remaining participants included in Analysis 1 (n=34); 10 were lost to follow up and the remaining 24 were included
in Analysis 2 plus 1 extra participant who was excluded from Analysis 1 but eligible for Analysis 2.
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Figure 6.3 Line graphs of individual participants depicting changes in SF-36 physical
functioning, Timed Up and Go, Anorexia Cachexia Scale and PatientGenerated Subjective Global Assessment from baseline, n=25
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6.4

Discussion
This study provides new information about the functional and nutritional

characteristics of patients with MPM. We report that functional and nutritional impairment
was common in the 2 years following MPM diagnosis and occurred in the presence and
absence of cancer treatment. For many participants in our longitudinal analysis, functional
and nutritional impairment persisted across multiple assessments.
Functional impairment was prevalent across the 2 years from MPM diagnosis.
Between 50 and 91% of participants at each time interval had poor subjective and objective
physical functioning. Previous studies have shown that patients with lung cancer have
poorer physical functioning than healthy adults, and that function deteriorates over time,10
however there is a lack of information on the prevalence of functional impairment. In a
study of older adults with cancer, 76% of participants reported limitations in physical
functioning and 70% of participants had suboptimal objective physical functioning.18 Our
results are consistent with these findings and comparable as many patients with MPM are
older adults at diagnosis due to the long latency period between asbestos exposure and
diagnosis.19 Together, the results suggest that functional impairment is common among
older patients with cancer.
Poor appetite was prevalent across the 2 years from MPM diagnosis. Poor appetite
was reported by 56 – 71% of participants across all time intervals in our study, which is
higher than the 40% reported by patients with advanced lung cancer.5 The participants
with advanced lung cancer were assessed prior to cancer treatment,5 and as chemotherapy
can adversely affect appetite, this could have contributed to the higher prevalence of poor
appetite reported in our study. Notably, the majority of participants with a poor appetite at
diagnosis were not receiving cancer treatment, which indicates poor appetite can occur
irrespective of treatment status. This indicates that an evaluation of appetite should be
included in management of patients with MPM regardless of whether they are receiving
cancer treatment.
As MPM is an incurable cancer and median survival is 12 months,1 it is encouraging
that a proportion of participants had normal function and nutritional status throughout
follow-up. However, it is concerning that more than half of participants had persistent or
recurrent functional and nutritional impairment, as the extended duration of impairment
could have a more profound impact on patient quality-of-life.
Patients with MPM who have functional and nutritional impairment could benefit
from supportive care interventions, however these impairments could go undetected in
clinical practice. Existing guidelines recommend routine assessment of physical
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functioning to identify functional impairment20 and the use of screening tools to identify
nutritional impairment.21 Our findings suggest that screening or assessment tools which
identify functional and nutritional impairment should be recommended for all patients
with MPM from the point of diagnosis. Functional impairment can be identified with selfreport questionnaires such as the SARC-F22 or objective tests such as the Short
Performance Physical Battery23 while nutritional impairments can be identified with the
use of a validated nutrition screening tool such as the Malnutrition Screening Tool.21
Resistance exercise training could be used to improve physical functioning in patients with
MPM23 although to date, interventions to address nutritional impairments via nutritional
support have not been tested in MPM.
There are several limitations to this study. Our study may not be representative of all
patients with MPM. The enrolment rate was 43% and poor health was the most common
reason for non-participation; therefore the actual prevalence of functional and nutritional
impairment in this clinical group may be higher than we have reported. Additionally,
participants identified as malnourished during the study were referred to a dietitian.
Dietitian intervention, including nutritional counselling and nutrition supplements, may
have contributed to improved nutritional status at subsequent assessments. We did not
track which participants received nutritional intervention. Functional and nutritional
impairments are associated with multiple factors including cancer stage25 and treatment,26,
27

baseline co-morbidities,28 and physical activity level.29 As the sample size of our study

was relatively small, we could not adjust for these confounding factors. Further research
with a larger sample size is needed to gain an understanding of the factors that contribute
to changes in functional and nutritional outcomes in patients with MPM.
This study is the first to provide a description of the functional and nutritional
characteristics in an unselected group of patients with MPM. The majority of participants
in our study received non-surgical cancer treatment or no cancer treatment, which is
representative of standard care pathways for patients with MPM. A strength of our study
is the prospective collection of functional and nutritional data from participants for up to
18 months from enrolment. Additionally, we used validated measures to evaluate selfreported as well as objective physical functioning, appetite and nutritional status.
In patients with MPM, functional and nutritional impairment was common and not
exclusive to participants receiving cancer treatment. For many participants, functional and
nutritional impairments were persistent or reoccurred during follow-up. Screening for
functional and nutritional impairment is recommended for all patients with MPM from the
time of diagnosis to identify those who could benefit from supportive care interventions.
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Abstract
Background: Cachexia is common in advanced cancer and is associated with negative
patient outcomes. In malignant pleural mesothelioma (MPM), no study has reported body
composition changes or factors associated with these changes. This study aimed to
describe changes in body composition over time and its relationship with activity levels
and dietary intake.
Methods: The study was a secondary analysis of data collected from a longitudinal
observational study of patients with MPM. Participants completed 3-monthly assessments
for up to 18 months. Participants with two dual-energy x-ray absorptiometry (DXA) scans
were included. Change in appendicular skeletal muscle mass (ASM) and total fat mass
(FM) were used to categorise participants into phenotypes. Activity levels were measured
with an Actigraph GT3X+ accelerometer and energy and protein intake were measured
with a 3-day food record and 24-hour recall.
Results: Eighteen participants were included (89% male, mean age 68.9±7.1 years).
Median time between DXA was 91 [IQR 84–118] days. Compared to participants with
ASM maintenance (n=8), fewer participants with ASM loss (n=10) survived ≥12 months
from follow-up (p=0.04). Participants with ASM loss increased sedentary time (p=0.028),
and decreased light activity (p=0.028) and step count (p=0.008). Activity levels did not
change in participants who maintained ASM (p>0.05). Energy and protein intake did not
change in either group (p>0.05).
Conclusion: Multiple patterns of change in body composition were identified in patients with
MPM. Muscle loss was associated with poorer survival and decreased activity levels.
Interventions that improve physical activity or muscle mass could benefit patients with MPM.
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7.1

Introduction
Malignant pleural mesothelioma (MPM) is an incurable cancer that results from

asbestos exposure.1 Patients with MPM have limited treatment options and a short median
survival of 12 months.1 It has been hypothesised that cancer cachexia could contribute to
the cause of death in MPM.2
Cancer cachexia is a form of malnutrition characterised by the loss of skeletal muscle
mass in the presence or absence of loss of fat mass, and is often accompanied by anorexia
and systemic inflammation.3 Cancer cachexia can lead to the development of low skeletal
muscle mass, which is associated with a range of negative outcomes in some advanced
cancer populations including poorer quality of life,4 lower activity levels,5 increased
treatment toxicity6 and poorer survival.6 Further, people with both low skeletal muscle
mass and excess fat mass (i.e. sarcopenic obese) have had an even greater risk of negative
outcomes.7
In our previous research we reported that 50% of patients with MPM had low skeletal
muscle mass close to the time of diagnosis, and of these 11% were obese.8 Although
clinicians report patients with MPM become emaciated over the disease course, and often
die with a low BMI,2 there are no studies in patients with MPM on changes in body
composition over time. Information on the patterns of change in body composition could
improve our understanding of the need for interventions which can prevent and treat
cancer cachexia in MPM.
Physical activity and dietary intake are modifiable factors which could be central to
the development of cancer cachexia. Physical activity and dietary protein intake stimulate
muscle protein synthesis9 and in sufficient quantities could protect against the
development of low skeletal muscle mass.10, 11 Additionally, lower levels of physical
activity and high dietary energy intake can create a positive energy balance resulting in
weight gain that is largely an increase in fat mass.12 There is little research into the
relationship between physical activity, dietary intake and changes in body composition in
cancer populations. Understanding these complex relationships is critical for the design of
interventions to prevent and treat cancer cachexia.
The aims of this study in patients with MPM were to describe the changes in body
composition over time and the relationship between body composition changes and
activity levels and dietary intake.
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7.2

Methods

7.2.1

Study design and participants

The study was a secondary analysis of data collected from a longitudinal
observational study which aimed to describe the functional and nutritional status of
patients with MPM. Patients were recruited from a tertiary specialist pleural disease clinic
in Perth, Western Australia and were eligible if they had cytological or histological
confirmation of MPM. Exclusion criteria were: aged <18 years, pregnant or lactating,
unable to read and understand English, unable to comply with the protocol or were
participating in an intervention study likely to influence body composition. Participant
consent and physician approval were required before commencing the study. Participants
completed assessments of body composition, activity levels and dietary intake during
routine hospital visits, approximately every 3 months and were followed until death or for
a maximum of 18 months. Participants that did not complete body composition scans at
two consecutive assessments were excluded from this analysis. The study was approved
by the Sir Charles Gairdner Group and Edith Cowan University Human Research Ethics
Committees (ID: 2014-124 and 13255).

7.2.2

Measurements

Demographic and medical variables
Demographic and medical data were obtained from participant medical records.
Disease progression at the time of follow up was determined by clinician examination of the
Computed Tomography scan completed closest to the time of the second body composition
scan. The Eastern Cooperative Oncology Group (ECOG) performance status was recorded
on the date of assessment.13
Anthropometric measures
Weight and height, measured with participants dressed in light clothing with shoes
removed, were used to calculate the BMI. Participants were classified as underweight, normal
weight, overweight or obese based on World Health Organisation (WHO) BMI criteria.14
Body composition
Body composition was assessed using whole body dual-energy x-ray absorptiometry
(DXA) scans (Hologic Discovery A, Hologic Inc., Marlborough, MA, USA). Appendicular
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skeletal muscle and fat mass was segmented from trunk lean and fat mass at the acromiohumeral and pelvic-femoral joints.15 Low skeletal muscle mass was defined as an
appendicular skeletal muscle mass/height2 of ≤7.26 kg/m2 for males and ≤5.45 kg/m2 for
females. Participants with low skeletal muscle mass were categorised as pre-sarcopenic,
consistent with diagnostic criteria from the European Working Group on Sarcopenia in
Older People.16 Participants with low skeletal muscle mass and a BMI ≥30.0 kg/m2 were
categorised as sarcopenic obese.7 Change in body composition variables were calculated as
the percent change between the second and first measurements.
To characterise changes in body composition over time, participants were categorised
into body composition phenotypes according to changes in skeletal muscle mass and fat
mass. Total lean mass measured with DXA includes both skeletal muscle and residual
mass (i.e., organs), however appendicular lean mass is predominantly skeletal muscle.17
Therefore, to report on changes in skeletal muscle mass we considered it more accurate to
use appendicular lean mass, also known as appendicular skeletal muscle mass, which
represents, on average 75% of whole-body skeletal muscle.17 The four body composition
phenotypes were: 1) loss of appendicular skeletal muscle mass and loss of total fat mass;
2) loss of appendicular skeletal muscle mass and maintenance or gain of total fat mass; 3)
maintenance or gain of appendicular skeletal muscle mass and loss of total fat mass and
4) maintenance or gain of appendicular skeletal muscle mass and maintenance or gain of
total fat mass. A loss was defined a change of <0.00 kg between the first and second
measurements; maintenance or gain was defined as a change of ≥0.00 kg between the first
and second measurements.
Activity levels
Sedentary behaviour and physical activity were objectively assessed following each
body composition scan using the Actigraph GT3X+ accelerometer (Actigraph, Pensacola,
FL, USA). Participants were instructed to wear the accelerometer on their hip continuously
24 hr/day for 3 days, to only remove for bathing or swimming and to record any non-wear
time in a logbook. Cut-points were applied to classify sedentary behaviour as <100
counts/minute (cpm), light activity as 100-1952 cpm and moderate and vigorous physical
activity (MVPA) as >1952 cpm.18, 19 Variables were calculated per day and then averaged
across all valid days, defined as at least 10 hours of data per day. Additional accelerometer
methodology for this study has been reported previously.5
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Dietary intake
Dietary intake was measured following each body composition scan using a 3-day
estimated food record at the initial assessment and a 24-hour recall at subsequent assessments.
To assist participants with completion of the food record, written and verbal instructions were
provided explaining how to complete the food record and accurately estimate portion sizes
using household measures. Returned food records were visually inspected by the researchers
and incomplete details were clarified with participants. Participants completed the 24-hour
recall in a face-to-face interview with a dietitian using the multiple pass method.20 The food
records and 24-hour recalls were analysed using Foodworks 8 software (Xyris Software Pty
Ltd, Queensland, Australia). Intake variables were calculated per day, and for the food
records, intake was averaged across all three days. Energy (kJ) and protein intake (g) were
expressed per kg of body weight per day respectively.

7.2.3

Statistical analyses

Statistical analyses were conducted using the Statistical Package for the Social
Sciences (v. 23, IBM Corporation, Somers, NY, USA). Data were expressed as mean ± SD
or median [IQR] where the data were not normally distributed. To examine the relationship
between changes in body composition and participant characteristics, activity levels and
dietary intake, participants were condensed into two groups: 1) muscle loss group; and 2)
muscle maintenance group, with definitions provided above. Fisher’s exact test was used
to test for differences in characteristics between participants with muscle loss and muscle
maintenance where the data were categorical. As the data were not normally distributed,
the Mann-Whitney test was used to test for differences in characteristics between
participants with muscle loss and muscle maintenance where the data were continuous, and
for differences in change in activity levels and dietary intake between muscle groups. The
Wilcoxon signed-rank test was used to test for differences in body composition, activity
levels and dietary intake between the first and second measurements.

7.3

Results

7.3.1

Participant characteristics

Of the 36 patients recruited to the longitudinal observational study, 18 (50%) were
included in the current study (Figure 7.1).
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The median time between the first and second body composition scans was 91 (IQR 84
– 118) days. Participant characteristics are presented in (Table 7.1). The majority of
participants were male (89%) and the mean age was 68.9 ± 7.1 years. Nine participants
(50%) received cancer treatment during the follow up period. Ten participants (56%) met
the criteria for muscle loss and eight participants (44%) met the criteria for muscle
maintenance. Three participants (30%) with muscle loss survived more than 12 months from
the second body composition scan, while all participants (100%) with muscle maintenance
survived more than 12 months from the second scan (p=0.04). No other differences in
participant characteristics were observed between muscle groups (p>0.05) (Table 7.1).

7.3.2

Changes in sarcopenia status

There was a 17% increase in the proportion of participants who were pre-sarcopenic
between the first and second body composition scans. Eight participants (44%) were presarcopenic at the first measurement and eleven participants (61%) were pre-sarcopenic at
the second scan. Three participants (30%) who were non-sarcopenic at the first
measurement were pre-sarcopenic at the second scan. None of the participants who were
pre-sarcopenic at the first measurement became non-sarcopenic. Of the participants who
were pre-sarcopenic at the first scan, none (0%) were obese. Of the participants who were
pre-sarcopenic at the second scan, one (9%) was obese.

7.3.3

Changes in body composition

When participants were condensed into the four body composition phenotypes, eight
participants (44%) had a loss of appendicular skeletal muscle and fat mass, two participants
(11%) had a loss of appendicular skeletal muscle and maintained fat mass, four participants
(22%) maintained appendicular skeletal muscle and lost fat mass and, four participants
(22%) maintained appendicular skeletal muscle and fat mass (Figure 7.2).
There were no significant changes in total, lean or fat mass during the follow up period
in the whole group (Table 7.2). Participants with muscle loss (n=10) experienced a
significant decrease in total mass (p=0.005), trunk lean mass (p=0.009), appendicular
skeletal muscle mass (p=0.005) and trunk fat mass (p=0.013) but not appendicular fat mass
(p=0.721). Participants with muscle maintenance (n=8) experienced a significant increase
in appendicular skeletal muscle mass (p=0.012) but not total mass (p=0.093) trunk lean
mass (p=0.484), trunk fat mass (p=0.401) or appendicular fat mass (p=0.889).
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7.3.4

Change in activity levels according to muscle change group

There were no significant changes in activity levels during the follow up period in the
whole group (Table 7.3). Participants with muscle loss had a significant decrease in
median step count (p=0.008), an increase in the proportion of waking hours spent as
sedentary (p=0.028) and a decrease in the proportion of waking hours spent in light activity
(p=0.028) (Table 7.3). There was no significant change in the proportion of waking hours
spent in moderate and vigorous physical activity (p=0.260). Participants with muscle
maintenance maintained step count (p=0.176), and the proportion of waking hours spent
as sedentary (p=0.499), in light activity (p=0.499) or in moderate and vigorous physical
activity (p=0.176) (Table 7.3).
There was a significant difference between participants with muscle loss and muscle
maintenance for change in step count (-1020 [IQR -4667 – 56] vs. 1234 [IQR -204 – 2221]
steps/day; p=0.008; Figure 7.3) and for the proportion of waking hours spent in light
activity (-4.8 [IQR -9.2 – 0.2] vs. -0.7 [IQR -2.0 – 7.5]; p=0.023; Figure 7.3) but not for
the proportion of waking hours spent as sedentary (4.9 [IQR -2.3 – 11.1] vs. 0.5 [IQR -8.6
– 2.2]; p=0.142; Figure 7.3).

7.3.5

Change in dietary intake according to muscle change group

There were no significant changes in energy and protein intake during the follow up
period in the whole group (Table 7.3) or in participants with muscle loss and those with
muscle maintenance (Table 7.3).
There was a significant difference between participants with muscle loss and muscle
maintenance for change in protein intake (-0.28 [IQR -0.48 – 0.15] vs. 0.74 [IQR -0.14 –
0.82] g/kg/day; p=0.025; Figure 7.3) but not for energy intake (-7.9 [IQR -45.0 – -0.9] vs.
28.9 [IQR -23.6 – 123.1] kJ/kg/day; p=0.193; Figure 7.3).
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Table 7.1

Participant characteristics, n=18
All participants
(n=18)

Muscle loss
(n=10)

Muscle maintenance
(n=8)

P
value

Age, years

68.9 ± 7.1

67.0 [61.5-74.3]

71.5 [62.5-75.0]

0.633

Sex, male

16 (88.9%)

8 (80%)

8 (100%)

0.477

25.2 [23.9-28.7]

25.9 [24.1-29.5]

24.3 [23.8-27.7]

0.237

Underweight

0 (0.0%)

0 (0.0%)

0 (0.0%)

-

Normal weight range

9 (50.0%)

3 (30.0%)

6 (75.0%)

Overweight

7 (38.9%)

5 (50.0%)

2 (25.0%)

Obese

2 (11.1%)

2 (20.0%)

0 (0.0%)

8 (44.4%)

4 (40.0%)

4 (50.0%)

0.520

BMI, kg/m2
BMI category

Pre-sarcopenic, yes
Histological subtype, epithelioid

15 (83.3%)

8 (80%)

7 (87.5%)

1.000

ECOG performance status at first scan*, 0-1

18 (100%)

10 (100%)

8 (100%)

-

Time from diagnosis to first scan*
<3 months

10 (55.6%)

5 (50.0%)

5 (62.5%)

-

3-12 months

5 (27.8%)

3 (30.0%)

2 (25.0%)

>12 months

3 (16.7%)

2 (20.0%)

1 (12.5%)

Time from first to second scan, days
Cancer treatment during follow up, yes

91.0 [84.0-118.0]

87.5 [82.5-92.5]

105.5 [87.5-143.5]

0.083

9 (50%)

5 (50%)

4 (50%)

1.000
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All participants
(n=18)
Type of cancer treatment
Cisplatin and Pemetrexed

Muscle loss
(n=10)

Muscle maintenance
(n=8)

3 (33.3%)

1 (20.0%)

2 (50.0%)

Carboplatin and Pemetrexed

3 (33.3%)

2 (40.0%)

1 (25.0%)

Vinorelbine

1 (11.1%)

1 (20.0%)

0 (0.0%)

Clinical trial – Cisplatin, Pemetrexed and
Durvalamab

2 (22.2%)

1 (20.0%)

1 (25.0%)

10 (55.6%)

6 (60.0%)

4 (50.0%)

Stable

4 (22.2%)

2 (20.0%)

2 (25.0%)

Response to treatment

2 (11.1%)

0 (0.0%)

2 (25.0%)

Data not available

2 (11.1%)

2 (20.0%)

0 (0.0%)

7 (38.9%)

7 (70.0%)

0 (0.0%)

11 (61.1%)

3 (30.0%)

8 (100.0%)

Disease progression at second scan*
Progressed

Time from second scan* to death
<12 months
≥12 months
*First or second body composition scan
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Table 7.2

Participant changes in body composition, n=18
All participants (n=18)

Muscle loss (n=10)
First scan

Second scan

P
value

First scan

Second scan

0.133

75.0 (70.4-91.6)

72.5 (66.9-88.7)

0.005*

74.1 (68.4-87.1)

75.7 (68.8-90.9)

0.093

49.5 (46.9-53.9)

0.248

51.4 (46.9-56.4)

48.7 (43.9-54.6)

0.005*

49.6 (46.8-53.5)

50.8 (49.0-53.7)

0.012*

26.6 (24.8-29.1)

25.4 (24.5-28.3)

0.085

26.9 (25.2-29.9)

25.2 (23.8-29.0)

0.009*

25.2 (24.7-28.9)

26.5 (24.8-28.2)

0.484

21.4 (18.9-22.2)

20.5 (19.7-22.2)

0.306

21.4 (18.6-23.0)

20.4 (17.3-21.8)

0.005*

21.2 (18.5-22.0)

21.8 (20.3-22.2)

0.012*

Total

24.3 (20.1-30.1)

24.2 (19.8-28.7)

0.215

25.9 (20.1-30.1)

24.3 (20.5-28.0)

0.037*

22.9 (16.8-30.1)

23.6 (16.2-31.1)

0.575

Trunk

12.3 (9.8-15.1)

11.2 (9.4-15.1)

0.184

12.4 (10.1-15.3)

10.8 (9.4-14.0)

0.013*

11.9 (7.8-15.5)

11.8 (7.7-17.0)

0.401

Appendicular

11.3 (8.3-13.8)

11.5 (8.4-13.9)

0.679

11.9 (8.3-15.2)

11.5 (8.7-14.2)

0.721

10.2 (8.2-13.0)

10.1 (7.5-14.0)

0.889

Mass (kg)

First scan

Second scan

75.0 (70.3-87.4)

74.1 (67.3-88.7)

Total

50.4 (47.3-53.9)

Trunk
Appendicular

Total

P
value

Muscle maintenance (n=8)
P
value

Lean mass

Fat mass

Data is presented as median (interquartile range); *p<0.05
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Table 7.3

Participant activity levels and dietary intake, n=17
All participants (n=17)
First scan

Second scan

Muscle loss (n=10)
P
value

First scan

Second scan

Muscle maintenance (n=7)
P
value

First scan

Second scan

P
value

Activity behaviours
Steps, n

5505 (4603-6404)

4736 (3608-6843)

Sedentary
behaviour, %

70.3 (61.7-73.1)

Light activity, %
MVPA, %

0.196 6013 (4111-9117) 4251 (1738-5372)

0.008* 5039 (4582-5653)

5590 (4196-7404)

0.176

73.1 (64.0-76.0)

0.196

67.0 (58.1-72.7)

73.7 (66.8-84.2)

0.028*

72.6 (62.8-73.2)

73.1 (63.4-75.7)

0.499

27.5 (26.4-35.0)

25.5 (22.3-34.5)

0.215

28.4 (26.0-39.6)

25.3 (15.4-30.8)

0.028*

27.1 (26.3-35.1)

26.2 (22.7-35.7)

0.499

0.8 (0.5-3.1)

0.9 (0.7-1.7)

0.836

1.0 (0.4-5.3)

0.7 (0.3-1.5)

0.260

0.6 (0.5-1.4)

1.7 (0.8-1.7)

0.398

Dietary intake
Energy intake, kJ/kg 129.6 (90.1-143.8) 121.8 (102.3-147.2) 0.981 122.8 (94.2-140.2) 119.0 (90.5-135.0)

0.241

Protein intake, g/kg

0.333

1.5 (0.9-2.0)

1.4 (1.1-1.8)

0.492

1.0 (0.9-1.8)

1.2 (0.7-1.6)

Data is presented as median (interquartile range); MVPA – Moderate and Vigorous Physical Activity; *p<0.05

174

135.3 (61.4-141.0) 139.3 (110.0-263.3) 0.176
1.6 (0.8-1.7)

1.5 (1.4-2.9)

0.091

Chapter Seven. Changes in Body Composition

Enrolled in longitudinal
observational study (n=36)

Excluded (n=18)

.

.
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.
.
.

Deceased (n=7)

Withdrawn (=2)
No longer attending hospital (n=2)

Participated but incomplete DA data (n=7)

.
.
.

Too unwell (n=4)
Too burdensome (n2)
Time constraints (participant) (n=1)

Eligible for inclusion (n=18)

.

Accelerometer (n=16)

Not wor

.

at

baseline (n=1)

Declined at follow up (n=D)

Food record (=17)
Not completed at baseline (n=I)

Figure 7.1 Participants included in the secondary analysis

4,22%

■ Loss of appendicular skeletal
muscle and fat mass

■ Loss of appendicular skeletal
8,45%

muscle and maintenance or gain

of fat mass
■ Maintenance or gain of
appendicular skeletal muscle
and loss of fat mass
■ Maintenance or gain of
appendicular skeletal muscle
and fat mass
2, 11%

Figure 7.2 Proportion of participants within each body composition phenotype, n=18
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7.4

Discussion
Our study is the first to prospectively assess changes in body composition in relation

to activity levels and dietary intake in patients with MPM. We identified multiple
patterns of body composition change among our participants. Notably, participants with
muscle loss and muscle maintenance had distinct survival, physical activity and dietary
intake characteristics.
Our participants could be categorised across all four body composition phenotypes.
The most common phenotype, which included 44% of participants, was the loss of
appendicular skeletal muscle mass and fat mass, which is consistent with the cachexia
phenotype.3 When we condensed the four body composition phenotypes into two groups:
1) muscle loss and 2) muscle maintenance; 56% of participants had muscle loss and 44%
had muscle maintenance. This result is particularly notable as the low mean BMI reported
in a previous post-mortem study indicated patients with MPM become emaciated over
the disease course.2 While muscle loss was common, our results suggested that a
proportion of participants with MPM had the ability to maintain muscle, at least for a
fraction of the disease course.
There were significant differences in survival between participants with muscle loss
and muscle maintenance. A small proportion (30%) of participants with muscle loss
survived at least 12 months from the second body composition scan while all (100%)
participants with muscle maintenance survived at least 12 months from the second body
composition scan. Therefore, muscle loss could be indicative of shorter survival in patients
with MPM. Similar findings have been reported in a large retrospective study of patients
with advanced cancer (n=368)21 where the authors stated that muscle loss became more
common as death approached. Tumour burden is thought to mediate the metabolic changes
that cause loss of muscle and fat mass22 highlighting the importance of efficacious cancer
treatments for the management of cachexia.3 There are currently limited treatment options
for those with MPM and in a previous clinical trial only 40% of patients responded to firstline chemotherapy treatment.23 Therefore, addressing lifestyle factors that contribute to
cancer cachexia could offer benefit.
Participants with muscle loss had a significant decline in activity levels over the
follow up period of 3 months, while participants with muscle maintenance sustained their
activity levels. As physical activity is required for muscle protein synthesis,9 a decrease in
physical activity may have contributed to muscle loss among our participants.
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Additionally, as the majority of participants (70%) with muscle loss were categorised as
pre-sarcopenic at follow up, participants may not have had the strength and endurance to
participate in their usual physical activity. The lack of physical activity could result in an
even greater reduction in muscle loss. Therefore, regardless of the causal pathway between
muscle loss and activity levels, resistance exercise training may offer benefit to patients
with MPM as it can improve skeletal muscle mass, strength and physical function.24
There were no statistically significant changes in dietary intake over the follow up
period for participants with muscle loss and muscle maintenance, however we made
clinically meaningful observations. Participants with muscle loss had a median energy and
protein intake that was within the recommended energy and protein intake range of 105 –
126 kJ/kg and 1.0 – 1.5 g/day, respectively,25 while median energy and protein intake
among participants with muscle maintenance exceeded these recommendations. In a larger
study (n=52) of patients with incurable non-small cell lung cancer (NSCLC), higher
energy and protein intakes (149 kJ/kg and 1.4 g/kg, respectively) were associated with
maintenance of skeletal muscle mass during chemotherapy.26 Approximately 40-50% of
patients with NSCLC are reported to have an elevated resting energy expenditure,27, 28
which could lead to muscle and fat loss unless dietary intake is increased proportionally.
As muscle loss developed in our participants meeting dietary intake recommendations, it
is possible that an elevated resting energy expenditure could have been a contributing
factor in these patients with MPM. Intakes of energy and protein that exceed
recommendations may be needed to preserve skeletal muscle mass in patients with MPM.
This study has several potential limitations worthy of consideration. Several factors
are known to affect muscle and fat metabolism, including disease progression,
inflammation, cancer treatment and older age.29 While these characteristics were
compared between participants with and without muscle loss, the sample size was too
small to allow further evaluation in relation to changes in body composition. Energy and
protein intake at baseline and follow up were measured using different dietary assessment
methods. Participant feedback indicated that a 3-day food record was too burdensome,
therefore we used 24-hour recalls at follow up assessments. Compared with a 24-hour
recall, a 3-day food record could be more representative of usual dietary intake as
measurement is carried out over a greater number of days. However, a 24-hour food recall
is not less accurate than a food record.20 Considering this population of advanced cancer
patients, participant burden was a key consideration in our study that should also be taken
into account in future investigations.

178

Chapter Seven. Changes in Body Composition

Our study provides an insight into changes in body composition experienced by
patients with MPM. A strength of our study is the use of DXA for body composition
analysis, which enabled us to complete reliable evaluation of appendicular skeletal muscle
mass and whole-body and regional fat mass.17 This data cannot be obtained through
computed tomography evaluation of body composition, which employs a single crosssection analysis, and existing prediction equations used to convert cross-sectional data to
appendicular skeletal muscle mass may be inaccurate.30 Additionally, we report deviceassessed sedentary behaviour and physical activity using an accelerometer, which has
greater accuracy when compared with self-report questionnaires.31

7.5

Conclusion
For the first time, we report on body composition changes over time in patients with

MPM. Our results indicate that multiple patterns of change in body composition exist in
this patient population. Muscle loss was associated with poorer survival and decreased
activity levels. Interventions that improve physical activity or muscle mass could benefit
patients with MPM.
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Abstract
Purpose: Little is known about the effects of nutritional status and dietary intake on
response to exercise interventions in advanced cancer. This study aimed to determine if
completion rates and response to an exercise intervention differ according to nutritional
status and dietary intake in patients with malignant pleural disease (MPD).
Methods: Patients with MPD participated in a 6-week resistance exercise intervention.
Outcome measures were assessed before and after the intervention. Nutritional status was
assessed with the Patient-Generated Subjective Global Assessment (malnutrition defined as
a rating of B or C). Dietary intake was assessed with 3-day food records (adequate intake
defined as energy ≥25 kcal/kg/day and protein ≥1.0 g/kg/day). Appendicular skeletal muscle
mass (ASM, kg) was segmented from whole-body dual-energy x-ray absorptiometry and
adjusted for height (kg/m2). Physical functioning was assessed with repeated chair rise,
Timed Up and Go, one-repetition maximum leg press and Six-Minute Walk Test.
Results: Thirty-three participants were recruited (median age 68 [IQR 62-73] years, 68%
men). Study completion rates were not significantly different between well-nourished and
malnourished participants (84% vs. 75%; p=0.616). Gain in ASM was significantly greater
in participants with adequate compared to inadequate intake (mean difference 0.40 [95%
CI 0.14-0.67] kg/m2; p=0.005). There were no differences between those with adequate and
inadequate intake for change in repeated chair rise (p=0.504) Timed Up and Go (p=0.734),
relative one-repetition maximum leg press (p=0.643) and Six-Minute Walk Test (p=0.600).
Conclusion: There were acceptable study completion rates for participants with
malnutrition. Dietary intake may not affect the physical functioning response to resistance
exercise, however adequate intake could optimize muscle gains. This could have
implications for the development of exercise and multimodal interventions in advanced
cancer populations.
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8.1

Introduction
Malignant pleural disease (MPD) indicates the presence of advanced cancer, and

occurs as a result of malignant pleural mesothelioma (MPM) or the metastatic spread of
cancer to the pleura.1 Malnutrition is common in patients with advanced cancer, including
those with MPM.2 Malnutrition is characterized by changes in weight and body
composition that result from inadequate dietary intake or the impaired absorption or
utilization of nutrients.3
A high proportion of malnourished patients with advanced cancer have low skeletal
muscle mass2 which has been associated with poorer quality of life,4 greater treatment
toxicity5 and shorter overall survival.6 Therefore, interventions which increase skeletal
muscle mass have the potential to improve quality of life, treatment tolerance and survival.
Resistance exercise training can increase skeletal muscle mass and improve physical
functioning in patients with cancer.7 While malnourished patients are represented in
exercise interventions targeting patients with advanced cancer,8 little is known about the
feasibility of exercise interventions in cancer patients with malnutrition, as nutritional
status is rarely assessed.8, 9 Due to higher fatigue levels,2 combined with the negative
impact of low skeletal muscle mass on physical functioning,10 malnourished patients
could have poorer adherence to exercise interventions than well-nourished patients. This
could indicate the need for additional support during exercise interventions for patients
that are malnourished.
There is a lack of data on the relationship between dietary intake and the response to
resistance exercise training in advanced or poorer prognosis cancer populations. Dietary
intake plays a central role in skeletal muscle homeostasis, yet intake is inadequate in a
high proportion of patients with advanced cancer.2 When dietary intake is inadequate,
amino acids from the diet may be used as an energy source, reducing availability for
skeletal muscle synthesis,11 and skeletal muscle may be broken down to provide the body
with amino acids for energy.11 Therefore, skeletal muscle growth and functional responses
to exercise could be impeded in cancer patients with inadequate dietary intake.7
The aim of this study in patients with MPD was to determine whether: 1) completion
rates, adherence and tolerance to a resistance exercise intervention differed according to
nutritional status and dietary intake; and 2) the body composition and physical functioning
response to resistance exercise training differed according to dietary intake.
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8.2

Methods

8.2.1

Participants

Participants were recruited from tertiary specialist pleural disease and medical
oncology clinics in Perth, Western Australia (WA). Participants were eligible if they had
cytological or histological confirmation of MPD. Exclusion criteria were aged <18 years,
pregnant or lactating, unable to read and understand English, unstable bone metastases or
metastases of the long bones, acute illness or disorder precluding exercise, physician
recommendation against participation and patient unable to give informed consent or
comply with the protocol. The study was approved by the Sir Charles Gairdner Group and
Edith Cowan University Human Research Ethics Committees (ID: 2014-124 and 13255).

8.2.2

Measures

Assessment schedule
Participants completed a baseline assessment fewer than 7 days prior to commencing
the exercise intervention and a post-intervention assessment fewer than 7 days after
completing their final exercise training session.
Demographic and medical data
Participant medical records were reviewed for demographic and medical data. At
baseline and post-intervention, participants were assigned an Eastern Cooperative
Oncology Group (ECOG) performance status rating of 0 to 4.12
Anthropometric data
Height (m) was measured at baseline and weight (kg) was measured baseline and
post-intervention. Participants were dressed in light clothing with shoes removed. Weight
and height data were used to calculate the body mass index (BMI) (kg/m 2).
Nutritional status, appetite and dietary intake
Nutritional status was assessed at baseline and post-intervention using the PatientGenerated Subjective Global Assessment (PG-SGA).13 Participants were categorized with
a global rating of A – well nourished, B – suspected malnutrition/malnutrition or C –
severe malnutrition. Participants with malnutrition (global rating of B and C) were
combined for data analysis. Participants who were well-nourished at baseline and post-
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intervention were considered well-nourished and participants who were malnourished at
either or both time-points were considered malnourished.
Participants completed a validated questionnaire at baseline and post-intervention to
assess appetite (Anorexia Cachexia Scale; ACS).14 A poor appetite was defined as a score
of ≤37 on the ACS, consistent with previously reported cut-points.15
Dietary intake was collected following the baseline and post-intervention assessments
with a 3-day food record. Written and verbal instructions were provided to participants,
explaining how to complete the food record and estimate portion sizes using household
measures (including measuring cups and spoons). Food records were analysed by an
Accredited Practising Dietitian (EJ) using FoodWorks 8 Professional (Xyris Software Pty
Ltd, Australia). Intake variables were calculated per day and averaged across three days
for each participant. Energy (kcal) and protein intake (g) were expressed per kilogram (kg)
of body weight per day.
The recommendations of the European Society of Parenteral and Enteral Nutrition
(ESPEN) expert group were used to classify energy and protein intake as adequate or
inadequate.16 These guidelines recommend patients with cancer achieve a minimum
energy intake of 25 kcal/kg/day and protein intake 1.0 g/kg/day.16 Participants with an
intake that met the ESPEN expert group recommendations at baseline and postintervention were considered to have adequate dietary intake. Participants with an intake
below the ESPEN expert group recommendations at either or both time-points were
considered to have inadequate dietary intake.
Body composition
Body composition was measured at baseline and post-intervention using whole body
dual-energy x-ray absorptiometry (DXA) (Hologic Discovery A, Hologic Inc.,
Marlborough, MA, USA). Appendicular skeletal muscle mass was segmented from trunk
lean mass at the acromio-humeral and pelvic-femoral joints and adjusted for height
(kg/m2).17 Low appendicular skeletal muscle mass was defined as ≤7.26 kg/m 2 for males
and ≤5.45 kg/m2 for females.18 Change in appendicular skeletal muscle mass (kg/m2) and
body fat (%) were determined by the absolute difference between the baseline and postintervention measurements.
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Physical functioning
Participants completed a series of standardized tests at baseline and post-intervention
to assess physical functioning. Lower body function was assessed with the repeated chair
rise (sec), where participants were asked to rise from a seated position and return to sitting,
five consecutive times.19 Functional mobility was assessed with the Timed Up and Go
(sec), where participants were asked to rise from a seated position, walk 8-feet forward,
turn around, walk back to the chair and sit down.20 Lower body strength was assessed with
the one-repetition maximum (1RM) leg press, or the maximum weight (kg) that can be
lifted one time.21 Relative 1RM was calculated as 1RM leg press divided by current
weight. Functional capacity was assessed with the Six-Minute Walk Test (m), where
participants were asked to walk as far as possible on a flat 50 m course in six minutes.22
Exercise intervention
Supervised resistance exercise training was undertaken by participants in small groups,
three times per week for six weeks with a total of 18 sessions. Participants had an additional
two-week period where they could make up for any missed sessions. Exercise training was
supervised by an Accredited Exercise Physiologist. The training involved resistance
exercises that were designed to target the major muscles of the upper and lower body, with
1 – 3 sets of each exercise performed at an intensity of 8 – 12 repetition maximum, defined
as the maximum weight that could be lifted 8 – 12 times. Exercise prescription was
progressive and modified by the Accredited Exercise Physiologist according to the
individual’s response.
Adherence and tolerance to the exercise intervention
Completion of the study was defined as attendance at both the baseline and postintervention assessments. Adherence to the exercise intervention was recorded as the total
number of exercise sessions attended out of a possible 18. Following each exercise session,
participants were asked to rate their perceived exertion during exercise and their tolerance
of the session. Perceived exertion was assessed with the Borg scale, where a score of 6
represents no exertion and a score of 20 represents maximal exertion.23 Tolerance was
assessed using a 7-point Likert scale, where a score of 1 indicated the exercise session was
extremely intolerable and a score of 7 indicated an extremely tolerable session. Average
perceived exertion and average tolerance of the exercise intervention were calculated for
each participant and determined by the sum of each participant’s data divided by the
number of exercise sessions attended.
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8.2.3

Statistical analysis

Statistical analyses were conducted using Statistical Package for the Social Sciences
(v. 25, IBM Corporation, Somers, NY, USA). Data are expressed as mean ± SD or median
[IQR] where the data were not normally distributed. Fisher’s Exact Test was used to assess
differences in study completion rates between well-nourished and malnourished
participants. Two-tailed independent t-tests, or the Mann-Whitney test where the data were
not normally distributed, were used to test for differences in participant characteristics and
change scores of variables according to nutritional status or dietary intake. Paired t-tests,
or the Wilcoxon signed rank test where the data were not normally distributed, were used
to assess if body composition and physical functioning variables changed significantly
from baseline to post-intervention.

8.3

Results

8.3.1

Participant characteristics

Participant flow through the study and baseline participant characteristics have been
reported previously (Appendix B).24 Briefly, thirty-three patients enrolled in the study with
a median age of 68 [IQR 62 – 73] years and a mean BMI of 25.7 ± 3.4 kg/m2. Participants
were predominantly male (68%), with a diagnosis of MPM (85%) and an ECOG
performance status rating of 0-1 (97%). All participants completed the PG-SGA and eight
(24%) were classified as malnourished. Thirty participants (91%) completed the appetite
questionnaire and food record, and of these, nine (30%) had a poor appetite and eleven
(37%) did not meet energy and protein requirements.

8.3.2

Nutritional status and dietary intake among participants who
completed the intervention

Of the 27 participants who completed the intervention, 26 (96%) had complete
nutritional status data available and 25 (93%) had complete dietary intake data. Regarding
the incomplete data, one participant did not complete the 3-day food record at baseline and
one participant declined to complete the PG-SGA and weight measurement postintervention; therefore energy (kcal/kg/day) and protein (g/kg/day) intake could not be
calculated for these participants. No differences were observed in demographic or disease
characteristics between participants according to nutritional status or dietary intake group
(Table 8.1 and Table 8.2). The majority of participants (73%) who completed the
intervention were well-nourished at baseline and post-intervention (Figure 8.1). Only 40%
had adequate energy and protein intake at both baseline and post-intervention (Figure 8.1).
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8.3.3

Differences in completion rates, exercise adherence and tolerance
according to nutritional status and dietary intake

Study completion rates were not significantly different between participants who
were well-nourished or malnourished at baseline (84% vs. 75%; p=0.616). Among
participants who completed the intervention, there were no significant differences between
participants well-nourished and malnourished with regard to the number of exercise
sessions attended (median 18.0 [IQR 18.0 – 18.0] vs. median 18.0 [IQR 13.0 – 18.0];
p=0.427), the average tolerance of exercise sessions (median 6.1 [IQR 5.8 – 6.5] vs.
median 5.7 [IQR 5.2 – 5.9]; p=0.073) or the average rating of perceived exertion of
exercise sessions (median 12.7 [IQR 12.1 – 13.8] vs. median 12.3 [IQR 12.3 – 12.8];
p=0.611; Table 8.3).
Study completion rates were not significantly different between those with adequate
and inadequate dietary intake at baseline (89% vs. 82%; p=0.611), although three
participants did not complete the baseline food record. Among participants who completed
the intervention, there were no significant differences between participants with adequate
and inadequate intake with regard to the number of exercise sessions attended (median
18.0 [IQR 14.5 – 18.0] vs. 18.0 [IQR 18.0 – 18.0]; p=0.567), the average tolerance of
exercise sessions (median 6.0 [IQR 5.9 – 6.3] vs. median 5.8 [5.3 – 6.5]; p=0.495) or the
average rating of perceived exertion of exercise sessions (median 12.6 [IQR 12.3 – 13.7]
vs. median 12.3 [IQR 12.0 – 12.9]; p=0.338; Table 8.3).

8.3.4

Changes in body composition following the exercise intervention,
according to dietary intake

Change in appendicular skeletal muscle mass differed significantly between the
adequate and inadequate dietary intake groups (mean difference 0.40 [95% CI 0.14 – 0.67]
kg/m2; p=0.005; Figure 8.2). Following exercise training, appendicular skeletal muscle
mass significantly increased in participants who had adequate dietary intake (mean change
+0.43 [95% CI 0.18 – 0.67] kg/m2; p=0.004); there was no significant change in participants
with inadequate dietary intake (mean change +0.03 [95% CI -0.13 – 0.19] kg/m2; p=0.737).
Change in body fat (%) did not differ significantly between the adequate and
inadequate dietary intake groups (median difference -0.15 %; p=0.765; Figure 8.2).
Following exercise training, body fat (%) did not change significantly in participants with
adequate dietary intake (median change -0.45 [IQR -2.7 – 0.4] %; p=0.314) or inadequate
dietary intake (median change -0.3 [IQR -1.2 – 0.5] %; p=0.414).
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8.3.5

Changes in physical functioning following the exercise intervention,
according to dietary intake

There were no differences between those with adequate and inadequate dietary intake
for change in the repeated chair rise (mean difference 0.43 [95% CI -0.90 – 1.76] sec;
p=0.504), Timed Up and Go (median difference -0.09 sec; p=0.734), relative onerepetition maximum leg press (median difference 0.02; p=0.643) or Six Minute Walk Test
(median difference -4.7 m; p=0.600; Figure 8.3).
Following exercise training, the chair rise improved significantly in participants with
both adequate dietary intake (median change -0.93 [IQR -2.25 – -0.37] sec; p=0.021) and
inadequate dietary intake (median change -1.23 [IQR -2.75 – -0.24] sec; p=0.004). Timed
up and go improved significantly in participants with adequate dietary intake (median
change -0.30 [IQR -1.55 – 0.39]; p=0.012) but not in those with inadequate dietary intake
(median change -0.39 [IQR -0.65 – 0.17] sec; p=0.221). Relative 1RM leg press improved
significantly in participants with both adequate dietary intake (median change 0.23 [IQR
0.06 – 0.38]; p=0.008) and inadequate dietary intake (median change 0.21 [IQR 0.05 –
0.32]; p=0.001). Six Minute Walk Test improved significantly in participants with adequate
dietary intake (median change 46.8 [IQR 27.7 – 100.0] m; p=0.011) but not in those with
inadequate dietary intake (median change 42.1 [IQR -11.3 – 120.0] m; p=0.075).
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Table 8.1

Demographic, disease and nutritional characteristics of participants who were well-nourished and malnourished, n=26
All participants (n=26)
n

Age#, years

67.0^

Well-nourished (n=19)

%

n

62.0 – 72.3^

68.0^

%
62.0 – 72.0^

Malnourished (n=7)
n
62.0^

%

P value

62.0 – 74.0^

0.651

1.000

Gender
Male

19

73.1

14

73.7

5

71.4

Female

7

26.9

5

26.3

2

28.6

BMI#, kg/m2

25.9

3.4

26.0^

24.7 – 30.0^

23.7^

19.8 – 26.3^

0.055

0.588

Cancer type
Mesothelioma

21

80.8

16

84.2

5

71.4

5

19.2

3

15.8

2

28.6

0-1

25

96.2

19

100.0

6

85.7

≥2

1

3.8

0

0.0

1

14.3

Cancer treatment prior to intervention,
yes

9

34.6

5

26.3

4

57.1

0.188

Cancer treatment during intervention,
yes

7

26.9

4

21.0

3

42.9

0.340

Low□

14

53.8

9

47.4

5

71.4

0.391

Normal

12

46.2

10

52.6

2

28.6

11

42.3

9

47.4

2

28.6

Non-mesothelioma
ECOG performance status at baseline

0.269

Appendicular lean mass at baseline
(DXA)

Normal appendicular lean mass over
study period
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All participants (n=26)

Well-nourished (n=19)

Malnourished (n=7)

n

%

n

%

n

%

P value

Inadequate

8

30.8

5

27.8

3

42.9

0.640

Adequate

17

65.4

13

72.2

4

57.1

10

38.5

8

44.4

2

28.6

0.659

7

26.9

2

10.5

5

71.4

0.006

19

73.1

17

89.5

2

28.6

17

65.4

16

88.9

1

14.3

Dietary intake at baseline*

Adequate intake over study period
Appetite at baseline
Poor■
Normal
Normal appetite over study period*

0.001

ECOG – Eastern Cooperative Oncology Group; DXA – Dual-Energy X-Ray Absorptiometry; #assessed at baseline, ^median, IQR, □DXA measured appendicular lean mass ≤7.26 kg/m2
for men and ≤5.45 kg/m2 for women; ■Score ≤37 on Anorexia Cachexia Scale; *Well-nourished, n=18 and malnourished, n=7
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Table 8.2

Demographic, disease and nutritional characteristics of participants with adequate and inadequate intake, n=25
All participants (n=25)

Age#, years

Adequate intake (n=10)

Inadequate intake (n=15)

n

%

n

%

n

%

P value

67.0^

62.0 – 72.5^

67.0^

59.3 – 71.0^

68.0^

62.0 – 73.0^

0.723

Gender
Male

18

72.0

7

70.0

11

73.3

0.856

Female

7

28.0

3

30.0

4

26.7

BMI#, kg/m2

25.9

3.5

25.6

4.1

26.0

3.0

0.775

20

80.0

9

90.0

11

73.3

0.307

5

20.0

1

10.0

4

26.7

0-1

24

96.0

9

90.0

15

100.0

≥2

1

4.0

1

10.0

0

0.0

Cancer treatment prior to intervention,
yes

9

36.0

4

40.0

5

33.3

0.734

Cancer treatment during intervention,
yes

7

28.0

3

30.0

4

26.7

0.856

Low□

14

56.0

7

70.0

7

46.7

0.250

Normal

11

44.0

3

30.0

8

53.3

10

40.0

3

30.0

7

43.8

Cancer type
Mesothelioma
Non-mesothelioma
ECOG performance status at baseline
0.211

Appendicular lean mass at baseline
(DXA)

Normal appendicular lean mass over
study period
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All participants (n=25)

Adequate intake (n=10)

Inadequate intake (n=15)

n

%

n

%

n

%

P value

Nutritional status at baseline (PG-SGA)
Well-nourished

20

80.0

8

80.0

12

80.0

Suspected malnutrition/ moderately
malnourished

5

20.0

2

20.0

3

20.0

Severely malnourished

0

0.0

0

0.0

0

0.0

72

8

80.0

10

66.7

0.467

7

28.0

3

30.0

4

26.7

0.856

18

72.0

7

70.0

11

73.3

16

64.0

6

66.7

10

66.7

Well-nourished over study period

18

1.000

Appetite at baseline
Poor■
Normal
Normal appetite over study period*

1.000

ECOG – Eastern Cooperative Oncology Group; DXA – Dual-Energy X-Ray Absorptiometry, PG-SGA – Patient-Generated Subjective Global Assessment; #assessed at baseline, ^median, IQR,
□DXA measured appendicular lean mass ≤7.26 kg/m2 for men and ≤5.45 kg/m2 for women; ■Score ≤37 on Anorexia Cachexia Scale *inadequate intake, n=15 and adequate intake, n=9

Table 8.3

Differences in adherence and tolerance to exercise between nutritional status and dietary intake groups
Well-nourished (n=19)

Sessions attended, #
Average tolerance
Average RPE

Malnourished (n=7)

Median

IQR

Median

IQR

18.0

18.0 – 18.0

18.0

13.0 – 18.0

6.1

5.8 – 6.5

5.7

12.7

12.1 – 13.8

12.3

Adequate intake (n=10)
P value

Inadequate intake (n=15)

Median

IQR

Median

IQR

0.427

18.0

14.5 – 18.0

18.0

18.0 – 18.0

0.567

5.2 – 5.9

0.073

6.0

5.9 – 6.3

5.8

5.3 – 6.5

0.495

12.3 – 12.8

0.611

12.6

12.3 – 13.7

12.3

12.0 – 12.9

0.338

RPE – Rating of Perceived Exertion
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100%
90%
80%

Malnourished or inadequate intake:
post-intervention only

70%
60%

Malnourished or inadequate intake:
baseline only

50%
40%
30%

■

20%
10%

Malnourished or inadequate intake:
baseline and post intervention

\Veil-nourished or adequate intake:
baseline and post-intervention

0%

Nutritional status

Dietary intake

Figure 8.1 Nutritional status and dietary intake at baseline and post-intervention
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Figure 8.2 Differences in the change in body composition. a) appendicular skeletal
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8.4

Discussion
We examined if nutritional outcomes impacted completion or efficacy of a 6-week

resistance exercise intervention. The majority of participants (73%) were well nourished
over the course of the intervention, however only 40% of participants maintained adequate
intake at pre and post intervention. There were no differences in completion rates,
adherence to, or tolerance of the exercise sessions according to nutritional status or dietary
intake group. Participants with adequate intake had a significant increase in appendicular
skeletal muscle mass, while those with inadequate intake had no change in appendicular
skeletal muscle mass. Notably, there were no significant differences in the physical
functioning response to exercise according to the dietary intake group.
We previously reported excellent adherence and tolerance to the exercise intervention
overall, and in this study we report that there were acceptable study completion rates among
both well-nourished and malnourished participants (84% and 75%, respectively) and both
nutritional status groups reported the exercise sessions were tolerable. Our results indicated
that malnourished patients with MPD are capable of completing a short resistance exercise
training program. To our knowledge, no other study in advanced cancer has directly
compared exercise intervention completion rates according to nutritional status. However,
in a previous 3-month combined nutrition and exercise intervention, where one-third of the
participants with advanced cancer were at nutritional risk, the majority of participants
(97%) completed the intervention.25 The individualized prescription of exercise was a
central component of our study and the previous intervention. Having flexibility in the
exercise prescription for participants with malnutrition, who have poorer baseline physical
functioning and greater fatigue, may be integral to their successful completion of exercise
interventions.
Participants with MPD who consumed adequate intake had a significant increase in
appendicular skeletal muscle mass following the exercise intervention. There was no
change in appendicular skeletal muscle mass among participants with inadequate intake.
To our knowledge, this is the first study in patients with an advanced cancer to evaluate
the relationship between dietary intake and body composition outcomes from resistance
exercise training. Our results raise the possibility that addressing inadequate intake or
maintaining adequate intake could optimize the skeletal muscle response to exercise. This
is a particularly important finding as low muscle mass is associated with a range of
negative outcomes for patients, including poorer quality of life,4 increased risk of
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treatment toxicities6 and poorer survival.6 Nutrition screening, using a tool such as the
Malnutrition Screening Tool (MST)26 could be a fast and effective way to identify patients
eating less than usual and requiring nutritional counselling and oral nutrition supplements
to meet dietary intake recommendations.26 As patients with MPD are at high risk of
inadequate intake,2 routine screening and access to nutrition support should be considered
alongside exercise interventions.
Optimizing physical functioning is also important for patients with advanced cancer.
We found no significant differences in physical functioning outcomes between
participants with inadequate and adequate energy and protein intake. Following the
exercise intervention, we observed positive changes among both dietary intake groups for
the chair rise and 1RM leg press. This suggests that resistance exercise training is
beneficial even for cancer patients who are unable to meet dietary intake
recommendations. This is particularly relevant for advanced cancer patients, as dietary
intake can remain suboptimal even following nutritional intervention.27
A limitation of the current study is the small sample size, therefore we were unable
to incorporate other confounding health issues such as cancer progression and treatment
into our statistical analysis and cannot draw conclusions about causality. The majority of
participants with malnutrition also had a good performance status and therefore may not
be representative of the broader population of malnourished patients with advanced
cancer, particularly those with poorer performance status. More unwell patients could be
less likely to commence, complete, adhere to and tolerate the exercise intervention.
Exertion and tolerance of the exercise intervention were measured using the Borg scale
and a 7-point Likert scale, respectively. Both measures are participant-rated and therefore
subjective and may not represent the level of objective physiological exertion or tolerance
experienced by participants. Additionally, as dietary intake was only assessed at two time
points, before and after the intervention, we are unable to determine the duration and
stability of any inadequate energy and protein intake. More frequent monitoring of dietary
intake for example weekly or fortnightly could capture the duration of inadequate intake.
Repeated 24-hour dietary recalls28 could be one way to increase the frequency of dietary
intake monitoring, without substantially increasing participant burden.
As resistance exercise interventions can increase skeletal muscle mass and improve
physical functioning, they have the potential to improve quality of life, treatment tolerance
and survival in patients with advanced cancer. However, the response to resistance
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exercise could be impeded by poor tolerance to exercise prescription and inadequate
intake. Compared to patients with early stage cancer, patients with advanced cancer, as in
the current study, are more likely to experience malnutrition and a poor appetite,29 which
may negatively affect their ability to participate in exercise and eat adequately during an
exercise intervention.
As exercise oncology research begins to include more patients with advanced cancer,30
the impact of the unique nutritional issues that characterize this patient group needs to be
evaluated to determine how to best optimize patient outcomes. This study offers insight into
how nutrition and exercise outcomes interact in patients with MPD and the potential to
improve response to exercise with combined interventions.
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9.1

Overview
This research aimed to provide information on the physical activity, nutritional status

and body composition of patients with MPD and their relationship with patient outcomes,
as well as examine the effects of nutritional status and dietary intake on outcomes of an
exercise intervention. This chapter is a summary of the findings from a literature review
and three experimental studies that were conducted in patients with MPD, and
acknowledges the strengths, limitations and implications of the work.
Chapter Two is a critical review of the literature. There is a lack of information in the
literature regarding the prevalence of inactivity, functional impairment, malnutrition and
low muscle mass in patients with MPD, and their associations with patient outcomes,
confirming the value of further investigation. There is also a limited understanding on the
effect of different body composition assessment methods on the classification of low
muscle mass and the subsequent conclusions that are drawn. Furthermore, there is little
information on the nutritional status and dietary intake of participants included in exercise
interventions, and the impact that these nutritional factors have on exercise outcomes.
In Chapter Three, the aim was to use accelerometry to characterise physical activity
levels and their relationship with patient outcomes. The majority of participants did not
meet physical activity guidelines; and compared to participants with good performance
status, participants with a poor performance status spent a greater proportion of their day
as sedentary and a lower proportion of their day participating in light activity. These results
indicated that patients with MPD were inactive, and performance status and survival were
associated with activity levels. Accelerometry was well tolerated as a tool for assessing
physical activity levels in this population.
In Chapter Four, the aim was to compare body composition assessment methods,
namely CT and DXA, which are commonly used in the classification of low muscle mass
in research. There was a moderate positive correlation between skeletal muscle index and
appendicular skeletal muscle index and a moderate agreement between the CT cut-points
from Prado et al1 and the DXA cut-points from Baumgartner et al2, but no significant
agreement between the other cut-points evaluated. These findings highlighted that
although the body composition assessment methods of CT and DXA were correlated, there
were differences between methods when they were used to classify low muscle mass.
In Chapter Five, the aim was to determine the prevalence of low muscle mass and
malnutrition and investigate their relationship with physical activity levels and quality of
life in patients with MPM. There were high rates of low muscle mass and malnutrition.
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Compared to participants with normal muscle mass, participants with low muscle mass
were more sedentary and participated in less light activity; and compared to participants
who were well-nourished, those with malnutrition had poorer quality of life. These results
indicated that low muscle mass and malnutrition were common among patients with MPM
and were associated with negative outcomes.
In Chapter Six, the aim was to determine the prevalence of poor physical functioning
and nutritional outcomes in the two years from MPM diagnosis and provide a description
of functional and nutritional status over time. Functional and nutritional impairment were
common throughout the 2 years post diagnosis and for many participants, impairments
persisted or reoccurred during the follow-up. These results indicate a need for screening
in clinical practice to identify patients with functional and nutritional impairment who
could benefit from supportive care interventions.
In Chapter Seven, the aim was to describe changes in body composition over time and
their relationship with activity levels and dietary intake. Multiple patterns of change in body
composition were found. Ultimately, compared to participants with muscle maintenance,
those with muscle loss had poorer survival and decreased activity levels over time.
Interventions that target muscle loss or physical activity may benefit patients with MPM.
In Chapter Eight, the aim was to determine if completion rates and response to an
exercise intervention differed according to nutritional status and dietary intake. There were
acceptable study completion rates for participants with malnutrition. Compared to
participants with inadequate dietary intake, participants with adequate intake had a greater
increase in muscle mass, however there were no differences in the physical functioning
response to exercise. This result suggests that adequate intake could optimise muscle
gains. Importantly, those with malnutrition or inadequate intake can still complete and
gain benefit from an exercise intervention. This could have implications for the
development of exercise and combined interventions in advanced cancer populations.

9.2

Limitations and strengths
The research has a small sample size relative to studies completed in other cancer

populations, such as those with advanced lung cancer.3, 4 This was expected given MPM
is a rare cancer with fewer than 800 new cases diagnosed across Australia each year.5
Despite the anticipated small sample size, research in MPM was needed given the lack of
existing data on physical activity, nutritional status and body composition. Research in
this field was particularly important as supportive care interventions could offer benefit to
a patient population with incurable disease and limited treatment options. Therefore, the
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overarching purpose of this research was to provide a platform from which intervention
studies could be developed.
The research includes a heterogeneous population of patients with MPM. Patients
with MPM could enrol in the studies at any time from the point of diagnosis and regardless
of their past, present or future cancer treatment plans. As a result, there are multiple
confounding factors that were not adjusted for in the statistical analysis due to the
relatively small sample size, which limit the conclusions that can be drawn from the
research. The alternative would have been to control for these confounding factors and
include patients at specified time points within the disease course or treatment journey.
However, this would have had a negative impact on the sample size for two reasons.
Firstly, the time of diagnosis was a particularly challenging time to recruit participants.
Twenty percent of the participants who declined to participate reported feeling too
overwhelmed with their recent diagnosis. Second, there is no standard treatment pathway
for patients with MPM and while approximately half of participants had treatment during
the course of their disease, the other half of participants did not. Therefore, the research
would not have been feasible if the eligibility criteria were restricted to patients who were
newly diagnosed or due to commence chemotherapy.
A lack of benefit to patients is a commonly reported barrier to participation in clinical
trials.6 Two of the experimental studies conducted, the cross-sectional and longitudinal
observational studies offered no direct benefit to participants. The recruitment rate for the
longitudinal observational study was 43%. Of the patients excluded, approximately onethird were ineligible, however the remaining two-thirds declined to participate. None of the
patients who declined participation reported a lack of benefit to themselves as a reason for
non-participation, however this may have been due to social desirability bias. Therefore,
the lack of benefit to patients may have had a negative effect on the participation rate.
The health of the patients with MPM may also have had an impact on the participation
rate. Almost one-third of patients who declined to participate reported being too unwell.
Assessments for this research were completed over one hour, which could be inconvenient
for unwell patients. Consequently, this research most likely included the more well
patients with MPM and the results may not be generalisable to the larger MPM population.
Considering ways that patients can participate with minimal time and effort could improve
future participation rates of unwell patients with MPM.
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Previous research has reported that the inconvenience and cost of travel for patients
with cancer are also important considerations for participation in clinical trials.7 Similarly
during the recruitment process in this research, patients indicated that one of the main
considerations for study participation was whether they would need to make additional
visits to the hospital. A high proportion of the participants were from regional or remote
Western Australia, and additional travel would have been a significant burden.
Consequently, the timing of study assessments in the longitudinal observational study was
flexible. This meant that on occasion there was a longer than expected time between study
assessments. The differences in the timing of follow up between participants created some
challenges during data analysis. However, the alternative would substantially limit
participation. The burden associated with attending assessments should be carefully
considered when planning future research in patients with MPD.
As the study was conducted in an advanced cancer population, participant burden was
a key consideration when planning the research. For example, informal feedback from
participants during the longitudinal observational study indicated that completing a 3-day
food record was burdensome. Therefore, an amendment was made to the study protocol
and participants were asked to complete a 3-day food record at the baseline assessment
only; and the shorter 24-hour recall was completed at subsequent assessments. Participants
appeared to be more engaged in the 24-hour recall process. While results of a 24-hour
recall may not represent habitual dietary intake, the method was more acceptable to
patients. Compared with a 3-day food record, the 24-hour recall could be more feasible in
patients with advanced cancer when dietary intake needs to be assessed at multiple time
points. This also indicates the need to be pragmatic in these types of studies.
The completion of body composition assessments was a significant challenge in this
study population. The DXA machine used for this study was a 10-minute walk from the
Respiratory and Medical Oncology clinics, which was difficult for most participants. This
was managed by using wheelchairs and the hospital buggy service to transport participants
to the DXA machine. Some participants were not able to lie flat on the DXA bed or
independently get on and off the DXA bed. This was managed by providing pillows and
physical assistance to participants. Although these challenges understandably led to some
participants declining to complete a DXA scan, there were no serious adverse events
related to body composition assessment or any other measurements, indicating that the
assessments were safe. However, this experience highlighted that DXA may not be the
most practical way to assess muscle mass in patients with advanced cancer; particularly in
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prospective research where participants have disease progression and become more unwell
over time. For future research it may be more feasible to measure muscle mass using CT.

9.3

Implications for practice and future research
This research provides preliminary data on functional and nutritional impairment in

MPM and indicates that these issues are prevalent in this patient population. While this
research did not investigate the proportion of participants who had received a referral to
an exercise physiologist, physiotherapist or dietitian for supportive care, current figures
suggests that functional and nutritional impairment in patients with cancer goes undetected
in a high proportion of cases,8, 9 which could have a negative impact on patient-centred
outcomes. Several factors could contribute to this finding, including a lack of awareness
of the benefits of interventions to address functional impairment,10 and insufficient
clinician skills to identify nutritional issues.11 Exercise physiologists, physiotherapists and
dietitians have an important role to play in providing education to clinicians to increase
awareness of functional and nutritional impairment in MPM, and to improve clinician
skills in identifying these problems. Existing guidelines recommend the integration of
functional assessment10 and nutrition screening12 into routine clinical care for patients with
cancer to facilitate timely access to supportive care interventions. The high rates of
functional and nutritional impairment reported in this research indicate there is a need for
health services to implement functional assessment and nutrition screening into routine
care of patients with MPM. At present, routine assessment of function and nutrition is not
conducted in the pleural outpatient clinic in Western Australia. Consequently, future
research will focus on implementing functional assessment and nutritional screening
practices into routine clinical care using an implementation science approach that
considers the barriers and enablers of change.
As MPM has no cure, improving survival and the ability to tolerate cancer treatments
is of high importance. A growing body of research suggests that low muscle mass and
poor muscle quality is associated with reduced time to disease progression and overall
survival13 and could increase the likelihood and severity of toxicity from chemotherapy.14
A study investigating muscle mass, muscle quality, survival and treatment toxicity in
MPM presents several methodological challenges. First, the study would require a much
greater sample size than the one recruited in this research. Based on the research in this
thesis, using DXA prospectively is unlikely to be feasible due to low incidence of disease 5
and the additional burden associated with DXA in unwell patients with advanced cancer.

210

Chapter Nine. Conclusions and Implications for Future Research

Additionally, DXA does not measure muscle quality.15 CT could be a more practical way
to undertake this research as scans are performed as part of routine clinical care, accessible
for retrospective analysis. CT also has the capacity to measure both muscle mass and
quality.15 Although CT is more practical, the findings of this work indicate existing cutpoints may have limited utility. Therefore, the relationship between muscle mass, muscle
quality, survival and treatment toxicity will be evaluated with data as continuous variables
as recommended by the American Society of Parenteral and Enteral Nutrition.16
Research presented in this thesis indicates that inadequate dietary intake and
malnutrition are common in patients with MPD and associated with poor outcomes such
as reduced quality of life. Additionally, adequate dietary intake may be required to
increase muscle mass during exercise training. Therefore, the next phase of this research
will be to determine if a multi-modal program of nutritional support with exercise training
could optimise the therapeutic effect of exercise. Considering aerobic exercise may
interfere with muscle maintenance or gain in patients with cancer,17 resistance training
will be the primary mode of exercise. Existing research indicates that intervention with
dietary counselling and oral nutrition supplements can improve energy and protein intake
in patients with cancer.16, 17 These interventions will be the foundation of the nutritional
support

program.

Additionally,

preliminary

research

indicates

amino

acid

supplementation with beta-hydroxy-beta-methylbutyrate (HMB), the active metabolite of
leucine, slows the breakdown of protein in muscle tissue and enhances muscle protein
synthesis, resulting in improvements in muscle mass.18 Given the substantial challenges
to maintaining and improving muscle mass in advanced cancer patients, HMB
supplementation could be a novel way to improve the effects of traditional nutrition
support in combination with resistance exercise training.

9.4

Conclusion
This research investigated physical activity, functional and nutritional status and

body composition in patients with MPD and its relationship with patient outcomes. In an
effort to better understand supportive care outcomes, this research also evaluated the
effects of nutritional status and dietary intake on outcomes of an exercise intervention.
There were high rates of inactivity, poor physical function, malnutrition and low muscle
mass among patients with MPD. Low muscle mass and malnutrition were associated with
negative outcomes. Muscle loss over time was associated with a decline in physical
activity, therefore interventions that target muscle mass or physical activity could offer
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benefit to these patients. The results of the exercise intervention indicated that
malnutrition should not preclude participation, however dietary intake could influence
body composition outcomes. Therefore, combined nutrition and exercise interventions
could be most impactful. Research is needed to investigate the relationship between low
muscle mass and survival, as well as the feasibility and efficacy of combined
interventions in patients with MPD.
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ABSTRACT

PEDDLE-MCINTYRE.CJ,V CAVALHERI T. BOYLE.I A MCVEIGH. E. JEFFERY, B. M. LYNCH, And K. VALLANCE. A
Review of Accelerometer-based Activity Monitoring in Cancer Survivorship Research. Med Sei Sports Eere., Vol $0, No , pp. I790--801,

2018. Background ln the cancer survivorship context, physical activity and sedentary behavior have been measured using different methods.
Purpose To conduct a narrative review of published research in canoer survivor populations to summarize the quality aend identify gaps in
reporting on accelerometer data collection, data processing and outcome measures in cancer survivors.Method An initial Pub Med. search of
articles published in English was conducted in January 20I7, and a final search was conducted inMay 20I7. Varables extracted included study
charactersties, methods for accelerometry data collection (e.g, devioe used), data processing (eg, cut points used), and data reporting (e.g, time
spent in different activity intensities) Results. A total of 46 articles were eligible for inclusion in the review. The majority of studies(34 of 46)
targeted a single cancer group ad 18 of these 34 studies were in survivors of breast cancer. Half ($4% of the studies used an AetiGraph
accelerometer, Methods of accelerometer data processing varied across studies. Definitions of nor-wear tire, vectors used during processing.
and filers applied during prooessing were reported by 51%, 60%, and 8% of studies, respectively. Most sades reported moderate and vigorous
physical activity (78%, 50% reported sedentary time, and 43% reported light-intensity activity. Cut points to categorize these activities varied
between studies. Conclusion This narrative review highlights inconsistency in the methods used to collect, process, and report accelerometry
data across cancer survivor studies. Accelerometry has potential to add detailed keowledge of the levels and patters of physical activities
and sedentary behaviors across the cancer spectrum. Recommendations are made to improve data processing and reporting methods to
maximize the scientific validity of future accelerometer research in this field Key Words: PHYSICAL ACTIVITY, SEDENTARY
BEHAVIOR, ACCELEROMETER, CANCER, MEASUREMENT

he past two decades have witnessed a plethora of
research examining the health benefits of physical
activity in people with cancer. Studies have demonstrated associations of physical activity and important cancer

outcomes including a lower risk of cancer recurrence, improved mortality, and beneficial effects on a range of patientreported outcomes (1,2). More recent research has indicated
that sedentary behavior may also impact the health of cancer
survivors (3). While physical activity and sedentary behavior are important targets for cancer survivorship research,
accurate and reliable measurement of these constructs remains a challenge.
Most research to date on physical activity and sedentary
behavior in cancer survivors has been characterised by the
use of self-reported assessments, most often using measures
that rely on a person's recall of their physical activity and/or
sedentary behavior. The reliability and validity of self-report
physical activity questionnaires are dependent on participants
activity levels (i.e., active adults have more measurement error
than less active adults) (4-6). Additionally, high-volume and
less discrete behaviors, such as sedentary time and light
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intensity activity that occur throughout the day are difficult
to capture by self-report. Self-reported measures of sedentary time and physical activity have been shown to have
only poor to fair agreement with objective measures of these
behaviors using accelerometry (7), although it could be
argued that these two methods are not measuring the same
constructs (6).
Using accelerometers to measure activity and sedentary
behavior is becoming increasingly common in the cancer
survivorship context. As accelerometry provides an objective
measure of important patient-centered outcomes, it is appealing to both researchers and clinicians. Accelerometry also
enables precise and reliable measurement across the movement continuum (ie., sleep, sedentary, and physical activity
behaviors) that occur at different intensities and patterns
throughout the 24-h day. Accurate quantification of physical
activity and sedentary behavior via accelerometry facilitates a
better understanding of these exposures and how they relate to
health outcomes in cancer survivors. Accelerometer data also
allow for the complex characterisation of physical activity
accumulation patters, including the identification of times of
day and days of the week in which individuals are more or less
active or sedentary. This information is valuable for developing interventions aimed at changing these behaviors (8).
Given the potential clinical applications of accelerometers
for cancer populations, differences in population characteristics (compared to the general population), and the increasing research focus on cancer survivorship, understanding
how accelerometers have been applied in cancer research is
of particular importance.
Although accelerometers have the capacity to provide
richer and more accurate data about physical activity and
sedentary behaviors compared with self-report measures, the
quality of the data produced is dependent on an array of
decisions made during data collection and processing. These
critical decisions include device type and placement, weartime protocols, epoch length, filter application, criteria for
non-wear time, criteria for a valid day of wear time, and
how to process data to obtain summary measures of sedentary time, light-intensity activity and moderate and vigorous
physical activity (MVPA) (9,10). These decisions can affect
the summary measures derived (e.g., minutes of MVPA per
day) and also the observed associations between these summary measures and health outcomes. It is therefore vital that
accelerometer data collection and processing decisions are
clearly reported in journal articles summarizing accelerometerbased studies. Failure to report this information means that
studies are not replicable and also makes it difficult to determine if discrepant results across studies are "real" differences
or simply due to measurement and data processing decisions (l). In this narrative review we aimed to: (a)
summarize the quality of reporting on accelerometer data
collection, data processing, and outcome measures of published research that has used accelerometers in cancer survivor
populations; (b) identify gaps in reporting accelerometer data
collecting, data processing, and outcome measures; and (c)

provide recommendations to improve the quality of future
accelerometer-based research.

METHODS
A comprehensive Pub.Med search of articles published
in English was conducted. The initial search was run in
January 20 I 7, and a subsequent final search was conducted
in May 2017. The natural language and MeSH terms included were as follows: "physical activity," "sedentary,"
"sitting," "neoplasms," "cancer," "malignancy," "tumor,"
"tumor," "accelerometry," "actigraphy," "acceleromet,"
" monitor," "device," "tracker," "global positioning." Reference lists of relevant review articles were also screened. Two
review authors (V.C. and J.V.) independently examined the
studies identified for inclusion in the review. Reviews, abstracts, editorials, study protocols, and studies that only used
pedometers/step counters or physical activity trackers to
measure physical activity were excluded. Data from the included studies were independently extracted and tabulated by
four review authors (C.P.-M., E.J, T.B., and J.M.), with data
from each study reviewed by at least two of these authors. The
parameter was recorded as not applicable (NA) when it did not
apply to the given study because of the device used(e.g., nonwear time protocol does not apply for studies that used the
Sense Wear Armband device because it only records when
being wom), or when the outcome measures were not relevant
(e.g., sedentary time was not reported in the article, therefore
no sedentary cut point was reported). In all cases, disagreements or discrepancies were resolved by consensus.
Outcome Measures
Study characteristics. Data were extracted regarding
population characteristics (e.g., cancer population, average
age), study design, timing of observations, and the accelerometer used.
Accelerometer data collection and analysis. Information

was extracted regarding how the device was delivered (i.e., in
person or via mail), device used (e.g., activPALIM), device
placement (e.g, hip), wear time protocols (i.e., instructions to
participants on daily time of wear and the total nwnber of days
of wear), software used for processing, the vector used in
processing, any filters applied during processing, epoch length
(in data collection and during processing), how non-wear time
was identified, how a valid day of wear time was defined,
minimum number of valid days of wear time required for
inclusion in analysis, which cut points were used to create
summary measures of sedentary time, light intensity activity
and/or MVP A, and any additional information on how total
physical activity was calculated. Where one of the included
articles referred to a previously published article rather than
describing any of the above items in their own methods
section, the relevant information was extracted from the
cited study.

OBJECTIVE ACTIVITY MONITORING
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Accelerometer data reporting. Data were collected
regarding time spent in: D) sedentary time or sitting/lying, 2)
light intensity activity or standing activity, and 3) MVPA or
stepping. The proportion of participants meeting physical
activity guidelines (ie., 2150 min MVPA or 75 min of
vigorous activity) was also extracted, as well as any additional information on how physical activity guideline cut
points were applied (e.g., 10-min bouts, physical activity
over 5 d of the week). Compliance with accelerometer wear
(i.e., number of participants that wore the device and were
included in the analysis) was recorded along with the average valid days of data, average wear time, and whether the
analysis was adjusted for waking wear time.

Over half (54%) of the studies used an ActiGraph® accelerometer. Sense Wear Armband (11%) and activPAL (11%)
devices were the next most common accelerometer models
used. Most studies measured physical activity and/or sedentary behavior with one accelerometer (98%), with only a single study using more than one research-grade accelerometer
simultaneously (2%) (20). The majority of studies (63%) used
a waist placement. Most studies used protocols of 7 d of wear
time (76%) and waking hours only wear time (65%).

How have studies reported physical activity and
sedentary behavior data? Table I and the Supplemen-

tary Table I (Supplemental Digital Content 2, description of
accelerometry data analysis methods, http://links. lww.com/
MSS/8280) report study characteristics, data reporting, and data
analysis methods of the reviewed studies. Of the 46 studies
included, 45 reported physical activity or sedentary behavior
data. One study only reported methods (20). Of these studies,
outcomes were most often reported as hours or minutes per
day (52%), with other studies reporting data as hours per
minute per week (20%) (12,19,26,29,32,44,45,50,56), steps
per day (15%) (17,23,27,34,35), total physical activity counts (n = 5) (18,24,30,46,5 1), or kilocalories per week
(= D) (43)
Sedentary time was reported in 50% of studies. Of
those, three studies did not report the cut point used to
define sedentary behavior (15,16,22). Among those reporting
cut points, the most commonly used sedentary cut points were
Matthews et al. (59) (i.e., <101 counts per minute, 61%)
(7,13,14,21,25,28,29,32,36,37,40,42,47,48,53), or using METs
(60) [i.e., <1.5 MET; 22% (17,39,41,52,55)]. Sedentary time
ranged in the studies from 189 min per waking day (52) to
713 min per waking day (41). Bouts of sedentary time were
reported in six studies (14,17,21,28,31,53). Prolonged sedentary bouts were described as 20- min (13,14,28,31) or
30- min (17,21,28,53). Time in 20-min sedentary bouts
ranged from 185 min per waking day (14) to 339 min per
waking day (31). Time in 30-min sedentary bouts ranged from
153 min per waking day (53) to 185 min per waking day (21).
Light intensity activity was reported in 43% studies.
Cut points to categorize light intensity activity were not
reported in one study (22) and were most often listed as a
combination of Freedson and Matthews cut points (59,61)
(i.e., 100-1951 counts per minute; 55%) (13,14,19,21,28,36,37,
40,47,49,53). Light intensity activity ranged from 125 mind '
(54) to 551 mind' (40).
Moderate and vigorous physical activity was reported in
78% of studies. Cut point references were provided for all
but three studies (22,43,50). Five studies cited cut points and
analysis methods from a primary article (15,16,19,44,46).
The most commonly used MVPA eut points were Freedson
(6D[ie, 1,952; 50% (12-14,19,21,25,28,32,36,37,40,4449,53)], or a MET cut point (62) (most commonly 2 3 METs,
20%) (17,29,39,41,52,56,57). Time in MVPA ranged from
3.7 mind'(36) to 150 mind'(22). MVPA in 10-min bouts
was reported in eight studies (13,14,17,21,31,32,41,53), and
ranged from 5.7 mind '(2I) to 5l mind '(31).

RESULTS
The initial search in January 2017 yielded a total of 271
records. The final search in May 2017 detected 43 additional records and four additional articles were detected
through other sources, making a total number of 314 records identified in the search. After screening of titles, abstracts, and full text, 46 articles were deemed eligible for
inclusion in the review (see Figure, Supplemental Digital
Content I, study flow diagram, http://links.lww.com/MSS/
B279). Where there was more than one article reporting on
the same data set, only the primary article reporting
accelerometry outcomes were included. Secondary articles
were excluded. In randomized controlled trials (RCTs) or
cohort studies, only the baseline data were included, and in
the case where the intervention and control group data were
presented separately, only intervention group data were
included.
Study characteristics. Study characteristics are reported
in Table I. The majority of studies (72%) targeted a single
cancer group, namely breast (n = 17) (12,14,16,20,22,29,36,4046,48,52,57), lung ( = 6) (17,18,21,27,38,39), colorectal (n = 5) (31,32,49,53,58), prostate cancer (n = 4)
(19,25,37,54), and non--Hodgkin lymphoma (n = 1) (13)
Other study populations were based on clinical characteristics,
such as advanced cancer (34), cachexia (24), or sites of disease,
such as brain metastasis (35) or malignant pleural effusion
(28). Most study designs were cross-sectional ( = 28), with a
further 10 prospective studies (16,20,22-24,26,27,48,49,52),
six RCTs (19,39,43-46), one nonrandomized clinical trial (33),
and one case series (34). The majority of cross-sectional and
RCT studies (n = 35) were either following completion of
active treatment (34%) (12,17,21,25,30,32,38,43,45,47,51,53)
or "postdiagnosis" (17%) (13,14,40,50,54,55), with
fewer studies focusing on before (11%) (15,33,39,41) or
during treatment (9%) (44,46,56), whereas a portion of
studies did not specify (26%) (18,19,28,29,31,36,37,42,57).
For the prospective studies and case series (n = II), assessments often began during treatment (27%) (20,23,52),
or following completion of primary treatment (30%)
(16,22,26,48,49), with only one beginning at diagnosis (27)
and two unspecified (24,34)
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The current physical activity guidelines for cancer survivors
[i.e., > 150 min of MVPA per week (63)] were applied in 38%

of studies. Seven studies specified that MVPA must occur in
10-min bouts (13,14,16,21,47,53,56), and two specified that
activity must occur on at least S d out of 7 d of the week
(16,29). In studies that applied the guidelines, the percentage

of participants meeting current physical activity guidelines for
cancer survivors ranged from 4% (16) to 94% (47).
Quality of reporting on data collection and pro-

cessing. Quality of accelerometer reporting for data collection and processing-related items is outlined in Figure L
Additional information regarding data collection and processingrelated items is available in Supplemental Table I (Supplemental
Digita1 Content 2, description of accelerometry data analysis

methods, http://links.lww.com/MSS/B280) and Supplemental
Table 2 (Supplemental Digital Content 3, summary of methods
used in accelerometer-based studies, http://links.lww.com/
MSSB281). Accelerometer data collection-related items were
generally well reponed and included accelerometer brand and
model (100%), monitor placement (91%), and wear protocol
(98% for number of days; 91% for hours per day). Delivery method was the exception, with only 54% of studies
reporting this infonnation.
In contrast, accelerometer data processing-related items
were generally poorly reported, particularly the definition of
non--wear time (reported by 51% of studies), filters applied
during processing (reported by 8% where applicable), valid
day definition and minimum number of valid days (reported
by 62% and 57% of studies, respectively), software and epoch
length for processing the accelerometer data (53% and 61%
respectively), and vectors used during processing (reported by
60% where applicable). The most reported data processingrelated items were cm points used to define sedentary time
(87%) and MVP A (91%). Device-specific software was most
commonly used to process accelerometer data (40% of all
studies), and just over half of the studies (54%) reported processing the accelerometer data using 60-s epochs.
Compliance was not reported in sufficient detail in 17
studies; three were not applicable as participants and were
only included in the study if they had provided valid accelerometer data (36,37,48). Compliance with accelerometer
wear ranged from 74% (24,27) 10 99% (40). The average (or
median) number of valid days of data was reported in 13
studies. A minimum wear-time criterion of 600 min was the
most common (40%). A variety ofcriteria were used to define
non-wear time and minimum number of valid days. When
reported, this ranged from 3.6 (56)10 7.0 4(12,48). Wear time
was reported in I0 studies and ranged from 14.I hd'(21) to
23.7h4'(56). Nine studies did not report wear time, but did
adjust analysis for wear time.
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£

£
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DISCUSSION
In our review, we identified accelerometer studies in
cancer survivor populations differed in how they defined and
reported on sedentary behavior and physical activity. With

1796

Official Journal of the American College of Sports Medicine

http://www.acsm-msse.org

Copyright $ 2018 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.

223

Appendix A. Accelerometer-based Activity Monitoring in Cancer Survivorship Research

_II

##ttkllttt###lilt#tllll#fill#ill
"

I

I

alt ill.all.la.a.ill ill#ill.lilt

I

II

I

I

I

I

I

I

I

•••••••
•••••••••
•••• •• •••••••••••
••••••••••• ••••••••••••
•••••••••••• ••••••••••
• • ••••••••
•••••• A • ••••••
ttD4it
••
•••• •••• ••• • •••••••••••••
It

l

EI

••

I

it

....•

-...-.

An4t
ii
l

i

ii

Ii

tit

I

ti
it

l

it

4
4040 A4

ii

I

Di ti

mm

a

ii..ii

tit

a
in

I
i

[URE I-Percentage of accelerometer par adata items reported (n = 46). Green cells, reported; red, not reported; white,NA.

regard to the quality of reporting on data collection and processing methods, data collection-related items were reported
in the majority of studies, whereas data processing-related
items were described in a smaller proportion of studies.
Accelerometry has potential to generate detailed knowledge of the levels and patters of physical activity and sedentary behavior in cancer survivors. It also provides
opportunities for the investigation of associations between
physical activity and sedentary behavior with health outcomes (including clinical outcomes such as fatigue, mortality, and recurrence), and insight on how cancer treatments
impact engagement in physical activity and sedentary behavior. Accelerometry research can contribute to identifying
minimal clinically important differences in physical activity
and sedentary behavior, as well as the specific characteristics
of what amounts of physical activity (or reductions in sedentary behavior) are needed to facilitate improved cancer
outcomes, Accelerometry output can also be translated into
meaningful messages for cancer survivors (i.e., convert
metrics into behavior targets for patients). The decreasing
cost of accelerometers and increasing access to open-source
data extraction and processing methodologies will make it
easier to integrate objective activity monitoring into cancer
survivor studies (64). However, to achieve beneficial health
outcomes in oncology and public health, carefully considered data processing and reporting decisions must be made.
In comparison to a recent review by Montoye et al. of
accelerometer-based intervention studies in the general
population (10), a similar percentage of studies in our review failed to report on epoch length (36% [present study]
vs 38%), days of data collected (9% vs 2%), minimum
valid days (52% vs 44%), and brand of accelerometer (0%
vs 2%). However, we found that the cancer survivorship
literature reported fewer studies failing to report compliance (40% [present study] vs 64%), delivery method (46%
vs 69%), non--wear time definition (49% vs 69%) and
minimum wear time (38% vs 50%). One possible reason
for this difference is that the earliest study included in our
review was published in 2005, whereas the Montoye review
included studies dating back to 1998, before standards
checklists of accelerometry data collection and reporting had

been published. Overall, the completeness of reporting on
methods used to collect, process, and report accelerometry
data in cancer survivor studies needs improvement. A formal
consensus process for internationally agreed standards for
accelerometer data collection, processing, and reporting has
been suggested to help address such limitations (65).
However, such guidelines have not yet been developed and
published. Therefore, as in other recent reviews (9,10), we
recommend that authors report all data collection and
processing-related accelerometer paradata (in the main text
and/or as supplementary material) to ensure that data can be
accurately compared across studies and that others are able
to replicate their methods. Examples of adequate reporting
of accelerometer paradata and a template for reporting
paradata are available in the recent review by Montoye et al.
(I0). Guidance related to data collection and data processing decisions relating specifically to Actigraph devices,
which were used in 54% of the studies included in the
present review, are available in a recent review by Migueles
ct al. (9).
Three quarters of the studies included in this review used
cut points to summarize accelerometer data into discrete
variables (e.g., sedentary behavior, MVPA). The most commonly used cut points across studies of cancer survivors were
<10I counts per minute for sedentary behavior (59) and
>1952 counts per minute for MVPA (61). Although the
widespread adoption of these particular cut points allows
comparison across studies (provided data collection and
processing protocols are comparable), their use requires
careful consideration in cancer survivor research. The same
intensity" measured by an accelerometer will impart a
different level of physiological stress on different people.
The commonly used >1952 counts per minute cut point for
MVPA was developed by Freedson et al, (61) based on indirect calorimetry data collected during treadmill activities
in a group of university students with a mean age 24 yr.
In the current review, the mean age of participants ranged
from 50 (52) t0 73 (19). Cancer survivors are often older,
have comorbid conditions as well as ongoing cancer-related
side effects, that impact functional capacity. Therefore, cut
points developed from young healthy volunteers may not be
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representative of physiologically "light" or "moderate" intensity activity in cancer survivor populations. Thus, consideration of accelerometer cut point algorithms validated for
specific cancer survivor populations (and subpopulations)
will be important (9). When appropriate, using the total
volume of physical activity could also allow comparisons to
be made across studies, while avoiding some of the issues of
generic application of cut points which could be problematic
in certain cancer groups (e.g., advanced cancer or those on
treatment). When cut points are applied, we recommend
authors acknowledge that there may indeed be limitations
of this approach and should be mindful to justify their choice
of cut points.
Almost 40% of the studies reviewed here repon the percentage of survivors that were meeting current physical activity
guidelines (e.g., 150 mine-wk ' of MVPA). Recent studies have
highlighted some concems with using accelerometer-measured
MVPA to classify individuals as sufficiently active based on
public health guidelines, and it has been argued that there
may be situations where it is preferable to consider the total
volume of physical activity rather than simply MVPA (66).
These concerns could be particularly salient for cancer
survivors who often face functional limitations and ongoing
side effects of disease and treatments that could impact
functional capacity. For example, an individual may have
functional/mobility issues, or a particular tumour (e.g, lung),
stage (e.g., stage IV), and/or treatment regime (e.g., lung
resection resulting in reduced pulmonary capacity) that precludes participation in what accelerometers categorize as
MVP A Thus, the application of physical activity guidelines
(developed in a young and healthy population) may not be
appropriate. Development of cancer population-specific (or
functional stale-specific) physical activity guidelines could
help with this issue and would also add value to oncology
care, by providing more specific guidelines for survivors
and cancer care professionals. Additionally, the development
of minimal clinically important differences for these populations
could assist with interpreting a meaningful change in physical activity and sedentary behavior levels beyond the application of physical activity guidelines. Funher research into
this area will help determine the optimal strategies to determine whether cancer survivors are achieving sufficient levels
of MVPA to confer health benefits. We recommend that authors carefully consider the use of physical activity guidelines
as an outcome measure, and when used, the rationale for including this outcome should be articulated and the limitations
of this approach acknowledged.
The most commonly used device in the studies included
in our review was the Actigraph®, with the majority of
these studies using a waist placement. Used in this manner,
the Actigraph@ device is not able to differentiate between
sitting and standing. Although some standing activities
(standing quietly) require little to no movement (<101 counts
per minute) and low-energy expenditure (<1.5 METs),
they are not considered sedentary behaviors because the
individual is not in a seated posture. For an individual standing
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still, the Actigraph@ will record the subject as engaging in
sedentary time (i.e., <101 counts per minute or <1-5 METs),
This issue is likely to be exacerbated in populations, which
may have high amounts of sedentary time, such as people
with advanced cancer. This has implications for assessing interventions designed to reduce sedentary behavior (i.e., sitting
time). Only 10% of studies reviewed here used thigh-worn
accelerometers, which have higher accuracy when measuring
sitting and reclining than waist or wrist worn accelerometers.
However, it is important to note that thigh-worm devices are
less accurate in capturing activities involving primarily upper
body motion (e.g., rowing, upper body resistance training).
Although the choice of device and body placement is dependent on several issues such as the study aims, cost, and
availability, future studies with a primary focus on sedentary
behavior should consider the use of devices which arc
able to better differentiate between sitting and standing
(e.g., activPAL9),
Although accelerometers offer many advantages over
self-reported measures, they do have important limitations.
For example, accelerometers do not capture cycling or
water-based activities, and they do not detect the context
within which physical activity or sedentary behaviors are
occurring (e.g., transport, occupational, screen time). In
contrast, self-report measures are important for providing
the context in which activities are occurring; depending on
the self-reported measures used, distinction can be made
between transport-related sedentary time and leisure sedentary time (e.g., screen-based), and planned/intentional
activity and occupational activity. Thus, we recommend
continued use of self-repon measures of physical activity
and sedentary behavior to complement objective assessment. Current ongoing research initiatives are using both
devices as well as self-repon measures for a complete assessment of the full activity spectrum (20).
The majority of studies (65%) reported collecting accelerometer data during waking hours. Even in studies that collected 24-h data, often only waking hours are reported (28).
Across a 24-h period, individuals engage in a combination of
sleep, sedentary behaviors, and physically active behaviors
(of light, moderate or vigorous intensity), and recent research
has considered these behaviors together rather than in isolation. New statistical techniques, such as compositional analyses or isotemporal substitution modeling, may help generate
a clearer understanding of the dynamic interplay between
movement behaviors measured during waking hours or the
entire day (67). For example, isotemporal substitution modeling allows the researcher to explore associations of altemating allocations of time in one behavior with another while
holding total time constant (68,69). Studies in the cancer
survivorship context have used this approach to examine the
reallocation of time and the projected impact on outcomes
such as health-related quality of life, fatigue, and waist circumference (55,70,71). Continued use of new and innovative
statistical approaches will help inform intervention research
in cancer survivor populations.
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can more precisely inform physical activity and sedentary behavior recommendations to health care professionals, stakeholders, and patients.

CONCLUSIONS
The use of accelerometer-based activity monitors has improved understanding of the spectrum of physical activity

and sedentary behavior undertaken in clinical and free-living
environments by cancer survivors. However, the specific

C.JP-M. andV. C. are supported by Cancer Council of Westem
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frequency, intensity, and duration of physical activity (or
sedentary behavior) required to improve cancer outcomes remains unknown. The continued expansion of accelerometry in
cancer survivor research will help to address these gaps in
knowledge and infonn more robust and detailed physical activity recommendations for cancer control. However, adequate reporting of accelerometer paradata is needed so that we
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Abstract
Purpose: To investigate the feasibility and efficacy of exercise to improve muscular
strength, physical functioning, body composition, and patient-rated outcomes in patients
with malignant pleural disease (MPD).
Methods: Thirty-three patients with MPD were recruited to complete an exercise training
intervention of progressive resistance exercise training three times/week for six-weeks.
Outcomes assessed at baseline and post-intervention included muscular strength (1repetition maximum leg press), functional capacity (6-Minute Walk Test), physical
functioning (Timed Up and Go; chair rise), body composition (Dual energy X-ray
Absorptiometry), quality of life (Short-Form 36 Health Survey; SF-36), physical activity
and sedentary behaviour (Actigraph accelerometer), ratings of intervention burden and
acceptability (7-point Likert scale; 1, not at all, to 7, very much). Attendance was assessed
as the number of exercise sessions attended out of a possible 18. Paired T-test or Wilcoxon
Signed Rank Test was used to assess changes over time.
Results: Mean participant age was 64 (SD=11) years. The majority had mesothelioma
(93%), Eastern Cooperative Oncology Group Performance Status 0-1 (97%), and were male
(70%), and had low appendicular skeletal muscle mass (56%). Twenty-six participants
(79%) completed the intervention; 24 (73%) completed post-intervention assessments. Post
intervention, significant improvements were found for mean six-minute walk distance (+59
m; 95% CI 24-93; p<0.05), 1-repetition maximum leg press (+17 kg; 95% CI 11-23;
p<0.001), Timed Up and Go (-0.51 sec; 95% CI -0.94 - -0.08; p<0.05), chair rise (-1.5 sec;
95% CI -2.2 - -0.9; p<0.001), and appendicular lean mass/height squared (+0.19 kg/m2; 95%
CI 0.04 – 0.34; p<0.05).
For patient-rated outcomes, only the mental health subscale of SF-36 changed significantly
(median change +2.6, IQR 0.0, 5.2; p<0.05). Overall, no post-interventions changes in
activity behaviors were observed (all p’s >0.05). Preliminary analysis indicates that changes
in body composition might mediate this response. Median attendance at supervised exercise
was 100% (inter-quartile range 72%-100%).
Conclusion: This pilot study indicates progressive resistance exercise training in patients
was feasibly in MPD and resulted in improvements in muscular strength, physical
functioning and body composition.
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B.1

Introduction
Despite medical advances, malignant pleural disease (MPD) remains an incurable

cancer with limited treatment options. Pleural malignancy can result from primary cancer
(i.e., mesothelioma), or from metastatic spread of cancer into the pleural space (common
in breast, lung, and ovarian cancer).1 The pleural effusion causes distressing

breathlessness, restricts daily activities, impairs quality of life (QoL), and can be
recurrent.1 The main goals in the treatment of MPD are to alleviate symptom burden
and allow patients to take part in their nomal physical activities of daily living for as
long as possible.
In MPD, poor performance status, or immobility, is often clinically attributed to
symptoms such as breathlessness, pain, fatigue and muscle wasting. Evidence suggests
that patients with MPD are very inactive, spending the large majority of their waking hours
sedentary.2 Even amongst patients early in their diagnosis with good performance status,
low appendicular skeletal muscle mass (ASM) is common and is associated with reduced
participation in daily physical activity.3 Muscle loss is a hallmark feature of cancer
cachexia that severely impacts quality of life, physical functioning, and treatment
tolerance. In advanced cancer populations, low muscle mass has been associated with
poorer quality of life,4 worse overall survival,5 and increased likelihood of dose-limiting
toxicities from chemotherapy.6
Appropriately prescribed exercise provides a significant opportunity to counteract
this aetiology of poor outcomes for patients with MPD. In advanced lung cancer, exercise
training has shown promise for increasing functional capacity and health-related quality
of life.7 However, there is little evidence to date on the effects of exercise on body
composition in this group.7 The purpose of this study was to assess the feasibility and
efficacy of a 6-week resistance exercise training intervention for improving physical
functioning, body composition, and physical activity profile in patients with MPD.

B.2

Methods

B.2.1

Participants

People with cytological or histological confirmation of MPD or those with a recurrent
large exudative pleural effusion with cytological or histological proven cancer outside the
thorax with no alternative cause were eligible to participate in the intervention. Potential
participants were excluded if they were aged <18 years, pregnant or lactating, unable to
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read and understand English, unable to give informed consent or comply with the protocol,
had unstable bone metastasis or metastasis of long bones, had acute illness or any
musculoskeletal, cardiovascular, or neurological disorder that could inhibit or put
participants at risk from participating in assessments or exercise intervention, were unable
to obtain physician consent, or were participating in a conflicting study.

B.2.2

Design and recruitment

The study was a single group pilot intervention study. Ethical approval was provided
by Sir Charles Gairdner Group and Edith Cowan University Human Research Ethics
Committees (ID: 2014-124 and 13255). Recruitment took place between September 2015
and July 2017 in a tertiary specialist pleural disease and medical oncology clinic in
Western Australia (WA).

B.2.3

Exercise training intervention

Supervised exercise sessions were scheduled to be completed three times a week for
6-weeks. An optional two-week make-up period was provided for participants who chose
to make up sessions with the goal of completing 18 exercise training sessions. Exercise
sessions began with a 5-minute warm up comprising of low-level aerobic activity such as
walking and stationary cycling. The resistance training involved eight resistance exercises
that targeted the major upper and lower body muscle groups (e.g., chest press, seated row,
leg press, leg extension). Resistance was increased by a 5-10% increment for the next
set/training session if participants were able to perform more repetitions than specified
during a set. Intensity was manipulated from 8-12-repetition maximum (RM) using 1-3
sets per exercise, with 1-2 minute rest periods between sets.8 Due to the advanced nature
of MPD, the potentially high symptom burden, and changes in participant status due to
treatment the exercise intervention was designed to be flexible with adjustments made as
required. To achieve this, at the start of every exercise training session, participants were
asked to rate their current level of pain (Visual Analog Scale; VAS; no pain/very severe
pain), describe any changes in shortness of breath, fatigue, or new symptoms since their
previous training session. It was then discussed between the exercise physiologist and
participant if the planned exercise program required any changes to the volume, intensity,
or rest periods.
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B.2.4

Outcome Measures

Demographic and medical variables
Self-report questionnaires were used to obtain demographic information (e.g., marital
status, education level, employment status, smoking status). Medical records and chest xrays were reviewed to obtain data regarding cancer diagnosis, pleural effusion
characteristics, cancer treatments, and comorbid conditions. Eastern Cooperative
Oncology Group (ECOG) performance status was rated on the day of baseline
assessment.9 Patients were categorised as either good performance status (i.e., ECOG 01) or poor performance status (i.e., ECOG ≥2).
Physical functioning
All study endpoints were assessed at baseline and post-intervention. Participants
completed a series of tests to assess different aspects of physical functioning. Muscular
strength was assessed by 1 RM for lower body using a seated leg press. 10 Lower body
1RM was divided by current body weight to determine relative 1RM. Cardiorespiratory
functional capacity was assessed by Six-Minute Walk Test (distance in metres).11
Participants were asked to walk as far as possible on a flat 50 m course in six minutes.12
Functional ability was assessed via repeated chair rise (time in seconds taken to rise from
seated and return to sitting ten times)13 and Timed Up-and-Go (TUG; time in seconds
required to rise from sitting, walk a distance of 2.44 metres, turn around and return to
sitting).14 Chair rise and TUG were performed in triplicate with one minute rest-periods
provided between trials, with the best outcome (i.e., the shortest time) used in analysis.
Participants were grouped according to change in leg strength from baseline to postintervention as gained (change ≥10%), and lost (change <10%). Participants were also
grouped for Six-Minute Walk Distance (6MWD) using a cut point of a 9.5% change post
intervention as this is considered a clinically meaningful difference.15
Anthropometric measures and body composition
Participant weight and height were measured at baseline. Participants were wearing
light clothing and footwear was removed. Body mass index (BMI; kg/m 2) was
calculated, and participants were categorised according to World Health Organization
(WHO) BMI criteria.16
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Body composition (i.e., regional and whole-body lean and fat mass) was derived
from whole-body dual-energy x-ray absorptiometry scans (DXA; Hologic Discovery A,
Waltham, MA, USA). Appendicular skeletal muscle (ASM), whole body and regional fat
mass were assessed using standard procedures.3 Low ASM, was defined as an
appendicular skeletal muscle mass/height2 of ≤7.26 kg/m2 for males and ≤5.45 kg/m2 for
females.17 Participants with low ASM were categorised as pre-sarcopenic.18 All
participants were grouped according to change in ASM from baseline to post-intervention
as gained (change >0.05 kg), and lost (change ≤ 0.05).
Physical activity and sedentary behavior
Objective activity behaviour was assessed via accelerometer (Actigraph GT3X+;
Actigraph, Pensacola, FL, USA) the three-days prior to and following the intervention at
baseline and post-intervention respectively. Participants were asked to wear the
accelerometer on their hip continuously (24hr/day) for three-days and record any nonwear time over that period. Accelerometers were programmed to record raw data at a
frequency of 30 Hz, which were later reduced to vertical axis movement counts per 60second epoch. Accelerometer data were downloaded and processed in SAS (version 9.3,
SAS Institute, Cary, NC, USA). Waking wear time was determined by an automated
algorithm and visual inspection by a trained rater.19 A valid day was defined as 8hr of
waking wear time.20 Commonly used cut off points were used to classify activity as
sedentary time (i.e., <100 counts/minute; cpm), light activity (i.e., 100-1952 cpm) or
moderate to vigorous physical activity (MVPA; >1952 cpm).21,22 All variables were
calculated per day and then averaged across all valid days.
Patient-reported Outcome Measures
Patient-reported outcome measures were assessed using a battery of validated
questionnaires.

Cancer-specific health-related QoL (HRQoL) and symptoms were

assessed by the Functional Assessment of Chronic Illness Therapy (FACIT) General,23
and Fatigue 24 scales. A score of ≤34 on the FACIT-Fatigue was categorised as clinically
meaningful fatigue.25 General HRQoL was assessed by The Medical Outcomes Study
Short-Form 36 (SF-36).26 Dyspnea was assessed using the Cancer Dyspnea Scale (CDS)27
and 100 mm visual analogue scale (VAS) anchored with “no breathlessness” at 0mm and
“maximum possible breathlessness” at 100mm.28
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Safety, tolerance, and attendance
Safety was measured by tracking the incidence and severity of adverse events related
to the intervention. Additionally, an adverse events log was provided to participants to
document any adverse events experienced throughout the exercise program. An additional
home diary was used to self-report any adverse events that took place at home (e.g., muscle
soreness). Following each exercise session participants were asked to rate their perceived
exertion using the Borg Scale (range 6-20)29 as well as session tolerance using a 7-point
Likert scale (anchored with ‘1/extremely intolerable’ and ‘7/extremely tolerable’). 30
Ratings of intervention burden and acceptability were assessed post-intervention using 7point Likert scales (anchored with ‘1/not at all’, and ‘7/ very much’).31 The number of
participants completing the intervention (i.e., attending baseline and post-intervention
assessment), as well as the number of exercise sessions attended was recorded. Attendance
was reported as the percent of sessions attended out of a possible 18.

B.2.5

Statistical analyses

Statistical analyses were conducted using Statistical Package for the Social Sciences
(v. 25, IBM Corporation, Somers, NY, USA). Data are reported using mean and standard
deviation or median and interquartile range (IQR) when not normally distributed.
Normality of the distribution for outcome measures was tested using the Kolmogorov–
Smirnov test. Changes in physical functioning, body composition, quality of life were
assessed using paired t-tests. Independent t-tests were used to test for differences between
groups in physical activity and sedentary time. The change in the proportion of
participants categorised as pre-sarcopenic was assessed using the McNemar test. This
was a pilot feasibility study. Therefore, due to the nature of the intervention and variation
in ability to complete tests, we used complete cases for the analyses. An alpha of 0.05
was used to determine statistical significance. No adjustment was made for multiple
comparisons.

Figures were created using GraphPad Prism (version 7, GraphPad

Software, La Jolla, California, USA).

B.3

Results

B.3.1

Participant characteristics

Participant flow through the trial is reported in Figure B.1. Briefly, between September
2015 and July 2017, 137 patients with MPD were identified, of whom, 118 (86%) were
eligible and 33 (28%) of those enrolled. The main reason for ineligibility was choosing an
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alternate conflicting study (n=15), and the main reason for non-enrolment was living too far
away from the intervention site (n=27). Twenty-six participants (79%) completed the
intervention. Of those enrolled, seven were lost-to-follow up, the main reason cited by
participants for dropout was fatigue (n=4).
Participant medical and demographic characteristics are presented in Table B.1. The
majority of participants were male (67%), with a diagnosis of mesothelioma (85%), and a
good performance status (i.e., ECOG 0-1; 97%) and had received some treatment for pleural
effusion (82%). On average, participants were 66 years old (SD 10.0), and half were
overweight or obese (54%). Thirteen participants (39%) received anticancer treatment prior
to entering the trial, while 11 (33%) received treatment during the intervention. Median
time from diagnosis of MPE was 6 months. At baseline, 19 participants (58%) had low
appendicular skeletal muscle mass, and 7 participants (23%) were clinically fatigued.

B.3.2

Changes in physical functioning and QoL

Those that completed the intervention demonstrated significant improvements across
all measures of physical functioning (all <0.002; Table B.2, Figure B.2). Only the mental
component score of the SF-36 changed significantly following the intervention (p=0.022).
All other outcomes showed no significant change following the intervention (Table B.2).

B.3.3

Changes in body composition

Changes in body composition following the intervention are reported in Table B.2.
Following exercise training there was a significant increase in ASM, [mean change 0.66,
(95% CI 0.20, 1.12) kg; p=0.007], and ASM relative to height [mean change 0.19, (95%
CI 0.05, 0.34) kg/m2; p=0.011]. Among those that completed the intervention (n=26),
there was a significant change in the proportion of participations that had pre-sarcopenia
from baseline (54%) to post-intervention (27%; p=0.039). Following the intervention,
52% remained not sarcopenic (n=11) with an average change of +0.16 (SD 0.30) kg in
ASM; 31% (n=8) became not sarcopenic with average increase 0.30 kg ASM (SD 0.19).
While, 23% (n=6) remained pre-sarcopenic with mean change of 0.10 kg ASM (SD 0.42),
and 4% (n=1) became sarcopenic (change -0.35 kg).
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B.3.4

Changes in physical activity behaviours and sedentary time
following exericse training

There was no significant change from baseline to post-intervention in accelerometer
waking wear time [mean difference 19.9, 95% CI (-25.12 – 64.98) min; p=0.369], or
number of valid days of wear (z=-1.633, p=0.102). Overall, between baseline and postintervention there was no change in the proportion of waking wear time spent as sedentary
[67.9 (SD 9.5)% to 67.4 (SD 9.6)%; mean difference -0.4, 95% CI (-3.4 – 2.5)%; p=0.765],
in light activity [29.1 (SD 9.6)% to 30.2 (SD 8.8)%; mean difference 1.1, 95% CI (-1.84.0)%; p=0.441) or MVPA [3.1(SD 2.5)% to 2.4(SD 2.4)%; mean difference -0.7, 95%
95% CI(-1.5-0.2)%; p=0.122].

B.3.5

Physical activity and sedentary behavior according to changes in
body composition, muscular strength, and functional capacity.

Changes in physical activity were examined to determine if they differed based on
response to the exercise intervention. Post-intervention, participants with a loss or no
change in ASM (n=8) demonstrated an increase in the proportion of waking hours spent
as sedentary [+5.1 (SD 6.5)%] compared with those that gained ASM [n=14; -3.4 (SD
6.2)%] resulting a significant difference between groups [mean difference 8.5, 95%
CI(3.3, 13.7)%; p=0.003]. Those that lost ASM demonstrated a reduction in light activity
(-3.8% SD 6.2) compared to those that gained ASM [+3.8 (SD 5.8)%], resulting in a
significant difference between groups [mean difference -7.6 95% CI(-13.0% - -2.1)%;
p=0.009]. There was no statistically significant difference between groups for changes in
MVPA [+1.9 (SD 3.2)% vs +5.5 (SD 8.1)%; mean difference -3.6, 95% CI(-9.9 – 3.7)%;
p=0.244; Figure B.3].
Within group changes indicate for the gain ASM group there was a significant
decrease in the proportion of waking hours spent as sedentary [mean change -3.4; 95%
CI(-0.5 - -2.5)%; p=0.026], an increase in light activity, [mean change 3.8; 95% CI(0.5 –
7.1)%; p=0.028], but no change in MVPA [mean change 0.4; CI(-1.8 – 1.0)%; p=0.583].
Conversely the loss or no change of ASM group increased sedentary time [mean change
5.1; 95% CI(-0.4 - -10.5)%; p=0.064], with no significant change in light activity [mean
change -3.8; CI(-8.9 – 1.4)%; p=0.131], and reduced MVPA [mean change -1.3; 95% CI(2.1- -0.5)%; p=0.006].
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We examined differences in physical activity and sedentary behaviour outcomes by
change in strength (leg press 1RM, >10% vs ≤ 10%) and a clinically meaningful change
in functional capacity (6MWD, >9.5% vs ≤ 9.5% change). There were no significant
differences between those with ≤ 10% increase from baseline 1RM (n=6) and those with
>10% increase from baseline 1RM (n=14). Both 1RM groups had a similar change in the
proportion of time spent sedentary [0.1 (SD 7.7)% vs -0.4 (SD 7.2)%; mean difference 0.6
95% CI(-7.0, 8.1)%; p=0.874], in light activity [-0.1 (6.5)% vs. 1.1 (7.0)%; mean
difference 1.2 (-8.2, 5.0)%; p=0.735], or MVPA [4.2 (5.8)% vs 5.3 (7.2)%, mean
difference 1.1 (-8.1, 6.0)%; p=0.754]. There were no significant differences between those
with >9.5% (n=8) and those with ≤ 9.5% increase from baseline 6MWD (n=12). Both
6MWD groups had a similar change in the proportion of time spent sedentary time [1.1
(SD 7.6)% vs 1.0 (SD 7.5)%; mean difference 2.0 CI(-9.0, 5.0)%; p=0.552)], light activity
[1.2 (SD 6.4)% vs 0.0 (SD 7.5)%; mean difference 1.2 95% CI(-5.4, 7.7)%; p=0.714], and
MVPA [5.5 (8.1)% vs 4.0 (4.1)%; mean difference 1.5 95% CI(-5.0, 8.1)%; p=0.632].

B.3.6

Patient Rated Outcomes

Following exercise training there was a significant improvement in the mental health
composite score of the SF-36 (p=0.022). There were no significant changes in other patient
reported outcomes following the intervention (Table B.2).

B.3.7

Safety, Tolerance and Attendance

There were no serious adverse events related to the intervention. There were two minor
adverse events related to exercise reported. Both were resolved with no medical
intervention required. One participant experienced a musculoskeletal injury during work
(i.e., not related to the intervention). Two participants were admitted to hospital during the
intervention for issues unrelated to the intervention (abdominal pain due to disease
progression; and pleurodesis). Session rating of perceived exertion with the Borg scale (620 scale; higher score is higher exertion) was median 11.6 (IQR 11.4-12.9), perceived
tolerance (1-7 scale) was median 6.0 (IQR 5.7, 6.3). For all participants enrolled, the
median attendance was 100% (IQR 7-100%; range 6%-100%). The reasons provided for
missed sessions included fatigue, undergoing treatment/appointments, vacation, and family
obligations. The main reason given for dropping out of the study was fatigue (n=4).
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Table B.1

Demographic and medical characteristics of patients, n=33
n

Age, years, mean (SD)

%
65.7 (10.0)

Gender, male

23

70

31

94

2

6

4

12

Secondary (high school)

10

30

Trade/certificate/diploma

11

33

Bachelor degree or higher

8

24

29

88

4

12

18

55

Past smoker

9

27

Current

7

21

Marital status
Married/de-facto
Divorced/widowed
Education Level
Primary

Employment Status
Retired/unemployed
Part-time/full time
Smoking status
Never

BMI,

kg/m2, mean

(SD)

26 (3)

Underweight

0

0

Healthy weight range

15

45

Overweight or obese

18

55

19

58

28

85

5

15

Pre-sarcopenic#

(DXA; n=33)

Diagnosis
Mesothelioma
Other
Time since diagnosis of cancer, months

7 (2, 14)^

Time since diagnosis of MPD, months

6 (3, 13)^

Histological subtype (if mesothelioma)
Epithelioid

19

58

Biphasic

3

9

Sarcomatoid

2

6

Desmoplastic

1

3

Unspecified

2

6

239

Appendix B. Resistance exercise training improves physical functioning and body composition

n

%

Adenocarcinoma

2

6

Other

2

6

Unknown

2

6

ECOG performance status 0/1

32

97

Received treatment prior to study

13

39

Chemotherapy alone

4

24

Radiotherapy

5

15

Surgery

3

9

TKI inhibitor

1

3

Chemotherapy + Immunotherapy

2

6

Chemotherapy + TKI

2

6

11

33

Chemotherapy alone

3

9

TKI

2

6

Immunotherapy alone

1

3

Chemotherapy + Immunotherapy

4

12

24

73

IPC

12

36

ICC

3

9

VATS

3

9

Therapeutic aspirate

6

18

Pleuroscopy

7

21

None

4

12

Unknown

2

6.

Histological subtype (not mesothelioma)

Received treatment during study

Side of effusion, right
Effusion treatment

No. of comorbid conditions, mean (SD)

2 (2)

Arthritis

11

33

Hypertension

9

27

Hypercholesterolemia

7

21

COPD

3

9

Ischemic heart disease

2

6

Clinically fatigued (n=30)**

7

23

IPC – indwelling pleural catheter; ICC – intercostal catheter; VATS – video-assisted thoracoscopic surgery;
ECOG – Eastern Cooperative Oncology Group;
COPD – chronic obstructive pulmonary disease; ** score of ≤34 on the FACIT-fatigue; TKI Tyrosine Kinase Inhibitor
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Table B.2

Changes in physical functioning, body composition, and quality of life following the intervention.
Baseline
Mean (SD)

Post-intervention
Mean (SD)

Mean change
(95% CI)

p-value

88.2 (37.7)

105.1 (42.1)

16.9 (11.2, 22.6)

<0.001

524.2 (104.7)

582.7 (108.1)

58.5 (24.4, 92.5)

0.002

Chair rise, sec

12.8 (3.4)

11.3 (3.4)

-1.5 (-2.2, -0.9)

<0.001

TUG, sec

6.4 (1.9)

5.9 (1.8)

-0.5 (-0.9, -0.1)

0.022

Total Mass, kg

77.78 (11.28)

78.17 (15.44)

0.39 (-0.64, 1.43)

0.443

Lean Mass, kg

49.57 (10.86)

50.18 (11.28)

0.61 (-0.08, 1.31)

0.080

Fat Mass, kg

25.82 (5.86)

25.57 (6.84)

-0.25 (-1.20, 0.70)

0.597

Fat Percentage, %

33.47 (5.63)

32.87 (6.68)

-0.61 (-1.63, 0.42)

0.235

Trunk, kg

25.68 (5.64)

25.62 (5.53)

-0.06 (-0.50, 0.38)

0.773

ASM, kg

20.83 (5.04)

21.49 (5.63)

0.66 (0.20, 1.12)

0.007

ASM kg/m2

6.83 (1.10)

7.03 (1.25)

0.19 (0.05, 0.34)

0.011

Body Fat Percentage, %

33.47 (5.63)

32.87 (6.68)

-0.61 (-1.63, 0.42)

0.235

Physical Functioning (n=24)
Leg press 1RM, kg
6MWD, m

Body Composition (n=26)
Whole Body

Lean

Fat

241

Appendix B. Resistance exercise training improves physical functioning and body composition

Baseline
Mean (SD)

Post-intervention
Mean (SD)

Mean change
(95% CI)

p-value

FACT-General

83.4 (17.2)

82.6 (18.4)

-0.8

0.703

Fatigue Scale^

39.5 (34.8, 48.3)^

43.5 (27.8, 48.2)^

---

0.736

Physical Component Score (SF-36)

45.2 (11.8)

43.8 (9.8)

-1.3 (-4.9, 2.3)

0.455

Mental Component Score (SF-36)^

52.6 (37.3, 58.8)^

55.4 (47.8, 59.6)^

---

0.022

VAS (mm)^

12.5 (1.1, 36.3)^

5.0 (0, 22.5)^

---

0.277

CDS Total^

3.5 (0, 10)^

3.0 (0.5, 10.5)^

---

0.897

Quality of life (n=26)

Dyspnea

6MWD, Six Minute Walk Distance; m, metres; sec, seconds; kg, kilograms; ht, height; ^ Median, IQR; VAS, Visual Analogue Scale; CDS, Cancer Dyspnea Scale
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137Malignant pleura disease patients identified

Reasons for ineligibility (et9
Chose alternate study (n15)
Medical contraindications (n1)
Doctor deemed too urwell (ne1)
Did not speak English (nef)
Long bone metastasis (ne1)
118 (86%)Malignant pleural disease patients eligible

Reasons for refusal (ma85)
Live too far away (e27)
Too urwell (e19)
Not interested (n16)
Too busy (n6)
Travelling (ne3)
Study was too much of time commitment (nee)
Overwhelmed with appointments (n6)
Not contactable (nee3)
33(28%) malignant pleural disease patients enrolled in
the exercise intervention
Patient rated outcomes (me30 ne3 not returned)
Aooeerometry (nee32; me1missed assessment)
DXA (ne33)
64MT (nee31, me2 t00 unwell')
Physical functioning (nee32 ne1too urwell)

•
•
•
•
•

Lost to follow-up (nae7, 21%
Toe fatigued (n 4)
Too unwell (ne1)
Too many appointments (n1)
Unable to contact par0ipant (n1)
26(79%) malignant pleural disease patients completed postintervention assessment
• Patient rated outcomes (n 26)
• DXA (ne26)
• 6MT (n24 me2too unwell)
• Physical functioning (nee24 me2too urwell')
• Aooelerometry (nee23 n1missing. n2?faulty
initialization)

Figure B.1 Participant flow through the trial
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B.4

Discussion
This study examined the feasibility and efficacy of a short resistance exercise training

program for improving physical functioning and body composition in patients with MPD.
There were several important findings: 1) the program was effective at improving
muscular strength, physical functioning, and functional capacity; 2) there was an increase
in ASM following the intervention and those that increased ASM had an improved
physical activity profile; 3) there were no changes in quality of life or fatigue following
the intervention, and 4) the program had good compliance and ratings of tolerability
among these patients with high disease burden.
Patients with MPD and mesothelioma have not been exclusively studied in the
exercise oncology literature. Compared to other thoracic cancer patients, this is a unique
subgroup, particularly those with mesothelioma due to the relatively long median survival
(~12 months), lack of extrathoracic spread of disease, and low rates of a history of
smoking. Improvements in muscular strength, functional capacity, and physical
functioning paired with the positive feasibility and safety data presented indicate that
exercise training could be a valuable supportive care intervention in this patient
population. Average improvements in functional capacity reported here meet the cut-point
for a clinical meaningful improvement,15 and are similar to research in other advanced
lung cancer populations.7,32 Importantly, worse physical functioning has been associated
with reduced survival in cancer popualtions.33 Functional capacity has been identified as
a strong independent predictor of survival in those with advanced lung cancer. 34,35
Importantly, there were no serious adverse events and participants report the favourable
measure of tolerability.

Therefore, a safe and tolerable intervention that improves

functional capacity could be particularly important for those with MPD.
Overall, there was an improvement in ASM following the intervention. A proportion
of participants (31%) even progressed out of being categorised as pre-sarcopenic. Recent
literature in other advanced cancer populations has indicated the importance of adequate
muscle mass due to associations with lower risk/rates of treatment toxicity, 6 and improved
survival. While this finding is preliminary and requires replication in larger randomised
trials, these results suggest that even a short-term individualised resistance exercise
training program could be effective for improving ASM, which could have important
implications for clinical outcomes. Previous research in advanced cancer populations
indicates some success in improving lean mass with exercise training (n=4 studies in
prostate cancer, lymphoma, and myeloma).36 Further research is needed to examine ways
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to optimise improvements in muscle mass in advanced cancer populations. Multi-modal
interventions that include exercise and nutrition support and pharmacological agents to
optimise improvements in body composition have potential to be most effective. 37
While the exercise intervention showed no overall effect for improving physical
activity behaviours, analysis indicated that participants that improved ASM also improved
physical activity profile such that less time was spent sedentary and more time was spent
in light activity. Previous research in MPD has indicated pre-sarcopenia is associated with
a similar physical activity profile; specifically, greater sedentary time and lower light
activity.3 This preliminary finding provides further evidence that ASM could be a key
mediator of physical activity. This is particularly important considering the importance
that clinicians and patients place on the ability to remain actively engaged in activities of
daily living. Further research is needed to more fully elucidate the relationship between
changes in ASM and physical activity and sedentary behaviour.
This study has several important limitations to consider. This was a pilot feasibility
study and therefore is subject to the inherent limitations of a small sample size, lack of
control group, and inability to control for confounding factors that could affect results.
One of the main confounders is treatment (including chemotherapy, fluid drainage of
effusion, pain control etc.). These treatments could improve some of the outcomes if
patient responded, but are unlikely to affect others, particularly body composition and
muscular strength. Additionally, while this group was a homogenous sample in terms of
MPD diagnosis, participants were heterogeneous in terms of treatment status (on/off),
types of treatment completed both during and following the diagnosis, and time since
diagnosis. The vast majority of participants had good performance status and the results
might not be generalisable to more unwell participants. However, this research does
provide important information to inform future research aimed at improving physical
functioning and body composition in this population of patients with advanced cancer.
The study employed well validated measures of body composition, physical functioning
and patient-rated outcomes.
Overall, this work found that resistance exercise training that was provided in flexible
and individualised prescription was feasible and beneficial for patients with MPD.
Improvements in ASM and reductions in the proportion of patients with pre-sarcopenia
indicate that resistance exercise could be an effective tool in addressing muscle loss in a
select population of patients with advanced pleural cancers.
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Supplementary Data
Supplemental Table B.3

Differences in baseline physical function and body composition
outcomes based on trial completion status.
Completers
(n=26)

Drop-outs
(n=7)

Mean Difference
(95% CI)

p

Physical Functioning (n=25)
Leg Press (kg)

89.9 (36.8)

64.0 (22.8)

25.9 (-4.1, 0.1)

0.089

530.1 (106.7)

442.8 (81.7)

87.3 (-8.3, 182)

0.072

12.8 (3.9)

16.3 (4.4)

-3.4 (-6.9, 0.1)

0.056

6.3 (1.9)

7.1 (1.2)

-0.7 (-2.2, 0.8)

0.346

Appendicular lean
mass (kg)

20.8 (5.0)

18.5 (4.5)

2.3 (-2.0, 6.6)

0.283

Appendicular lean
mass/ht2 (kg/m2)

6.8 (1.1)

6.3 (1.2)

0.5 (-0.5, 1.4)

0.339

6MWD (m)
Chair Rise (sec)
TUG (sec)

Body Composition (n=26)
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What is the purpose of this study?
Following a diagnosis of mesothelioma there can be declines in health and wellbeing. Many
people experience weight loss, poor appetite, tiredness, shortness of breath, and pain. No
research has examined how nutritional status (i.e., how well your diet is meeting your nutritional
needs), physical functioning (e.g., ability to do tasks such as walking and lifting), and body
composition (i.e., how much fat and muscle you have) changes over time for patients with
mesothelioma. Therefore, one purpose of this research is to assess changes in nutritional
status, body composition, and physical functioning over time.
Research has demonstrated that exercise is a safe and effective intervention for the
management of various adverse effects associated with cancer and cancer treatments.
However, this information is based on research studies involving predominantly breast and
prostate cancer patients. Currently, it is unknown if exercise can help lessen the negative
symptoms associated with mesothelioma and its treatment. Therefore the second purpose of
this research is to find out if a short, supervised exercise program could be useful for people
with mesothelioma.

What does participation in this study involve?
As a participant in this study you will receive standard medical care. There are two groups in
this study: 1. the nutrition group, 2. the exercise group.
If you have mesothelioma you can choose to take part in the nutrition group. This involves
nutrition and physical function assessments every 6 weeks. Assessments will alternate
between brief assessments (takes about 30 minutes) and complete assessments (takes
about an hour) as described below.
If you have malignant pleural disease as a result of another primary cancer (e.g., lung
cancer, breast cancer), or if you have mesothelioma then you may choose to take part in the
exercise intervention. This is a 6-week supervised exercise program. You would have
assessment before the exercise program, after the exercise program as described below.
All participants will be asked to complete a series of tests or assessments. You will be
thoroughly instructed on each of the assessments and supervised by qualified professionals at
all times throughout these sessions.
Assessments can be done at Sir Charles Gairdner Hospital (SCGH; in the Cancer Centre
Gymnasium, outpatients department), the Harry Perkins Institute of Medical Research, or at the
Edith Cowan University (ECU) Health & Wellness Institute in Joondalup. The brief assessments
can be done at ECU in Mt Lawley. If you are unwell and unable to travel it could be possible to
arrange for us to do the brief assessment at your home.
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Assessments:
Questionnaires
For the brief and complete questionnaires you will be asked to complete standardized
questionnaires to assess quality of life and cancer-related symptoms. The brief questionnaire is
expected to take you approximately 10 minutes to complete. The complete questionnaire will take
approximately 15 minutes of your time. Before starting the exercise program you will be asked to
complete a form with details such as your home address and contact phone number and also a
health questionnaire that will provide information about your medical history, activity history, and
other information that we will need to safely develop your tailored exercise program. Before and
after the exercise program you will asked to completed standardized questionnaires to assess
your quality of life, fatigue, shortness of breath, psychological distress, sleep quality, your physical
activity level, your physical functioning and your motivation towards and thoughts about the
exercise program. The questionnaires are anticipated to take you approximately forty minutes to
complete at each of the assessment time points.
• Body Composition Scan
Dual Energy X-Ray Absorptiometry (known as DXA) will be used to assess your body
composition (i.e., how much fat, muscle, and bone you have). This assessment involves lying
still on a specifically designed platform for approximately 5 minutes and a scanning arm will move
above your total body. A low-dosage x-ray will pass from underneath the platform to the scanning
arm. The total radiation dose for all scans undertaken during the scan is very low, only a little
more than normal background radiation from an airplane flight and much less than, for example,
an international flight. A maximum of five scans will be completed in the nutrition study.
• Nutritional status
You will be asked to answer 4 questions about your weight and how much food you have
been eating. Then you will undergo a brief physical exam to assess for any signs of muscle
wasting and fat loss. The nutritional status assessment will take approximately 15 minutes
to complete.
• Physical Function
A series of tests will be used to assess physical functional performance. Before physical
function tests are performed, demonstrations, practice time, sufficient warm-up will be
undertaken. You will be supervised during all tests and your safety will be observed at all
times. Each of these tests will be performed three times. These tests involve:
o Timed up and go: you will be seated in a chair, rise to stand, walk 8 feet, turn around
and return to sitting.
o Hand grip strength: You will be asked to squeeze a hand grip machine as hard as you
can for each hand.
o If you take part in the exercise study you will also complete a chair rise test: You will
be seated in a chair and asked to rise and sit 5 consecutive times, without the use of
your arms for support, as fast as possible.
• Walking test
For the Six-Minute Walk Test, you will be asked to walk 50 meters in a corridor, turn and
return to the starting position for a total of six minutes. During this time you can take breaks
if you need to.
• Fooddiary
You will be asked to record all of the food and drinks you consume over a 3-day period. It is
recommended that you complete the diary at the time of eating or drinking. A food diary and
instruction manual will be provided.
• Food recall
You will be asked to recall all of the food and drinks you consumed over the previous day. This
will take approximately 15 minutes and can be completed in person or over the phone.
INTERMIX Participant Information Sheet v1 .3 /30.03.2016
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• Strength Test
You will be asked to perform a one repetition maximum test, which is the most weight that can
be lifted one time with your legs using correct technique. This will be performed on a leg press
weight-training machine that you will be using during the exercise training sessions. You will
be supervised and instructed by a qualified professional during this test. If you have disease
that has spread to the bone you will not have to complete this test.
• Monitor of Physical activity level
You will be asked to wear a monitor to measure your activity for 3 days. The device is very
small and lightweight and is worn around the waist 24 hours a day.
• Blood Sample
You will be asked to have blood taken for this research. Your blood will be analysed for
substances that produce an inflammatory response in the body. Your blood samples would be
stored in our secure research facilities at Sir Charles Gairdner Hospital for up to 5 years. Blood
samples will collected by a member of the Pleural Medicine Clinical staff or at an accredited
Australian National Association of Testing Authorities laboratory when you get other blood tests
done (i.e., PathWest). You will not receive the results of these blood samples.
Exercise program:
If you are eligible and would like to, you can participate in a 6-week exercise program. If you
indicate that you are interested in the exercise study, an exercise coordinator will follow-up with
you. Your specialist doctor will be required to give consent for you to take part in this exercise
study. Prior to beginning the exercise program, you will be asked to complete a demographics
and health history questionnaire. This is to ensure that the exercise program can be
individualized so that it is appropriate for you and specific to your current health status.
The exercise program involves 3 supervised exercise sessions each week of resistance
exercise (i.e. lifting weights). The sessions will be approximately 60 minutes long and
conducted in small groups of up to 5 participants at the exercise clinic in the Cancer Centre at
Sir Charles Gairdner Hospital, or at sites throughout Perth (i.e., Murdoch, Mt Lawley,
Joondalup, and Crawley). You can choose the location that is most convenient for you.
Accredited exercise physiologists experienced in working with people with cancer will be
supervising your exercise program, which will be specifically tailored to you and your
capabilities. The resistance exercise will involve 6-8 exercises that target the major upper and
lower body muscle groups using weight training machines and other forms of resistance such
as hand weights. The intensity will be moderate to vigorous (i.e. somewhat hard to hard) and
will be manipulated by varying the amount of weight you are lifting, how many times in a row
you lift it and how many sets of each exercise you perform. You might also complete aerobic
exercise training at a moderate intensity. This could be walking on a treadmill, cycling on a
stationary bike or rowing on a stationary ergometer or exercising or a cross trainer machine.
Your program will be modified and progressed according to how you are feeling.
At the end of the 6-weeks you will have a two-week period to make up any missed sessions, if
you choose to do so. It is completely up to you if you would like to make up any missed
sessions or not.
What are the possible benefits of participating?
The direct benefit for you is that all study activities, including the nutrition assessments,
exercise program and assessments, are provided at no cost to you. Participating in an exercise
program may maintain or improve your physical wellbeing. Additionally, it is hoped that this
study will contribute important new information about the management of mesothelioma.
What are the possible side effects and risks?
Because there are no additional medical procedures involved in this study, there are few
foreseeable major risks or side-effects associated with participation. However, as is the case
with anyone who exercises, any exercise may result in mild discomfort and muscle soreness.
INTERMIX Participant Information Sheet v1 .3 /30.03.2016
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There is also the possibility of muscle pulls or strains associated the functional assessment,
exercise assessment or the exercise program, common to any type of physical activity. In line
with standard practice in exercise physiology, we will monitor and modify your program
whenever necessary. In order to minimize these risks you will perform an adequate warm-up
and cool-down before and after any exercise bout, be fully instructed on the correct lifting
technique, familiarized with the movements involved in this investigation and supervised at all
times by qualified professionals. Risk of falling may exist in the performance of some tasks,
however, you will be closely supervised to minimize the risk of falling. During exercise it is
possible to experience symptoms such as abnormal blood pressure, fainting, light-headedness,
shortness of breath, muscle cramps or strain, nausea, and in very rare cases heart rhythm
disturbances or heart attack. These potential risks are common to any form of physical activity.
You will be asked to report any symptoms you experience during exercise and your safety will
be of primary importance at all times. You will be given a log where you can write this
information down. The Sir Charles Gairdner Hospital Cancer Centre gymnasium is associated
with full medical facilities in the unlikely event that any medical assistance is needed. The other
exercise sites have emergency action procedures in place in the unlikely event that medical
assistance is needed.
DXA scans are routine clinical tests but carry a small risk to you as they involve exposure to
radiation. The level of radiation exposure is very small (10-30 micro Sieverts [µSv]) in comparison
to the natural annual radiation dose in western communities (approximately 3000µSv). A person
would receive radiation exposure of approximately 80 µSv on an airline flight of 8 hours or 30 to
40 µSv during a typical chest x-ray.
The discomforts associated with having blood taken are minimal. There is a risk that sometimes
bruising and infection may occur and that the arm might become sore. Risk of bruising or
infection will be minimised because all samples will be taken by a trained phlebotomist, medical
doctor or nurse with extensive experience. The total amount of blood needed during each testing
session will not be less than 10 ml (2 teaspoons). No syringes, needles or other devices capable
of carrying infection from one person to another shall be reused. All of these items, which are
disposable, will be destroyed after each use. All contaminated items will be disposed of promptly
in special containers.
If you experience discomfort during any of the tests, please let the study staff know immediately.
You may experience some anxiety or discomfort in answering the questions about your quality of
life, distress, and well-being. If you do experience this, you can choose to stop filling out the
questionnaire at any time. Your responses will be kept strictly confidential. Some of the questions
before and after the exercise program will ask about the level of distress you are experiencing. If
our study identifies that you are experiencing significant distress, we will ask you if we can notify
your GP or cancer specialist so that the appropriate referral for support services can be made.
You may experience some distress when responding to questions about you weight and food
intake during the nutritional status assessment. If you do experience any distress during
assessment please tell the researcher. You can choose to stop any assessments at any time. If
you are found to be malnourished, and are not currently under the care of a dietitian, your
permission will be sought to contact your GP or cancer specialist who can make a referral to a
dietitian.

What will happen to the information collected as part of this research study?
By signing the consent form you consent to the study doctor and relevant research staff
collecting and using personal information about you for the research project. They may also need
to get some of your health information from other health service providers e.g., another hospital,
pathology laboratory, radiography (please note that your CT/MRI scans may be reviewed), GP or
INTERMIX Participant Information Sheet v1.3 /30.03.2016
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other medical specialist. Any information obtained in connection with this research project that
can identify you will be kept private and confidential. It will be stored securely and only authorised
persons, who are aware that it must be kept confidential, will have access to it. Your study details
will be given a unique number so your identity will not be revealed. As required for safety
reasons, your emergency contact details (their name, phone number, and relationship to you) as
well as any medical history relevant for exercise training will be given to the exercise physiologist
who will be supervising your exercise training and kept in your exercise-training diary. This
information will be kept in a secured locked location at the exercise-training site while not in use.
Your exercise-training log will not have your full name on it, only your study id. The trial records
will be kept in the Department of Respiratory Medicine during the study in a locked filing cabinet
in a locked office and archived. A copy of the data without identifying information will be kept at
ECU Joondalup. This data will be kept for at least 5 years from the time the study is closed. They
may be destroyed at any time thereafter. Your exercise training log will contain only information
required for exercise training and will be transferred to and from exercise sites with care and
stored in a locked area at all possible times. Your health records and any information obtained
during the research project are subject to inspection for the purpose of verifying the procedures
and the data. This review may be done by the relevant authorities and authorised representatives
of the institution relevant to this Participant Information Sheet, Sir Charles Gairdner Hospital or as
required by law. By signing the Consent Form, you authorise release of, or access to, this
confidential information to the relevant research personnel and regulatory authorities as noted
above. It is anticipated that the results of this research project will be published and/or presented
in a variety of forums. In any publication and/or presentation, information will be provided in such
a way that you cannot be identified, except with your permission. By taking part in this study you
agree not to restrict the use of any data even if you withdraw. Your rights under any applicable
data protection laws are not affected. Information about your participation in this research project
may be recorded in your health records.
In accordance with relevant Australian privacy and other relevant laws, you have the right to
request access to the information collected and stored by the research team about you. You also
have the right to request that any information with which you disagree be corrected. Please
contact the research team member named at the end of this document if you would like to
access your information. Any information obtained for the purpose of this research project that
can identify you will be treated as confidential and securely stored. It will be disclosed only with
your permission, or as required by law.
Are there any costs involved?
There will be no direct costs incurred as a result of participation in this study. However, there
will be expense associated with travelling to, and parking at, Sir Charles Gairdner Hospital or
ECU Joondalup to complete the assessments or exercise training. About one hour of parking
will be required If you attend exercise training or an assessment at Sir Charles Gairdner
Hospital (approximately $3.00/hour) or ECU Joondalup (approximately $1.50/hour). You will
not be paid for participation in this study.
Voluntary participation and withdrawal
Participation in this study is entirely voluntary. Whether you decide to participate in the study or
not, your decision will not prejudice you in any way. No explanation or justification is needed if
you choose not to participate. If you do decide to participate, you are free to withdraw your
consent and discontinue your involvement at any time without reason or justification. If you
decide to withdraw from this research project, please notify a member of the research team
before you withdraw. A member of the research team will provide a form for Withdrawal of
Participation for you to sign.
If you do withdraw your consent during the research project, the study doctor and relevant
study staff will not collect additional personal information from you, although personal
information already collected will be retained to ensure that the results of the research project
can be measured properly and to comply with law. You should be aware that data collected by
the research team up to the time you withdraw will form part of the research project results. If
you do not want them to do this, you must tell them before you join the research project.
INTERMIX Participant Information Sheet v1.3 /30.03 2016
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Will I receive any feedback?
A summary of study results will be made available to all interested participants upon
completion of the trial. On request, we will provide you with a brief summary report of your
individual results with relation to how your physical function test results changed following the
exercise intervention.
Who has reviewed the research project?
All research in Australia involving humans is reviewed by an independent group of people called
a Human Research Ethics Committee (HREC). The ethical aspects of this research project have
been approved by the HREC of Sir Charles Gairdner Hospital.
This project will be carried out according to the National Statement on Ethical Conduct in Human
Research (2007). This statement has been developed to protect the interests of people who
agree to participate in human research studies.

Further information and who to contact?
The person you may need to contact will depend on the nature of your query.
If you want any further information concerning this project or if you have any medical problems
which may be related to your involvement in the project (for example, any side effects), you can
contact the principal study doctor, Professor Y C Gary Lee on phone 6457 4968, or any of the
following people:
Dr Carolyn McIntyre
Ms Emily Jeffery

Phone: (08) 6304 3987
Phone: (08) 6304 2082

Email: c.mcintyre@ecu.edu.au
Email: ejeffery@our.ecu.edu.au

Complaints contact person
If you have any complaints about any aspect of the project, the way it is being conducted or any
questions about being a research participant in general, then you may contact:
Reviewing HREC approving this research and HREC Executive Officer details
Reviewing HREC name

Sir Charles Gairdner Group

HREC Executive Officer

Sean Howarth

Telephone

08 6457 2999

Email

sean.howarth@health.wa.gov.au
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Consent Form - Adult providing own consent
Title

Investigating nutritional status, physical functioning, and the
effects of an exercise intervention in malignant pleural
mesothelioma

Protocol Number

version 1.2

Coordinating Principal Investigator/

Professor YC Gary Lee

Principal Investigator

Dr Carolyn McIntyre, Ms Emily Jeffery

Associate Investigators

Prof Rob Newton, Assoc/Prof Philippa Lyons-Wall
Prof Jeanette Greaney, Prof Anna Nowak
Sir Charles Gairdner Hospital, Perth, Western Australia
Edith Cowan University Health and Wellness Institute

Location
Declaration by Participant

1.I have read the Participant Information Sheet or someone has read it to me in a language that I
understand.
2.I understand the purposes, procedures and risks of the research described in the project.
3. have been able to have a member of my family or a friend with me while I was told about the
study if I so wish. I have had an opportunity to ask questions and I am satisfied with the answers I
have received.
4.I freely agree to participate in this research project as described and understand that I am free to
withdraw at any time during the project without affecting my future health care. My participation in
the study does not affect any right to compensation, which I may have under statute or common
law.
5.I understand that my personal details and the details of my emergency contact will be kept by the
exercise physiologist for safety reasons.
6.I understand that I will be given a signed copy of this document to keep.
7. I understand that, if I decide to discontinue the research project treatment, I may be asked to
attend follow-up visits to allow collection of information regarding my health status. Alternatively, a
member of the research team may request my permission to obtain access to my medical records
for collection of follow-up information for the purposes of research and analysis.
If you are unclear about anything you have read in the Patient Information Sheet or this
Consent Form, please speak to your doctor before signing this Consent Form.
Name of Participant (please

print)

_

Signature

Date

Declaration by Study Doctor/Senior Researcher'
I have given a verbal explanation of the research project, its procedures and risks and I believe
that the participant has understood that explanation.
Name of Study Doctor/
Senior Researcher'

(lease pnnt)

Signature

Date

t A senior member of the research team must provide the explanation of, and information concerning, the research project.

Note: All parties signing the consent section must date their own signature.

XXXX Consent Formv1.2/ 30.03.2016
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Appendix G Participant Screening Form
INTERMb - Nutrition Study
SCREENING/ELIGIBILTY- CRF 1

I
I
h

Patients Initials:
Date of Birth: (dd/mm/yy)
Patient ID no: (First name/Nutr/no.) e.g

I

Sex:

[MOFO [

I

f

James/NU TR/OT

DATE_•

Age:

Current ECOG

_

• ELIGIBILITY/INELIGIBILITY CHECKLIST
a. Eligible:
Established diagnosis of malignant pleural mesothelioma:
Yes O

No O

Yes @

No O

Patients who are pregnant or lactating

Yes @

No O

• Inability to read and understand English

Yes @

No O

Inability to give informed consent or comply with the protocol

Yes @

No O

Unable to obtain physician consent

Yes @

No O

Participation in the exercise intervention

Yes @

No O

Histo-cytologically proven pleural mesothelioma
b. Ineligible (any "Yes' answers means the patient is INELIGIBLE ):
Age <18 years

I confirm that the patient meets all the criteria for entry into the trial and is eligible
for rticination

Yes O No @

[ informed consent form signed by patient and a copy of the Patient Information Sheet has been given to
the participant.
[mis patient is in sufficient health to participate in the study

Physician's Name (PRINT):

Signature:

Date:

Please photocopy this form. File the original in the patient trial notes
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The researcher will complete the rest of the form:
A

Additive score of the Boxes 1-4

5

Disease and its relation to nutritional requirements (See Worksheet2)
Al] relevant diagnoses (Specify) _
Primary disease stage (if known) _-...
Numerical score from Worksheet 2
Age_____

B

6

Metabolic demand (See Worksheet 3)

Numerical score from Worksheet 3

C

7

Physical (See Worksheet 4)

Numerical score from Worksheet 4

D

Global Assessment (See Worksheet 5)

Total PG-SGA Score

D Well nourished or anabolic (SGA-A)
Moderate or suspected malnutrition (SGA-B)
Severely malnourished (SGA-C)

(Total numerical score of A+B+C+D above)

□
□

Worksheets for PG-SGA Scoring
Boxes 1-4 of the PG-SGA are designed to be completed by the patient The PG-SGA numerical score is
determined by 1) the parenthetical points noted in boxes 1-4 and 2) the worksheets below for items not marked
with parenthetical points. Scores for boxes 1 and 3 are additive within each box and scores for boxes 2 and 4 are
based on the highest scored item checked off by the patient

Worksheet 1- Scoring Weight (Wt) Loss

Worksheet 2-Scoring Criteria for Condition

Wt loss in 1 month
10% or greater
5-9.9%
3-4.9%
2-29%
0-1.9%

Points
Category
Cancer
1
AIDS
1
Pulmonary or cardiac cachexia 1
Presence of open wound, fistula 1
Presence of trauma
1
Age greater than 65 years
Score for Worksheet 2

Points Weight loss in 6 months
4
20% or greater
10-19.9%
3
6-9.9%
2
1
2-59%
0-1.9%
0
Score for Worksheet 1

Worksheet 3-Scoring Metabolic Stress
Score for metabolic stress is determined by a number of variables known to increase protein and calorie needs. The score is additive so that a
patient who has a fever of> 102 degrees (3 points) and is on 10mg prednisolone chronically (2 points would have an additive score for this
section of 5 points

Stress
Fever
Fever duration
Steroids

None (0)
no fever
no fever
no steroids

Moderate (2)
2101 and <102
72 hours
2>10and < 30 mg

Low(1)
> 99 and <101
=< 72 hours
< 10 mg

High (3)

> 102

> 72 hours
30 mg

2

Score for Worksheet 3
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Appendix H. Patient Generated Subjective Global Assessment

Worksheet 4--Physical Examination
Physical exam includes a subjective evaluation of 3 aspects of body composition; fat, muscle & fluid status. Definition of categories: 0 = no
deficit, 1+ = mild deficit, 2+ moderate deficit, 3+ severe deficit

Fat stores:
Orbital fat pads
Triceps skin fold
Fat overlying lower ribs

0
0
0

Global fat deficit rating
Muscle status
Temples (temporatis muscle)
Clavicles (pectoralis & deltoids)
Shoulders (deltoids)
lnterosseous muscles
Scapula (latis simus dorsi, trapezius, deltoids)
Thigh (quadriceps)
Calf (gastrocnemius)

0
0
0
0
0
0
0

Global muscle deficit rating
Fluid status
Ankle oedema
Ascites

0
0

Global fluid status rating

1+
1+
1+

2+
2+
2+

3+
3+
3+

1+

2+

3+

1+
1+
1+
1+
1+
1+
1+

2+
2+
2+
2+
2+
2+
2+

3+
3+
3+
3+
3+
3+
3+

1+

2+

3+

1+
1+

2+
2+

3+
3+

1+

2+

3+

Point score for the physical exam is determined by the overall subjective rating of
total body deficit.
No deficit
Mild deficit
Moderate deficit
Severe deficit

score
score
score
score

=
=
=
=

O points
1 point
2 points
3 points

Score for worksheet 4

D

Worksheet 5--PG-SGA Global Assessment Categories

Category

Well-nourished

Moderately malnourished or
suspected malnutrition

Weight

No wt loss OR Recent nonfluid wt gain

~5% wt loss within 1 month
(or 10% in 6 months) OR No
wt stabilisation or wt gain
(i.e. continued wt loss)

wt stabilisation or wt gain
(i.e., continued wt loss)

Nutrient intake

No deficit OR Significant
recent improvement

Definite decrease in intake

Severe deficit in intake

Nutrition impact Symptoms

None OR Significant recent
improvement allowing
adequate intake

Presence of nutrition impact
symptoms

Presence of nutrition impact
symptoms

Functioning

No deficit OR Significant
recent improvement

Moderate functional deficit
OR recent deterioration

Severe functional deficit OR
recent significant
deterioration

Physical Exam

No deficit OR Chronic defict
but with recent clinical
improvement

Evidence of mild to
moderate loss of SQ fat &/or
muscle mass &/or muscle
tone on palpation

Obvious signs of malnutrition
(e.g., severe loss of SQ
tissues, possible oedema)

Severely malnourished

> 5% wt loss in 1 month (or
>10% in 6 months) OR No

Global PG-SGA rating (A, B or C)
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Appendix I

Questionnaire – Baseline

Sir Charles
Gairdner Hospital

Edith Cowan University
Health and Wellness Institute

UarIo wellness clinic

Nutritional Status, Activity, and the Effects of Exercise in
Mesothelioma

Assessment: Complete
Study ID:

_

Date: '__/__

Instructions:
• Please take your time completing these important questionnaires
and answer all questions as honestly as you can.
• Please note: there are questions on both sides of each page in this
package.
• Your responses provide extremely valuable information regarding
the effects of exercise in cancer survivors and have the potential to
influence the information and services provided to cancer survivors
worldwide.
• We really appreciate your time and value the contribution you are
making to advancing the scientific knowledge surrounding exercise
for cancer survivors.
• If you have any questions whatsoever please don't hesitate to ask.

THANK YOU!
INTERMIX CRF 18 V1/15.3.2015
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Appendix I. Questionnaire – Baseline

These first questions ask for your views about your health. This information will help keep
track of how you feel and how well you are able to do your usual activities. For each of the
following questions, please circle the one number that best describes your answer.

1. In general, would you say your current health is:
Excellent

Very Good

Good

Fair

Poor

1

2

3

4

5

2. Compared to one year ago, how would you rate your health in general now?
Much better
now than one
year ago

Somewhat
better now than
one year ago

About the
same as one
year ago

Somewhat
worse now than
one year ago

Much worse
now than one
year ago

1

2

3

4

5

3. The following questions are about activities you might do during a typical day. Does your
health now limit you in these activities? If so, how much?
Yes,
limited
a lot

Yes,
limited
a little

No, not
limited
at all

a) Vigorous activities, such as running, lifting heavy
objects, participating in strenuous sports.

1

2

3

b) Moderate activities, such as moving a table, pushing
a vacuum cleaner, bowling, or playing golf.

1

2

3

c) Lifting or carrying groceries.

1

2

3

d) Climbing several flights of stairs.

1

2

3

e) Climbing one flight of stairs.

1

2

3

f) Bending, kneeling, or stooping.

1

2

3

g) Walking more than a mile.

1

2

3

h) Walking several hundred yards.

1

2

3

i) Walking one hundred yards.

1

2

3

j) Bathing or dressing yourself

1

2

3
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4. During the past 4 weeks, how much of the time have you had any of the following
problems with your work or other regular daily activities as a result of your physical
health?
All of
the
time

Most
of the
time

Some
of the
time

A little
of the
time

None
of the
time

a) Cut down on the amount of time you
spent on work or other activities.

1

2

3

4

5

b) Accomplished less than you would like.

1

2

3

4

5

c) Were limited in the kind of work or other
activities.

1

2

3

4

5

d) Had difficulty performing the work or
other activities (for example, it took extra
effort).

1

2

3

4

5

5. During the past 4 weeks, how much of the time have you had any of the following
problems with your work or other regular daily activities as a result of any emotional
problems (such as feeling depressed or anxious)?
All of
Most
Some
A little
None
the
of the
of the
of the
of the
time
time
time
time
time
a) Cut down on the amount of time you
1
2
3
4
5
spent on work or other activities.
b) Accomplished less than you would like.

1

2

3

4

5

c) Did work or other activities less
carefully than usual.

1

2

3

4

5

6. During the past 4 weeks, to what extent has your physical health or emotional problems
interfered with your normal social activities with family, friends, neighbors, or groups?
Not at all

Slightly

Moderately

Quite a bit

Extremely

1

2

3

4

5

7. How much bodily pain have you had during the past 4 weeks?
None

Very mild

Mild

Moderate

Severe

Very severe

1

2

3

4

5

6

8. During the past 4 weeks, how much did pain interfere with your normal work (including
both work outside the home and housework)?
Not at all

A little bit

Moderately

Quite a bit

Extremely

1

2

3

4

5
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9. These questions are about how you feel and how things have been with you during the
past 4 weeks. For each question, please give the one answer that comes closest to the
way you have been feeling. How much of the time during the past 4 weeks...

All of

Most

Some

A little

None

the

of the

of the

of the

of the

time

time

time

time

time

a) Did you feel full of life?

1

2

3

4

5

b)Have you been very nervous?

1

2

3

4

5

c) Have you felt so down in the dumps
that nothing could cheer you up?

1

2

3

4

5

d) Have you felt calm and peaceful?

1

2

3

4

5

e) Did you have a lot of energy?

1

2

3

4

5

depressed?

1

2

3

4

5

g) Did you feel worn out?

1

2

3

4

5

h) Have you been happy?

1

2

3

4

5

i) Did you feel tired?

1

2

3

4

5

f) Have you felt downhearted and

10. During the past 4 weeks, how much of the time has your physical health or emotional
problems interfered with your social activities (like visiting friends, relatives, etc.)?

All of the time

Most of the

Some of the

A little of the

None of the

time

time

time

time

2

3

4

5

1

11. How TRUE or FALSE is each of the following statements for you?
Definitely

Mostly

true

true

Don't
know

Mostly
false

Definitely
false

a) I seem to get sick a little easier
than other people.

1

2

3

4

5

b) I am as healthy as anybody I
know.

1

2

3

4

5

c) I expect my health to get worse.

1

2

3

4

5

d) My health is excellent.

1

2

3

4

5
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Below is a list of statements that other people with cancer have said are important to their
quality of life. Please indicate the extent to which you have experienced each of the
statements during the past 7 days by circling the appropriate number using the following
scale.
During the PAST 7 DAYS:

not
at all

a little some- quite very
bit
what a bit much

PHYSICAL WELL - BEING

1. I have a lack of energy

0

1

2

3

4

2. I have nausea

0

1

2

3

4

3. Because of my physical condition, I have trouble
meeting the needs of my family

0

1

2

3

4

4. I have pain

0

1

2

3

4

5.1 am bothered by side effects of treatment

0

1

2

3

4

6. I feel sick

0

1

2

3

4

7.1 am forced to spend time in bed

0

1

2

3

4

8. I feel close to my friends

0

1

2

3

4

9. I get emotional support from my family

0

1

2

3

4

10.I get support from my friends

0

1

2

3

4

11. My family has accepted my illness

0

1

2

3

4

12. I am satisfied with family communication about
my illness

0

1

2

3

4

13. feel close to my partner (or the person who is
my main support)

0

1

2

3

4

0

1

2

3

4

SOCIAL/FAMILY WELL - BEING

Regardless of your current level of sexual activity, please
answer the following question. If you prefer not to answer
it, please check this box [ and go to the next section

14. am satisfied with my sex life
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During the PAST 7 DAYS:

not
at all

a little some- quite

bit

what

a bit

very
much

EMOTIONAL WELL - BEING
15. I feel sad

0

1

2

3

4

16.I am satisfied with how I am coping with my illness

0

1

2

3

4

17. I am losing hope in the fight against my illness

0

1

2

3

4

18. I feel nervous

0

1

2

3

4

19. I worry about dying

0

1

2

3

4

20. I worry that my condition will get worse

0

1

2

3

4

21. I am able to work (include work at home)

0

1

2

3

4

22.My work (include work at home) is fulfilling

0

1

2

3

4

23. I am able to enjoy life

0

1

2

3

4

24. I have accepted my illness

0

1

2

3

4

25. I am sleeping well

0

1

2

3

4

26.I am enjoying the things I usually do for fun

0

1

2

3

4

27. I am content with the quality of my life right now

0

1

2

3

4

FUNCTIONAL WELL - BEING
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ADDITIONAL CONCERNS

not
at all

a little some- quite very
bit
what a bit much

1. I have a good appetite

0

1

2

3

4

2. The amount I eat is sufficient to meet my needs

0

1

2

3

4

3. I am worried about my weight

0

1

2

3

4

4. Most food tastes unpleasant to me

0

1

2

3

4

5. I am concerned about how thin I look

0

1

2

3

4

6. My interest in food drops as soon as I try to eat

0

1

2

3

4

7. I have difficulty eating rich or "heavy" foods

0

1

2

3

4

8. My family or friends are pressuring me to eat

0

1

2

3

4

9.I have been vomiting

0

1

2

3

4

10. When I eat, I seem to get full quickly

0

1

2

3

4

11. I have pain in my stomach area

0

1

2

3

4

12. My general health is improving

0

1

2

3

4
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FATIGUE SYMPTOMS
not
at all

a little some- quite very
bit
what a bit much

1. I feel fatigued

0

1

2

3

4

2. I feel weak all over

0

1

2

3

4

3. I feel listless ("washed out")

0

1

2

3

4

4. I feel tired

0

1

2

3

4

5. I have trouble starting things because I am tired

0

1

2

3

4

6.I have trouble finishing things because I am tired

0

1

2

3

4

7. I have energy

0

1

2

3

4

8.I am able to do my usual activities

0

1

2

3

4

9.I need to sleep during the day

0

1

2

3

4

10. I am too tired to eat

0

1

2

3

4

11. I need help doing my usual activities

0

1

2

3

4

12. I am frustrated by being too tired to do
the things I want to do

0

1

2

3

4

13. I have to limit my social activity because I am tired

0

1

2

3

4
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Please circle the number that best describes how you feel NOW:

0

1

2

3

4

5

6

7

8

9

10

Worst Possible
Pain

No Tiredness
0
(Tiredness = lack of energy)

1

2

3

4

5

6

7

8

9

10

Worst Possible
Tiredness

No Drowsiness
0
(Drowsiness = feeling sleepy)

1

2

3

4

5

6

7

8

9

10

Worst Possible
Drowsiness

No Nausea

0

1

2

3

4

5

6

7

8

9

10

Worst Possible
Nausea

No Lack of
Appetite

0

1

2

3

4

5

6

7

8

9

10

Worst Possible
Lack of Appetite

No Shortness of
Breath

0

1

2

3

4

5

6

7

8

9

10

Worst Possible
Shortness of Breath

No Depression
0
(Depression = feeling sad)

1

2

3

4

5

6

7

8

9

10

Worst Possible
Depression

No Anxiety
0
(Anxiety = feeling nervous)

1

2

3

4

5

6

7

8

9

10

Worst Possible
Anxiety

0

1

2

3

4

5

6

7

8

9

10

Worst Possible
Wellbeing

No
0
1
2
3
Other Problem (for example constipation)

4

5

6

7

8

9

10

Worst Possible

No Pain

Best Wellbeing
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Activity Monitor Instructions and Log

ACTIVITY MONITOR INSTRUCTIONS
The activity monitor measures the amount of physical activity you do in your
everyday life. It is also used to measure the amount and quality of your sleep.

1. Please start wearing the monitor from:

2. Please take off the monitor:

If you have any questions about the activity monitor please call and leave a
message:

6304 2329

If there is no answer, please leave a message. It will be checked and responded to
as soon as possible between 8:00am and 4pm Monday to Friday.
•

Where do I wear the activity monitor?
o The monitor needs to be worn at the hip area of your waist with the black
button facing the top (Do not twist the button).
o The monitor can be worn either above or beneath clothing, and it is not
necessary for it to make contact with the skin.
o The monitor must be held snugly against the body to work properly (i.e. must
be secure and not bounce or slide when you're moving).

•

How
o
o
o
o
o

•

What happens if I get the activity monitor wet?
o It's preferable if the monitor doesn't get wet but it is water resistant so will
not be affected by getting slightly wet.
o If you are a swimmer please take the device off before getting into the
pool/ocean.
o Note the device is water resistant and not water proof.

long do I wear the activity monitor for?
We ask that you wear the monitor for a period of 3 days.
It is very important to wear the monitor 24 hours a day if possible.
This includes when you are asleep at night.
The monitor should be taken off to bath/shower.
You need to take off the activity monitor on the date and time listed
above.
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ACTIVITY MONITOR LOG
Study ID:

_

Date: '__/__

Please use this form to document any time that you didn't wear the monitor
during the three-day period, or any issues you had wearing the monitor

DETAILS
Day 1

Day 2

Day 3
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Page 1 of 1

284

Appendix K

Food Record
..

Sir Charles
Gairdner Hospital

Edith Cowan University
Health and Wellness Institute

uario

{Hl

EDITH COWAN

wellness clinic

Food Diary
Participant ID:

_

Started diary on:

(date)

Finished diary on:

(date)

You are welcome to contact the researcher during business hours to
discuss your questions or concerns about the food diary.

Contact person: Emily Jeffery
Contact details:

(08) 6304 2082
eieffery@our ecu edu. au
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Food diary guidelines
1. Record everything that you eat and drink for three (3)
consecutive days
•
•
•
•
•
•

Start each day on a new page
You can use more than one page for each day
Record the date at the top of the page
We recommend you carry your food diary with you at all times throughout the
three day recording period, so that nothing is forgotten
Write down the time that you eat and drink
Write down what you eat and drink as close as possible to the time that you
consume it

2. Describe your food and drink in as much detail as possible
•
•
•
•
•

Record the type and brand of each item e.g. Sunblest (brand) multigrain (type)
bread
If eating meat, include the cut of meat (e.g. rump steak) and whether fat has been
trimmed (e.g. chicken skin removed)
Describe your cooking method. For example, boiling, frying, BBQ, roasting or
baking. If fat (e.g. oil) has been added, please state the brand and the amount
Where foods or drinks have been eaten outside the home (e.g. take-away)
please describe what it is and where it has been bought
Record all accompaniments such as butter, gravy, sauce, salt and sugar

3. Describe the amount of food and drink you consume
•

•
•

•
•

Use household measures (cups and spoons) to record the amount of food and
drink you consume. For example, 1 cup of boiled, white rice or 1 tsp of Flora
canola margarine.
You can weigh your food and drink if you like, but it is not required.
For mixed dishes (e.g. a salad or stir fry), estimate each ingredient separately.
For example, garden salad: 1 lettuce leaf, 4 slices cucumber, 4 cherry tomatoes
and 1 tsp Kraft 99% fat free French dressing.
You can also record your recipes in the 'notes' section at the end of each page.
Then just tell us how much is your portion e.g. half or one-quarter.
Ensure you record all fluids (including water) and estimate the volume consumed
in ml or by the type of cup e.g. pint glass, paper cup, coffee mug.
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Food diary example
Time
7.30am

Food and Drink Eaten
Description
Quantity
eg. Weetbix
eg. 3 biscuits/ 45g
Cornflakes -- Kelloggs
45g
Milk- Brownes Calcium Plus
1.5 cups
2 tsp
Sugar- white
Toast, white bread- He/gas
2 large thick slices
3 teaspoons
Margarine -- Flora Light
Tea -Lipton
1 cup
Milk- Brownes Skim
30ml
3 tsp
Sugar- white

10.30am

Granita - Arnotts
Black Coffee
Green Apple -- Granny Smith

1 biscuit
1 cup
1 medium

1 pm

Bought from deli:
1 x cheese & salad sandwich
White bread -- unknown
Butter- unknown
Cheese grated, unknown
Lettuce
Tomato
Beetroot, canned
Apple -- Red Delicious
Water- Mount Franklin
Homemade chocolate slice from deli

2 standard slices
Thickly spread
½ a cup
2 small leaves
3 medium slices
3 slices
1 large
1 bottle 750ml
1 medium slice

3.30pm

7.30pm

9.00pm

Spaghetti, white -- Maggi
Bolognaise Sauce - lean mince
Parmesan Cheese -- Kraft
Red wine, Shiraz
Salad
- carrots
- tomatoes
- lettuce
French dressing -- Kraft Fat Free

320g
1.5 cups (half the recipe)
3 tsp
2 glasses

Ice cream (vanilla) -Streets Blue
Ribbon

3 large scoops

3
1
4
1

slices
whole
small leaves
tbsp

Notes:
Bolognaise Sauce: 500g lean mince, 1 x 420g can tinned whole tomatoes, 2
tablespoons Leggo tomato paste, 1 tablespoon canola oil, ½ cup dry white wine,
oregano, thyme, basil, salt and pepper
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Appendix L

Standard Operating Procedure – Dual
Energy X-Ray Absorptiometry

INTERMlx
DXA standard procedures

Prior to the scanning day

•

Advise participants:

[l wear comfortable clothing with no metal (e.g. zips, metal buttons)

D

Not to undertake strenuous exercise on the morning of the scan

D

Eat breakfast but avoid a very large breakfast

Equipment

•

Hologic DXA (Horizon A), Level 2, Harry Perkins Institute of Medical Research

•

Sample spine (calibration equipment)

Set up

1. Calibration
•

Turn on computer.

•

Turn on DXA by pressing the green button.

•

Double click on QDR account.

•

A pop-up will show asking to back up computer, click "no".

•

Make sure NHANES--BCA is enabled:
•

Click "Utilities".

•

Click "System Configuration".

•

Click "Analysis".

•

At the bottom of the screen, make sure the box is ticked.

•

Click and open up "Daily QC".

•

Collect sample spine from calibration equipment cupboard and remove the
outer black cover.

•

Place the spine on DXA bed (largest vertebral body is closest to computer)
and adjust position ensuring the red lasers crossover in the middle of the
small air bubble and the middle number 1 at the opposite end of spine.

•

On computer click continue.

•

If the spine has been correctly positioned and scanned then the message
'daily QC passed' should appear and click OK.
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Testing Instructions

1. Ask patient if there is any chance of pregnancy. DO NOT scan if pregnant.
2. Ask the patient to remove any metallic items they have on/with them e.g.
glasses, loose change, zips, metal buttons etc. Provide a towel/robe if necessary
i.e. if they had to remove their jeans.
3. Ask the patient if they have any internal objects that could interfere with the
scan such as:

a. Pacemaker leads
b. Radioactive seeds
c.

Metal implants

d. Surgical staples

e. Radio-opaque catheters or tubes
f. Wedding rings that cannot be removed
i.

Make a note on testing sheet if any of the above has been
identified.

4.

Measure and record the patient's height and weight.

5.

Make sure 'NHANES-BCA' is enabled prior to scanning each client.

6.

Click on 'perform exam' and then 'new patient'.

7. Enter the patient details including height, weight, gender, DOB, ID and press 'ok'.
8.

Instruct the client to lie supine with their feet closest to the computer.

9.

Position the individual so that they are central and within the scanning field as
marked by the black lines with their head positioned 2cm from the end of the
bed.

10. Palms are faced down on the bed. If patient does not fit within scanning field, ask
them to place their hands vertical.
11. Feet are positioned wide and angled towards each other and held together by
strapping tape. Explain to client that this position is used to scan both bones of
the lower limbs.
a.

For hygienic reasons, new strapping tape is to be used for each patient.

12. Explain to the patient what the scan is looking at, i.e. body composition and BMD
and that the scanning process will last for 3-4 minutes.
13. Instruct the patient to lie motionless on the table as movement can affect the
scan quality.
14. Select perform 'whole body' scan and click on 'scan now' when the patient is
correctly aligned on the table.
15. DEXA table must be cleaned with alcohol wipe after use.
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Appendix M Standard Operating Procedure –
Timed Up and Go Test

INTERMIX
'Timed up and go test' standard procedures

Equipment required

•

Armed chair

•

Tape measure

•

Masking tape

•

Small marker or bean bag

•

Stop watch

Set up

1.

Position armed chair up against a wall

2.

Measure 2.44 m (8 ft) from the front of the chair and mark the distance with
masking tape

3.

Position a marker at the 2.44 m line

Testing instructions

1.

Explain the purpose of the test

a. This test is designed to mimic the activities of daily living
2.

Explain the process of the test

a. In this test, you begin seated, stand up (unassisted if able), walk around
cone and return to sitting as quickly as possible. You may use the arms on
the chair when you return to sitting.
3.

Inform participant that they will be tested 3 times with a 1 minute rest in
between

4.

Demonstrate the timed up and go

5. Ask participant if they have any questions before they start

INTERMIX 'Timed up and go test' standard procedures v1.1 4.5.16
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Appendix M. Standard Operating Procedure – Timed Up and Go Test

6.

Instruct participant to sit in the chair with back firmly against the back of the
chair and arms across chest. Feet are shoulder width apart on the floor with
knees positioned at 90°

7.

Instruct participant to commence with "3, 2, 1, Go"

8.

Researcher to start stopwatch on "Go" and stop the stopwatch once the
participant returns their upper back to the backrest

9.

Participant to have a 1-minute rest. If greater than a 1-minute rest is required,
document this on the data collection form

10. Complete two more trials to give three trials in total. If participants are unable to
complete 3 trials, document this on the data collection form
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Appendix N Data Collection Form

COMPLETE ASSESSMENT --- DATA COLLECTION SHEET
ID ntfnbef'_

Initials:

Date:

Assessor Name:

_

1. [ Baseline

_

_

[]Weeks

2.

D Informed Consent

3.

D Check medical history: (Is there any reason not to do the functional testing?)

[l Physician Consent

4. Performance Status:
5.

_
cm (only at baseline)

Height:

[l Demographic Info & Health History

kg

Weight:

6. Grip Strength: {30 second rest between trials)

D Seated, elbow flexed at 90°, forearm neutral, wrist 0-30° of dorsiflexion
D Instructed to exhale when squeezing dynamometer
D Hand dominance (R or L) __
D Hand dynamometer position used (1-5)
RIGHT: Trial 1:

_

Trial 2:

_

Trial 3:

_

BEST:

LEFT:

_

Trial 2:

_

Trial 3:

_

BEST:

Trial 1:

_

7. Timed up and go (1 min rest between trials)

D Used arms to assist in standing
Trial 1:sec
8.

Trial2:sec

Trial 3:sec

BEST:_sec

D DXA full body scan: remove shoes, socks, ALL metal (jewellery, underwire bra) and any
prosthetics

9.

[l PGsGA Completed

10.

D

3 Day diet record and ActiGraph explained (baseline)

INTERMIX CRF17V1.0115.3.2015
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Appendix N. Data Collection Form

11. Collect/Give out:

Give out:

D

Questionnaire (complete)

D

3 day food record

Collect:

D

Check all data has been returned from
previous assessment

[ ActiGraph
How will the ActiGraph, questionnaire, and food diary
be returned?

Cl

Cl

oroo off

[l

Mai (Return Tracking ID:

oate for next assessment confirmed

INTERMIX CRF17V1.0115.3.2015

Page 2 of 1

294

Appendix O Sample Resistance Exercise
Training Program

EXERCISE TRAINING LOG

Participant ID:

EXER/_

First name / EXER/ number
Emergency Contact Details:
Name:

_

Contact Details: ---------------------------Relationship:

_

Relevant Medical information:

Medications:

If there are any medical issues with participants, please contact our physician support:
Dr Maree Azzopardi -- 0412 866 477

In a last resort, contact the Pleural Medicine Hotline:
0421 253 918
INTER Mix CRF21 V1.0/ 01/06/2015
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Appendix O. Sample Resistance Exercise Training Program

SESSION RATING OF PERCEIVED EXERTION (RPE)

6
7
8
9

No exertion at all
Extremely light
Very light

10

11

Light

12
13

14
15
16
17
18
19
20

Somewhat hard
Hard (heavy)
Very hard
Extremely hard
Maximal exertion

TOLERANCE OF SESSION
Please rate the number that best represents how you feel

I have found the exercise session to be:
1

2

3

Extremely
lntolerabl
e

Quite
lntolerabl
e

Slightly
lntolerabl
e

INTER Mix CRF21 v1 .0 / 01/06/2015
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5

6

7

Slightly
Tolerabl
e

Quite
Tolerabl
e

Extremel
y
Tolerable

Appendix O. Sample Resistance Exercise Training Program

Date Session
Missed

Reason (if available)

Adherence Log:

INTER Mix CRF21 v1 .0 / 01/06/2015
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Appendix O. Sample Resistance Exercise Training Program

Date:

Participant ID:_/EXER/_

_

TRAINING PROGRAM LOG - WEEK 1 (session1)
1. Please rate your current level of pain (if any):
No pain t-----------------------1 Very severe pain

2.

Has pain affected your ability to undertake usual activities of daily living since your last exercise
training session?
•

If yes, has the interference increased or decreased?

Yes

No

Increased

Decreased

3. Has shortness of breath changed since your last exercise training session?
•

If yes, has it increased or decreased?

5.

No

Increased

4. Has how tired you feel changed since your last exercise training session?
•

Yes

If yes, has it increased or decreased?

Decreased

Yes

No

Increased

Decreased

Have you experienced any other pain, new symptoms/issues?

_

6. Warm up: 5 mins cardio - Cycling or Walking
7.

Resistance Exercises: Target= 2 sets of 12 reps

1.

Leg Press

reps X

kg

reps X

kg

2.

Chest Press

reps X

kg

reps X

kg

3.

Seated Row

reps X

kg

reps X

kg

4.

Leg Extension

reps X

kg

reps X

kg

5.

Shoulder Press

reps X

kg

reps X

kg

6.

Leg Curl

reps X

kg

reps X

kg

7.

Lat Pull Down

reps X

kg

reps X

kg

8. Cool down: Stretching
• Hamstrings:

x 15-30 sec

9. Session RPE:

• Quadriceps:
_

10. Tolerance of Session:

Notes:

INTER Mix CRF21 v1 .0 / 01/06/2015
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Copyright Permission

Permission regarding copyright has been obtained from the following publishers:

Oxford University Press
Thank you for your order with Rightslink / Oxford University Press
no-reply@copyright.com <no-reply@copyright.com>
Mon 20/01/2020 12:22 PM
To: Emily JEFFERY

Header

Thank you for your order!
Dear Miss. Emily Jeffery,
Thank you for placing your order through Copyright Clearance Center's RightsLink"

service.

Order Summary
Licensee
Order Date:
Order

Number:
Publication:
Title:
Type of Use:
Order Total:

Miss. Emily Jeffery
Jan 19, 2020
4752840327308

The American Journal of Clinical Nutrition
The five-level model: a new approach to organizing body-composition

research

Thesis/Dissertation
0.00 AUD

View or print complete details of your order and the publisher's terms and conditions.

Sincerely,
Copyright Clearance Center

Tel +1-855-239-3415/+1978-646-2777

customercare@copyright. com

Copyright Clearance Center

Copyrighl Clearance Center
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This message (including attachments) is confidential, unless marked otherwise. It is
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without further distribution and reply to the sender that you have received the message
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John Wiley and Sons
Corvright

wg

oon
Center

RightsLink

#

2

Home

Help

A
Email Support

Emily Jeffery v

Lean Tissue Imaging
Author: Steven B. Heymsfield, Carla M. M. Prado

WILEY

Publication: JOURNAL OF PARENTERAL AND ENTERAL NUTRITION

Publisher: John Wiley and Sons
Date: Sep 19, 2014
Copyright 4 2014, John wWley and Sons

Open Access Article
This article is available under the terms of the Creative Commons Attribution Non-Commercial License CC BY-NC (which may be updated from time to time) and permits non
commercial use, distribution and reproduction in any medium, provided the original work is properly cited.
For an understanding of what is meant by the terms of the Creative Commons License, please refer to Wiley's Open Access Terms and Conditions.
Permission is not required for
completing your order.

noncommercial reuse. For commercial reuse, please hit the "back" button and select the most appropriate commercial requestor type before

IE
02020Copyright All Rights Reserved ] Copyright Clearance Center, inc. ] Privacy statement
Comments? We would like to hear from you. £-mail us at customercrecopyright.com

]

Terms and Conditions

Springer Nature

RE: Request for permission to use article in thesis
Journalpermissions <journalpermissions@springernature.com>
Thu 16/01/2020 12:43 AM
To: Emily JEFFERY
Dear Emily,
Thank you for your Springer Nature permissions query. Author retains the right to use his/her
article for his/her further scientific career by including the final published journal article in other
publications such as dissertations and postdoctoral qualifications provided acknowledgement is
given to the original source of publication.
You do not need permission to reuse your article in a thesis/dissertation.
Best regards,
Paloma Hammond
Rights Assistant
Springer Nature
The Campus, 4 Crinan Street, London Nl 9XW, United Kingdom
E paloma.hammond@springernature.com
https://www.macmillanihe.com/
http://www.nature.com
http://www.springer.com
https://www.palgrave.com/gp/
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